Mise en page 1 - ISTH 2009

POSTER PRESENTATIONS 

MONDAY, 9 JULY 2007 

* Presenting Author 

Coagulation factors and inhibitors 

Tissue factor, TFPI, Factor VII 

P-M-001 

P-M-002 

P-M-003 

P-M-004 

P-M-005 

P-M-006 

P-M-007 

P-M-008 

P-M-009 

P-M-010 

P-M-011 

PLATELET ACTIVATION TRIGGERS ACTIVATION OF THE TISSUE FACTOR 

REGULATOR, PROTEIN DISULPHIDE ISOMERASE 

P. J. Hogg* (AU), V. M. Chen, K. A. Hotchkiss 

SOURCE OF TISSUE FACTOR LEADING TO DISCREPANT PLASMA FVII LEVELS IN 

EIGHT FVII-DEFICIENT PATIENTS OF AFRICAN ORIGIN 

M. H. Horellou* (FR), J. Chalendard, F. Juin, J. Conard, M. Gouault-Heilmann, 

J. Tapon-Bretaudière 

TISSUE FACTOR GENE TAG-SNPS AND HAPLOTYPES AND THE RISK OF 

MYOCARDIAL INFARCTION 

G. Quaquaruccio* (IT), M. Latella, M. Graziano, A. Di Castelnuovo, R. Lorenzet, 

E. Napoleone, P. Giannuzzi, M. Gattone, D. Assanelli, N. Novak, M. Trevisan, 

G. De Gaetano, M. B. Donati, L. Iacoviello 

INCREASED CELL ASSOCIATED TISSUE FACTOR ACTIVITY FOLLOWING TOTAL KNEE 

ARTHROPLASTY 

G. J. Johnson* (US), L. A. Leis, R. R. Bach 

STATINS INHIBIT LPS-INDUCED MONOCYTE-ASSOCIATED, BUT NOT PLATELET- OR 

MICROPARTICLE-ASSOCIATED TISSUE FACTOR (TF) EXPRESSION IN VIVO AND EX 

VIVO 

C. S. Ross (US), I. Slaba, A. Spiel, B. Jilma, G. Kemeny, R. R. Bach, N. S. Key* 

ON THREE CASES OF INHERITABLE FACTOR VII DEFICIENCY 

N. I. Kolaitis* (GR), P. Koliou, L. Dova, G. Vartholomatos, H. Kapsali 

COAGULATION FACTOR VIIA VARIANTS WITH REDUCED SUSCEPTIBILITY TO 

INHIBITION BY ANTITHROMBIN III 

K. S. Larsen* (DK), O. H. Olsen, H. R. Stennicke, L. C. Petersen, H. Ostergaard 

THE ABILITY OF TF TO PROMOTE TUMOUR CELL IMMUNE EVASION, MEDIATED VIA 

SURFACE VCAM-1 

C. Li* (UK), M. E. W. Collier, A. Frentzou, C. Ettelaie 

SEROTONIN ENHANCES THE PROCOAGULANT PROPERTIES AND PLATELET 

ACTIVATION INDUCED DURING PLATELET UP TAKE OF TISSUE FACTOR 

I. Lopez-Vilchez* (ES), A. M. Galan, M. Diaz-Ricart, F. Navalon, J. G. White, G. Escolar 

ACTIVE SITE INHIBITED FACTOR VIIA HAS A PROTECTIVE ROLE IN RENAL 

ISCHEMIA/REPERFUSION INJURY VIA ANTI-INFLAMMATORY MECHANISMS 

S. T. B. G. Loubele* (NL), P. Leenders, R. Van Oerle, K. Hamulyak, W. A. Buurman, 

H. M. H. Spronk, D. Van Der Voort, H. Ten Cate 

ACTIVE SITE INHIBITED FACTOR VIIA REDUCES MYOCARDIAL INFARCT SIZE AFTER 

ISCHEMIA/REPERFUSION INJURY IN MICE VIA TISSUE FACTOR/NFKAPPAB- 

MEDIATED MECHANISMS 

S. T. B. G. Loubele* (NL), P. Leenders, R. Van Oerle, K. Hamulyak, C. A. Spek, 

H. M. H. Spronk, D. Van Der Voort, H. Ten Cate 

164



P-M-012 

P-M-013 

P-M-014 

P-M-015 

P-M-016 

P-M-017 

P-M-018 

P-M-019 

P-M-020 

P-M-021 

P-M-022 

THROMBOSPONDIN-1 (TSP1) PROMOTES THROMBIN GENERATION ON THE 

SURFACE OF FIBROBLASTS (HS-68) AND INDUCES UPREGULATION OF 

CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE AND PROTEIN EXPRESSION 

J. M. Manns* (US), M. C. Rico, L. L. Mason III, R. A. Dela Cadena 

CHARACTERISATION OF AN INHIBITORY ANTIBODY FRAGMENT TO HUMAN TISSUE 

FACTOR 

M. S. Meiring* (ZA), P. N. Badenhorst 

INHIBITORY ACTIVITY OF TISSUE FACTOR PATHWAY INHIBITOR BETA EXPRESSED 

BY E COLI AND EXPRESSION IN NORMAL HUMAN TISSUE 

D. Moatti* (US), J. J. Hathcock, Y. Nemerson 

BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF KDN-7438, A NOVEL 

SYNTHETIC TISSUE FACTOR/FACTOR VIIA INHIBITOR 

Y. Moritani* (JP), T. Shigenaga, C. Sakata, T. Ishihara, M. Miura, T. Kawasaki, T. Homma, 

A. Matsuzawa, A. Hirabayashi 

EFFECT OF LOW MOLECULAR WEIGHT HEPARIN ON HUMAN ENDOTHELIAL TISSUE 

FACTOR PATHWAY INHIBITOR RELEASE 

S. A. Mousa* (US), K. B. Johansen 

HEPARANASE INDUCES TFPI EXPRESSION AND EXTRACELLULAR ACCUMULATION 

IN ENDOTHELIAL AND TUMOR CELLS 

Y. Nadir* (IL), B. Brenner, S. Gingis-Velitski, F. Levy-Adam, N. Ilan, E. Zcharia, E. Nadir, 

I. Vlodavsky 

LEPTIN INDUCES TISSUE FACTOR EXPRESSION IN HUMAN MONOCYTES 

R. Lorenzet (IT), A. Di Santo, C. Amore, G. Baccante, C. Di Febbo, E. Porreca, 

G. De Gaetano, M. Donati, E. Napoleone* 

GENETIC POLYMORPHISM R353Q OF FACTOR VII HAS PROTECTIVE EFFECT IN 

THREATENED MISCARRIAGE 

L. A. Nikitina* (RU), O. N. Sadekova, O. Y. Azarova, E. M. Demidova, V. N. Bochkov, 

L. M. Samokhodskaya 

IMPROVING THE PHARMACOKINETICS OF RECOMBINANT FACTOR VIIA CYS407 BY 

CYSTEINE-DIRECTED PEGYLATION 

H. Ostergaard* (DK), A. V. Groth, T. N. Krogh, J. M. Petersen, J. Krarup, 

B. B. Sørensen, H. R. Stennicke 

BLOOD BORNE TISSUE FACTOR: CELLULAR LOCALIZATION AND SPECIFIC 

ACTIVITIES 

B. Østerud* (NO), J. Olsen 

ACTIVATION LOOP 3 AND THE 170 LOOP INTERACT IN THE MOST ACTIVE 

CONFORMATION OF FACTOR VIIA 

E. Persson* (DK), O. H. Olsen 

Monday Posters 

Factor VIII, Factor V 

P-M-023 

FACTOR VIII A2 DOMAIN INTERACTION WITH LRP: 

IN VITRO AND IN VIVO ANALYSES 

I. Hilden* (DK), P. K. Holm, D. M. Karpf, H. Østergaard, G. Bolt, M. Kjalke, 

T. D. Steenstrup, T. Krogh-Meibom 

165



P-M-024 

P-M-025 

P-M-026 

P-M-027 

P-M-028 

P-M-029 

P-M-030 

P-M-031 

P-M-032 

P-M-033 

P-M-034 

P-M-035 

P-M-036 

P-M-037 

THE ROLE OF THE ACIDIC COOH-TERMINAL REGION OF FACTOR VA HEAVY CHAIN 

DURING ACTIVATION OF PROTHROMBIN BY PROTHROMBINASE 

J. Hirbawi* (US), M. A. Bukys, T. Orban, M. A. Barhoover, M. Kalafatis 

FACTOR V LEIDEN PROTECTS AGAINST DIABETIC NEPHROPATHY IN MICE 

B. Isermann* (DE), I. Vinnikov, B. Hummel, T. Madhusudhan, M. Kashif, S. Herzog, 

A. Bierhaus, P. P. Nawroth 

ACTIVATION OF HUMAN LUNG ENDOTHELIAL CELLS INDUCES THE RELEASE 

OF A FVIII STORAGE POOL 

M. G. Jacquemin* (BE), R. Lavend'Homme, J. Saint-Remy, K. Peerlinck 

INHIBITOR DEVELOPMENT IN SEVERE HEMOPHILIA A: IS THE RISK ASSOCIATED 

WITH PRODUCT TYPE? 

N. Jain* (US), C. Zinderman, J. Baker, R. Wise, T. Silverman 

PLATELET FACTOR V DEFICIENCY IN A PATIENT WITH AN ACQUIRED INHIBITOR OF 

VA PROCOAGULANT FUNCTION 

S. B. Jeimy* (CA), E. F. Krakow, N. Fuller, S. Tasneem, M. Crowther, C. P. M. Hayward 

THE ROLE OF THE FACTOR V B DOMAIN IN FACTOR V-MMRN1 BINDING AND 

DISSOCIATION 

S. B. Jeimy* (CA), N. Fuller, S. Tasneem, M. Quinn-Allen, H. Zhu, R. M. Camire, 

W. H. Kane, C. P. M. Hayward 

COMPARISON OF HUMAN RFVIII AND MURINE RFVIII IN A STANDARDIZED FVIII 

DEPENDENT BLEED MODEL IN FVIII -/- MICE 

G. J. Jesmok* (US), Z. Cui, D. Canivel, P. Lollar, E. T. Parker, K. A. Landskroner 

REMOVAL OF PORCINE PARVOVIRUS SPIKED INTO SAMPLES OF HUMAN 

RECOMBINANT FACTOR VIII 

Y. Jouvenot* (US), D. Fordham, K. Brisack, A. Hesslein, S. Liu 

IMMUNE RESPONSE TO ADMINISTRATION OF PLASMA-DERIVED COAGULATION 

FACTOR VIII IN FACTOR VIII-DEFICIENT MICE 

A. Kallas* (EE), S. Kuuse, T. Maimets, M. Pooga 

LOW INCIDENCE OF INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED 

PATIENTS WITH HAEMOPHILIA A 

A. Klukowska* (PL), P. Laguna, M. Jansen, J. Feddern 

IGE SPECIFIC FOR HUMAN FVIII FROM A PATIENT WITH HEMOPHILIA A BINDS TO 

THE C2 DOMAIN AND INHIBITS FVIII FUNCTION 

C. Königs* (DE), K. Klich, C. Kessel, C. Heller, E. Aygören-Pürsün, H. Stoll, J. G. Kadar, 

W. Kreuz 

EVALUATION OF PEG-FVIII MOLECULES WITH PROLONGED HALF-LIVES IN A 

MURINE FVIII-DEPENDENT BLEEDING MODEL 

K. A. Landskroner (US), Z. Cui, D. Canivel, J. Newgren, H. Tjandra, J. Strauss, 

G. F. Pierce, G. J. Jesmok, T. Liu*, H. Jiang 

TEN YEARS FOLLOW UP OF HEREDITARY HAEMORRHAGIC PARIENTS IN DENTAL 

PRACTICE 

P. E. Makris* (GR), S. P. Makris, M. P. Makris 

COMPARISON OF PEGYLATED LIPOSOMAL FVIII INFUSION RATES IN HEMOPHILIA A 

U. Martinowitz* (IL), S. Lelazari, J. Luboshitz, A. Lubezki, J. Spira 

166



P-M-038 

P-M-039 

THROMBIN GENERATION ASSAY: CLINICAL USE IN MONITORING FVIII BYPASSING 

AGENT THERAPY DURING SURGERY IN A SEVERE HAEMOPHILIA A PATIENT WITH 

INHIBITOR 

Á. N. McCormick* (UK), T. Sunner, S. Rangarajan, G. F. Savidge 

FUNCTIONAL CHARACTERIZATION OF STRUCTURAL EPITOPES IN THE C2 DOMAIN 

OF FACTOR VIII 

S. L. Meeks* (US), J. F. Healey, R. T. Barrow, E. T. Parker, P. Lollar 

P-M-040 

P-M-041 

P-M-042 

THE FACTOR VIII C1 DOMAIN CONTRIBUTES TO EFFICIENT LRP/LDL RECEPTOR 

BINDING 

A. B. Meijer* (NL), V. Limburg, H. Meems, C. Van Der Zwaan, K. Mertens 

PATTERN OF FACTOR VIII INHIBITOR IN PATIENTS WITH HEMOPHILIA A 

A. Modaresi* (IR), H. Mansouri Torghabe 

BREAKPOINT CHARACTERIZATION IN HEMOPHILIA PATIENTS WITH LARGE 

DELETIONS IN THE FVIII GENE REVEALS INVOLVEMENT OF VARIOUS MUTATION 

MECHANISMS 

C. Mühle* (AT), J. Schröder, J. Oldenburg, H. Schneider 


Vitamin K dependent factors, incl. Factor IX 

P-M-043 

P-M-044 

P-M-045 

P-M-046 

P-M-047 

P-M-048 

P-M-049 

P-M-050 

N-GLYCAN SIALYLATION IS IMPORTANT FOR IN VIVO RECOVERY OF RECOMBINANT 

FACTOR IX 

M. J. Griffith* (US), D. M. Monroe, K. E. Van Cott, A. Walker, S. Waugh, A. Kumar, 

W. N. Drohan 

EFFECT OF VITAMIN K FOR WARFARIN REVERSAL ON ELEMENTS OF THE TISSUE 

FACTOR PATHWAY 

J. Needham* (UK), A. Blann, A. E. Milne 

PRION PROTEIN (PRPSC) REMOVAL BY CHROMATOGRAPHY PURIFICATION AND 

NANOFILTRATION OF FIXS AND PCC 

A. Neisser-Svae* (AT), L. Hoffer, L. Biesert, T. Schmidt, J. Roemisch, T. Svae 

PHARMACOKINETICS OF A PROTHROMBIN COMPLEX CONCENTRATE IN HEALTHY 

VOLUNTEERS 

H. Ostermann* (DE), S. Knaub 

MAGNESIUM IONS BIND TO THE FACTOR X (FX) GLA DOMAIN AND PROMOTE FX 

ACTIVATION BY FACTOR VIIA BOUND TO SOLUBLE TISSUE FACTOR (TF) BUT ACT 

INHIBITORY WHEN BOUND TO LIPIDATED TF 

E. Persson* (DK) 

PROTEOLYTIC CONVERSION OF CLOTTING FACTOR XA INTO A FIBRINOLYSIS 

ACCELERATOR 

E. L. G. Pryzdial* (CA), S. C. Meixner, K. Talbot 

REMOVAL OF HUMAN PARVOVIRUS B19 FROM FACTOR IX BY VIRUS FILTRATION 

S. Stagg (UK), A. Shackell, S. Fernando, P. L. Roberts, D. Evans, P. A. Feldman* 

A CHROMOGENIC METHOD FOR DETERMINATION OF FIXA IN PURIFIED 

PREPARATIONS 

P. Rosén (SE), M. Andersson, S. Rosén* 

167



P-M-051 

P-M-052 

P-M-053 

P-M-054 

P-M-055 

P-M-056 

P-M-057 

P-M-058 

AGE- AND GENDER-RELATED DIFFERENCES OF PLASMA PROTHROMBIN ACTIVITY 

LEVELS 

T. Sakata (JP), A. Okamoto, T. Morita, Y. Kokubo, K. Sato, A. Okayama, H. Tomoike, 

T. Miyata* 

FX DEFICIENCY: CHARACTERISTICS AND TREATMENT OUTCOME OF SEVEN CASES 

Z. Salcioglu* (TR), G. Aydogan, F. Akici, Z. Baslar, N. Aktay Ayaz, H. H. S. Sayilan Sen, 

O. Yanilmaz, H. Aldemir 

CIRCULATING MATRIX GLA PROTEIN: A POTENTIAL MARKER FOR VASCULAR 

COMPLICATIONS OF TYPE 2 DIABETES MELLITUS 

H. M. H. Spronk* (NL), H. R. Hansen, L. J. Schürgers, C. Vermeer, P. H. Reitsma, 

H. Ten Cate 

UNEXPECTED FINDING OF RAISED UNDERCARBOXYLATED FII (PIVKA-II) IN FVII 

DEFICIENCY 

S. Tulpule* (UK), S. Rangarajan, B. Madan, J. Cutler, M. Shearer 

A TURKISH PATIENT WITH COMBINED DEFICIENCY OF VITAMIN K-DEPENDENT 

CLOTTING FACTORS 

C. Ucar Albayrak* (TR), U. Caliskan 

FACTOR IX GENE VARIANTS AND THE RISK OF VENOUS THROMBOSIS 

R. Van Minkelen* (NL), S. R. Poort, A. Van Hylckama Vlieg, M. C. H. De Visser, 

H. L. Vos, F. R. Rosendaal, R. M. Bertina 

LONG-TERM WARFARIN THERAPY IS ASSOCIATED WITH TISSUE CALCIFICATION: 

INFLUENCE OF TREATMENT DURATION, AGE, AND GENDER 

P. Whittaker* (US), J. L. Donovan, K. Przyklenk 

DETERMINATION OF THE OESTROGEN RESPONSIVENESS OF A POLYMORPHIC 

ELEMENT IN THE HUMAN FACTOR IX GENE PROMOTER 

B. Adams (UK), P. R. Winship* 

Thrombin, thrombin receptors 

P-M-059 

P-M-060 

P-M-061 

P-M-062 

P-M-063 

P-M-064 

EFFECTS OF E5555, A PROTEASE-ACTIVATED RECEPTOR-1 ANTAGONIST, ON THE 

INFLAMMATORY MARKERS IN VITRO 

M. Kogushi* (JP), H. Yokohama, S. Kitamura, I. Hishinuma 

VARIEGIN, A NOVEL CLASS OF THROMBIN INHIBITOR FROM THE SALIVARY GLAND 

EXTRACT OF THE HARD TICK AMBLYOMMA VARIEGATUM 

C. Y. Koh* (SG), M. Kazimirova, A. Trimnell, P. Takac, M. Labuda, P. Nuttall, R. M. Kini 

ANTICOAGULANT PROPERTIES OF HD1, A (PRO)THROMBIN-DIRECTED DNA 

APTAMER 

C. A. Kretz* (CA), A. R. Stafford, J. C. Fredenburgh, J. I. Weitz 

STABILITY OF COAGULATION SYSTEM BASELINE STATE: A MATHEMATICAL MODEL 

N. A. Malush* (RU), M. A. Khanin, K. V. Tyurin 

STABILITY OF COAGULATION SYSTEM BASELINE STATE: A MATHEMATICAL MODEL 

N. A. Malush* (RU), M. A. Khanin, K. V. Tyurin 

CHANGES IN THROMBIN GENERATION KINETICS FOLLOWING HEMORRHAGIC 

SHOCK AND RESUSCITATION IN PIGS 

W. Z. Martini* (US), A. E. Pusateri, S. Colvin, J. R. Hess, J. B. Holcomb 

168



P-M-065 

P-M-066 

THROMBIN INDUCES MMP-10 IN HUMAN ENDOTHELIAL CELLS: 

PATHOPHYSIOLOGICAL IMPLICATIONS IN DISSEMINATED INTRAVASCULAR 

COAGULATION 

J. Orbe* (ES), J. A. Rodriguez, R. Montes, J. Hermida, J. C. Reverter, R. Serrano, 

J. A. Paramo 

RELEVANCE OF CA2+ ENTRY TO PLATELET AGGREGATION BY ACTIVATION OF 

THROMBIN RECEPTORS 

P. C. Redondo* (UK), I. Jardin, N. Ben-Amor, A. Bartegi, G. M. Salido, J. A. Rosado 

P-M-067 

P-M-068 

P-M-069 

PAR1 AGONISTS ACCELERATE ULCER HEALING IN RATS 

A. V. Rusanova* (RU), A. M. Makarova, T. V. Vasilieva, S. M. Strukova, Z. D. Bespalova 

THROMBIN CONCENTRATION AND PERMEABILITY OF FIBRIN CLOT 

A. V. Savushkin* (RU) 

MODULATION OF DENDRITIC CELL FUNCTION BY TISSUE FACTOR AND 

COAGUALTION PROTEASES 

S. Shrivastava* (UK), A. Dorling 


P-M-070 

P-M-071 

P-M-072 

P-M-073 

P-M-074 

P-M-075 

ANTI-APOPTOTIC EFFECTS OF SERINE PROTEINASES OF HEMOSTASIS AT 

GLUTAMATE-INDUCED NEUROTOXICITY 

S. M. Strukova* (RU), L. R. Gorbacheva, T. P. Storojevykh, V. G. Pinelis 

FACTOR V REMOVAL FROM BOVINE THROMBIN USED AS A TOPICAL HEMOSTAT IN 

SURGERY: IMPROVED PURITY THROUGH A NEW MANUFACTURING PROCESS 

A. Terrab* (US), D. Pawlak, D. Hoppensteadt, J. Fareed 

VALIDATION OF AN IMPROVED PRION AND VIRUS ELIMINATION PROCESS IN THE 

MANUFACTURE OF BOVINE THROMBIN, A TOPICAL HEMOSTAT USED IN SURGERY 

A. Terrab* (US), D. Pawlak 

MECHANISM OF BLOOD COAGULATION TRIGGERING: A MATHEMATICAL MODEL 

K. V. Tyurin* (RU), M. A. Khanin, A. Platonov 

THROMBIN GENERATION PARAMETERS IN A PLATELET-POOR PLASMA MODEL 

SYSTEM AND THEIR USE IN PATIENTS WITH SINGLE FACTOR DEFICIENCY 

J. R. Wu* (US), B. Bai 

GLYCOPROTEIN IB ALPHA BINDS THROMBIN VIA TO BOTH EXOSITE I AND II OF 

THROMBIN 

S. Yegneswaran* (US), R. McClintock, J. Roberts, Z. M. Ruggeri 

Protein C, Protein S, thrombomodulin 

P-M-076 

P-M-077 

P-M-078 

THE THROMBOMODULIN PROTEIN C SYSTEM PROTECTS AGAINST DIABETIC 

NEUROPATHY VIA TWO INDEPENDENT MECHANISMS 

B. Isermann* (DE), J. Blautzik, I. Vinnikov, S. Herzog, H. Weiler, A. Bierhaus, 

P. P. Nawroth 

DETERMINATION OF PROTEIN C LEVEL IN NEONATES WITH SEPSIS LIKE ILLNESS 

M. Karimi* (IR), N. Pishva, M. Shahbazi, A. Afrasiabi, N. Jamalian 

CLOTTING AND INFLAMMATION MARKERS WHEN INCLUDING RECOMBINANT 

ACTIVATED PROTEIN C (RAPC) IN SEPSIS THERAPY 

L. G. Klimovich* (RU) 

169



P-M-079 

P-M-080 

P-M-081 

P-M-082 

P-M-083 

P-M-084 

P-M-085 

P-M-086 

P-M-087 

P-M-088 

P-M-089 

P-M-090 

P-M-091 

THE PROTECTIVE ROLE OF PROTEIN C IN ENDOTOXIN-INDUCED SHOCK 

A. J. Lay* (US), D. Donahue, M. Tsai, F. J. Castellino 

DIRECT PROTECTIVE EFFECT OF ACTIVATED PROTEIN C ON MAST CELLS 

DEGRANULATION 

A. Makarova* (RU), L. Gorbacheva, T. Zamolodchikova, M. Smirnov, S. Strukova, 

L. Rumsh 

FREE PROTEIN S LEVELS DURING PREGNANCY 

P. A. Martinez* (AR), E. Reimer, J. Gilio 

PROTEIN S-C4BP COMPLEX STIMULATES ACTIVATED PROTEIN C-MEDIATED 

INACTIVATION AT R306 BUT INHIBITS INACTIVATION AT R506 IN FACTOR VA 

L. Maurissen* (NL), S. Thomassen, G. Nicolaes, B. Dahlbäck, G. Tans, J. Rosing, 

T. Hackeng 

FUNCTIONAL ANALYSIS OF SNPS SPECIFIC FOR HAPLOTYPE 1 (H1) OF THE GENE 

CODING FOR THE ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) 

P. Medina* (NL), F. España, H. L. Vos, R. M. Bertina 

CHEMOTHERAPY AFFECTS ACTIVATED PROTEIN C GENERATION TO A GREATER 

DEGREE IN NEWBORN THAN IN ADULT PLASMA 

T. Mewhort-Buist (CA), S. Patel, L. R. Berry*, A. K. C. Chan 

BASAL EXPRESSION OF ENDOTHELIAL CELL PROTEIN C RECEPTOR IS REGULATED 

BY ENDOGENOUS ALDOSTERONE, PRODUCED VIA ALDOSTERONE SYNTHASE 

M. Mirshahi (FR), E. Ducros*, S. Mirshahi, F. Leviel, A. Berthaut, J. Soria 

HUMAN MALIGNANT CELLS EXPRESS FUNCTIONALLY ACTIVE ENDOTHELIAL 

PROTEIN C RECEPTOR 

M. Mirshahi (FR), E. Ducros*, S. Darvishi, S. S. Mirshahi, J. Soria, A. Rafii Tabrizi 

UP-REGULATION OF ACTIVATED PROTEIN-C RECEPTOR ON HUMAN ENDOTHELIAL 

CELLS BY ALDOSTERONE 

M. Mirshahi (FR), E. Ducros*, S. Mirshahi, J. Soria 

PROTEIN C IN PATIENTS WITH METABOLIC SYNDROME 

E. G. Oganova* (BY) 

THE PROTEIN S THROMBIN SENSITIVE REGION CONTRIBUTES REGULATION OF 

WARFARIN TREATED DES-GAMMA-CARBOXYLATED PROTEIN S SECRETION: 

A STUDY OF A NOVEL SPLICE SITE MUTATION OF PROTEIN S GENE AND ITS 

MOLECULAR CONSEQUENCES 

H. Okada* (JP), S. Kunishima, M. Hamaguchi, A. Takagi, K. Yamamoto, J. Takamatsu, 

T. Matsushita, H. Saito, T. Kojima, T. Yamazaki 

TRANSCRIPTOME ANALYSIS OF THE PAR-1 MEDIATED ACTIVATION PATHWAY IN 

HUMAN MONOCYTES AND INTERACTIONS OF ACTIVATED PROTEIN C 

C. Pereira* (CH), E. B. Bachli, G. Schoedon 

THROMBIN GENERATION IN BEHÇET’S DISEASE: RELATIONSHIP WITH THROMBOSIS 

J. C. Reverter* (ES), G. Espinosa, C. Bores, G. De La Red, J. Monteagudo, A. Vidaller, 

D. Tassies 

170



Laboratory methods and experimental models 

P-M-092 

P-M-093 

FIBRIN GENERATION IS NOT SUPPRESSED IN PATIENTS WARFARINISED FOR 

VENOUS THROMBOEMBOLISM (VTE) 

J. L. Curnow* (AU), M. C. Morel-Kopp, M. Aboud, C. M. Ward 

PROTEOMIC ANALYSIS OF PLASMA FROM HAEMOPHILIA A PATIENTS AFTER 

FACTOR VIII CONCENTRATE INFUSION 

L. Dai* (UK), M. Mitchell, S. Rangarajan 

P-M-094 

P-M-095 

P-M-096 

THE NECESSITY OF CONTINUOUS INDIVIDUAL CALIBRATION IN CONTINUOUS 

FLUOROGENIC MEASUREMENT OF THE THROMBIN GENERATION CURVE 

E. De Smedt* (NL), R. Al Dieri, H. Spronk, H. Ten Cate, K. Hamulyak 

A NOVEL FLOW CYTOMETRIC METHOD FOR THE DETECTION OF RETICULATED 

PLATELETS BY AN ANTI-BROMODEOXYURIDINE MONOCLONAL ANTIBODY 

A. Gasparollo* (IT), A. Steffan, R. Tassan, M. Degan, V. Gattei, L. De Marco 

IN VITRO ASSESSMENT OF ANTICOAGULATION REVERSAL WITH ROTEM 

THROMBOELASTOMETRY 

A. Gatt* (UK), J. J. Van Veen, A. Woolley, P. C. Cooper, S. Kitchen, M. Makris 


P-M-097 

P-M-098 

P-M-099 

P-M-100 

P-M-101 

P-M-102 

P-M-103 

P-M-104 

P-M-105 

SIGNIFICANT VARIATION IN THROMBIN GENERATION POTENTIAL IN “ADEQUATELY” 

ANTICOAGULATED PATIENTS 

A. Gatt* (UK), J. J. Van Veen, A. Bowyer, P. C. Cooper, S. Kitchen, M. Makris 

ADDITION OF PRION REDUCTION FACTORS FROM SINGLE STEP EXPERIMENTS MAY 

OVERESTIMATE MANUFACTURING PROCESS CLEARANCE CAPABILITY 

W. Schäfer (DE), H. Pham, T. Martinelli, A. Gröner* 

AN INTEGRATED APPROACH TO EFFECTIVE PATHOGEN REDUCTION FOR A 

PLASMA-DERIVED VWF / FVIII CONCENTRATE 

A. Gröner* (DE), T. Nowak, W. Schäfer 

EFFECTIVE PATHOGEN REDUCTION FOR A PLASMA-DERIVED PROTHROMBIN 

COMPLEX CONCENTRATE THROUGH MULTIPLE DEDICATED MEASURES 

A. Gröner* (DE), T. Nowak, W. Schäfer 

PAEDIATRIC REFERENCE RANGES FOR COAGULATION DIAGNOSTICS 

S. Halimeh* (DE), G. Kappert, H. Rott, H. Trobisch 

ARGATROBAN IN PATIENTS AFTER CARDIOVASCULAR SURGERY: INFLUENCE ON A 

THROMBIN GENERATION ASSAY 

S. Harder* (DE), M. Merz, A. Koster 

DETERMINATION OF THE ANTICOAGULANT ACTIVITY OF IDRAPARINUX IN PATIENTS 

BY PROTHROMBIN-INDUCED CLOTTING TIME AND HEPTEST 

J. Harenberg* (DE), C. Giese, A. Hagedorn, I. Träger 

CORN TRYPSIN INHIBITOR AND THE CONTACT FACTOR PATHWAY IN THE THROMBIN 

GENERATION TEST (TGT) 

J. Hogwood* (UK), E. Gray 

AGE-RELATED REFERENCE RANGES FOR NEOPLASTINE R (PT) AND 

CEPHASCREEN (APTT) IN HEALTHY CHILDREN 

R. Summerhayes (AU), V. Ignjatovic*, M. Hall, P. Monagle 

171



P-M-106 

P-M-107 

P-M-108 

P-M-109 

P-M-110 

P-M-111 

P-M-112 

P-M-113 

P-M-114 

P-M-115 

P-M-116 

P-M-117 

MONITORING OF ORAL ANTICOAGULANT THERAPY IN CHILDREN: COMPARISON OF 

COAGUCHEK XS WITH VENOUS INR 

A. Greenway (AU), V. Ignjatovic*, R. Summerhayes, F. Newall, P. T. Monagle 

POTENTIAL USE OF AUTOMATED THROMBIN CLOTTING TIME (TCT) ASSAY FOR 

MONITORING UFH THERAPY 

V. Ignjatovic (AU), F. Newall*, L. Johnston, P. Monagle, R. Summerhayes 

REFERENCE VALUES FOR THROMBOELASTOGRAPHY IN HEALTHY CHILDREN 

P. Monagle* (AU), K. Chan, R. Summerhayes, V. Ignjatovic 

SOURCE AND USE OF REFERENCE RANGES IN HAEMOSTASIS: PRACTICE 

AMONGST UK NEQAS FOR BLOOD COAGULATION PARTICIPANTS 2005-6 

I. Jennings* (UK), D. P. Kitchen, S. Kitchen, T. A. L. Woods, I. D. Walker 

PROTEINOMIC PROFILING OF TISSUE FACTOR MEDIATED PROTHROMBIN 

ACTIVATION PRODUCTS AND THEIR INHIBITION BY DIRECT ANTITHROMBIN AND 

ANTI-XA AGENTS 

W. P. Jeske (US), M. Florian*, J. Maddineni, H. Zhu, D. Hoppensteadt, J. Fareed 

HUMAN VASCULAR ENDOTHELIAL CELLS INFLUENCE THE WHOLE BLOOD 

THROMBIN GENERATION ASSAY 

D. W. Jones* (UK), K. A. Tappenden, M. J. Gallimore, I. J. Mackie, H. P. Wendel, 

M. Winter, G. Evans 

AN EXTERNAL QUALITY ASSESSMENT PROGRAMME FOR PATIENT SELF-TESTING 

FOR MONITORING INRS- 2 YEARS OF RESULTS 

D. P. Kitchen* (UK), S. Kitchen, I. Jennings, T. A. L. Woods, I. D. Walker 

IMPLEMENTING AN EXTERNAL QUALITY ASSESSMENT PROGRAMME FOR USERS 

OF COAGUCHEK XS AND COAGUCHEK XS PLUS FOR MONITORING INRS 

D. P. Kitchen* (UK), S. Kitchen, I. Jennings, T. A. L. Woods, I. D. Walker 

LIPIDS, MICROPARTICLES AND COAGULATION FACTORS AS DETERMINANTS OF 

LAG PHASE AND RATE OF THROMBIN GENERATION IN PLASMA 

C. Kluft* (NL), P. Meijer, R. Kret, V. Kaufmann, J. Mager, B. R. Binder 

THE THROMBIN GENERATION TEST NEEDS TO BE SUPPLEMENTED WITH 

ADDITIONAL TESTS TO FULLY DOCUMENT THE EFFECTS OF THROMBIN 

INHIBITORS: EVALUATION FOR MELAGATRAN 

C. Kluft* (NL), P. Meijer, R. Kret 

FUNCTIONAL COAGULATION ANALYSIS IN PATIENTS WITH BLOOD COAGULATION 

DISORDERS OR HYPERCOAGULABILITY: SIGNIFICANCE OF WHOLE BLOOD 

ROTATION THROMBELASTOGRAPHY IN COMPARISON WITH CONVENTIONAL BLOOD 

COAGULATION ANALYSIS 

P. N. Knoebl* (AT), S. Kopp, M. Mladenov, G. Stiegler, P. Quehenberger 

COAGUCHEK XS IN COMPARISON TO BCS ANALYZER. RESULTS IN AN OUTPATIENT 

ANTICOAGULATION CLINIC, FOCUSED IN METAL VALVE DISEASE 

P. Kotsi (GR), C. Tsoucala*, I. Anastasopoulou, A. Chanos, A. Karafoulidou 

172



Haemorrhagic disorders 

Haemophilia A and B 

P-M-118 

HEMOSTASIS IN FACTOR VIII DEFICIENT MICE IS IMPROVED AFTER THE INFUSION 

OF MONOCYTE-DERIVED MICROPARTICLES 

A. Akram (CA), J. M. Teitel, J. J. Freedman, P. L. Gross* 

P-M-119 

P-M-120 

P-M-121 

INCREASED AGE RELATED EXPRESSION OF FVIII IN TWO UNRELATED FEMALES 

WITH SEVERE HEMOPHILIA A AND NONRANDOM X-INACTIVATION 

R. A. Gruppo* (US), V. V. Balasa, S. Davies 

INCREASED FIBRINOLYISIS ASSOCIATED WITH DEFECTIVE COAGULATION 

CONTRIBUTES TO IMPAIRMENT OF HEMOSTASIS IN HEMOPHILIA 

S. He* (SE), A. Eelde, M. Blomback 

MOLECULAR CHARACTERIZATION OF A 4.4MBP DELETION OF THE HUMAN X 

CHROMOSOME IN A PATIENT WITH HAEMOPHILIA B 

J. Hewitt* (CA), E. Chou, L. A. Brown, D. G. Huntsman, C. Brown, S. Yong, 

L. D. Wadsworth, J. Wu, R. T. A. MacGillivray, V. C. Smith 


P-M-122 

P-M-123 

P-M-124 

P-M-125 

P-M-126 

P-M-127 

P-M-128 

P-M-129 

LOW INTENSITY LASER THERAPY SPEEDS WOUND HEALING IN HEMOPHILIA B MICE 

M. Hoffman* (US), A. G. McDonald, D. M. Monroe 

THE EXPRESSION OF PLATELET RECEPTORS AND MARKERS OF PLATELET 

ACTIVATION IN PATIENTS WITH HEMOPHILIA A AND VON WILLEBRANDS DISEASE 

M. Holmström* (SE), S. Schulman, M. Sten-Linder, N. Soutari, N. Egberg 

GENETIC DEFECT DETECTION OF HEMOPHILIA A BY LONG RANGE POLYMERASE 

CHAIN REACTION AND DENATURING HIGH-PERFORMANCE LIQUID 

CHROMATOGRAPHY 

S. Hu* (TW), Y. Chen, S. Cheng, T. Chao, W. Tsai, J. Chiang, S. Huang 

GENETIC DEFECT DETECTION OF HEMOPHILIA A BY LONG RANGE POLYMERASE 

CHAIN REACTION AND DENATURING HIGH-PERFORMANCE LIQUID 

CHROMATOGRAPHY 

S. Hu (TW), Y. Chen*, S. Cheng, T. Chao, W. Tsai, J. Chiang, S. Huang 

ANALYSIS OF DISCREPANT ASSAY-DETERMINED ACTIVITY LEVELS OF FACTOR VIII 

ASSOCIATED WITH R531H MUTATION 

H. Inaba* (JP), Y. Yatomi, K. Shinozawa, M. Otaki, T. Suzuki, K. Amano, K. Fukutake 

HAEMOPHILIA MANAGEMENT THROUGH AN INTER-REGIONAL NETWORK IN MIDDLE 

ITALY 

A. Dragani* (IT), E. Marchesini, M. Carloni, E. Oliovecchio, F. Ferrante, O. Iuliani, 

G. Agnelli, A. Iorio 

SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS OF PROPHYLACTIC 

CLOTTING FACTOR CONCENTRATE IN HEMOPHILIA 

A. Iorio* (IT), K. Stobart 

THE HEMOPHILIA REGISTRY OF THE ITALIAN ASSOCIATION OF HEMOPHILIA 

CENTRES 

A. Iorio* (IT), A. Gringeri, J. Hassan, P. Iannaccaro, M. Morfini, G. Rossetti, A. Scaraggi, 

M. Schiavoni, P. Schinco, A. Tagliaferri 

173



P-M-130 

P-M-131 

P-M-132 

P-M-133 

P-M-134 

P-M-135 

P-M-136 

P-M-137 

P-M-138 

P-M-139 

P-M-140 

P-M-141 

P-M-142 

LIVING DONOR LIVER TRANSPLANTATION FOR HBV-ASSOCIATED HEPATOMA 

IN A HEMOPHILIC PATIENT 

H. C. Kim* (KR), H. J. Wong, J. Y. Chung, K. H. Koh 

INHIBITOR DEVELOPMENT IN 3 PATIENTS WITH HEMOPHILIA A AFTER INTENSIVE 

EXPOSURE TO FVIII CONCENTRATES BY CONTINUOUS INFUSION – DATA FROM 

SLOVENIA 

L. Kitanovski* (SI), D. Andoljsek, M. Benedik Dolnicar 

SECOND INTERIM ANALYSIS OF A LONG-TERM PHARMACOVIGILANCE PROJECT 

WITH A PLASMA DERIVED FVIII CONCENTRATE 

R. Klamroth* (DE), R. Zimmermann, C. Zacharias, S. Knaub, K. Kurnik for the 

Beriate ® P Pharmacovigilance Group 

FEMALE HEMOPHILIA A - TWO UNUSUAL CASES DUE TO SKEWED 

X-INACTIVATION 

K. E. Knobe* (SE), M. J. Soller, E. Sjörin, R. C. R. Ljung 

STUDIES OF MRNA IN PATIENTS WITH UNDETECTABLE MUTATIONS IN GENOMIC 

DNA 

K. E. Knobe* (SE), E. Sjörin, R. C. R. Ljung 

GASTROINTESTINAL BLEEDING DUE TO MECKEL’S DIVERTICULUM IN A 

HEMOPHILIAC WITH INHIBITORS 

P. L. Koh* (SG), K. Prabhakaran, T. C. Quah 

THE ROLE OF RACE AND ETHNICITY IN THE CLINICAL OUTCOMES OF SEVERE 

HEMOPHILIA A PATIENTS WITH INHIBITORS 

R. Kruse-Jarres* (US), N. M. Pajewski, C. A. Leissinger 

COMPARISON OF THE IMMUNOGENICITY OF DIFFERENT THERAPEUTIC 

PREPARATIONS OF HUMAN FACTOR VIII IN THE MURINE MODEL OF HEMOPHILIA A 

S. Lacroix-Desmazes (FR), S. Delignat*, S. Dasgupta, A. Navarrete, S. V. Kaveri, 

Z. Tellier, S. Chtourou 

PROPOSITION FOR A MULTI-STEP MUTATION DETECTION IN HAEMOPHILIA A 

N. Lannoy* (BE), I. Abinet, C. Verellen, C. Vermylen, C. Hermans, K. Dahan 

A WHOLE BLOOD CLOTTING METHOD MEASURING EX VIVO EFFECTS OF RFVIIA 

AND FVIII IN HAEMOPHILIA BLOOD 

L. F. Larsen* (DK), M. Ezban, U. Hedner, E. M. Nicolaisen, L. Tengborn 

PRIMARY KNEE ARTHOPLASTY USING RECOMBINANT FACTOR VIIA (RFVIIA) AS 

FIRST-LINE THERAPY IN HAEMOPHILIA PATIENTS WITH HIGH RESPONDING 

INHIBITORS 

Y. D. Laurian* (FR), G. Tagariello, V. Jimenez Yuste, A. Kurth, T. Lambert, R. Nunez, 

N. Goddard, M. Morfini 

CRYOPRECIPITATE-REMOVED PLASMA AS A SOURCE OF FACTOR IX IN THE 

TREATMENT OF HEMOPHILIA B 

L. P. Lepatan* (PH), F. G. Hernandez, M. M. Montoya, J. B. Ong, E. V. Rodriguez, 

M. N. Chua 

SEVERE HEMOPHILIA A AND FACTOR VIII INHIBITOR OCCURS IN A YOUNG GIRL 

WHO HAS A CARRIER MOTHER, TURNER SYNDROME AND CHROMOSOMAL 

STRUCTURAL ABNORMALITIES WITH 45,X(22)/46,X,IDIC(X)(Q21)(8) 

H. Y. Lin* (TW), M. Chen, H. H. Chang, Y. L. Yang, C. Y. Chung, C. S. Chang, 

M. C. Shen 

174



Haemophilia therapy 

P-M-143 

P-M-144 

EFFICACY AND SAFETY OF HIGH DOSES OF FEIBA FOR MAJOR SURGERY 

IN A PATIENT WITH HAEMOPHILIA A AND HIGH-TITRE INHIBITOR 

G. Gamba* (IT), R. Longoni, R. Vanelli, N. Montani, L. Bocchi 

EVALUATION BY SURFACE PLASMON RESONANCE OF VWF EFFECT ON 

MONOCLONAL ANTIBODY DIRECTED TO FVIII LIGHT CHAIN REACTIVITY 

S. Grancha* (ES), J. I. Jorquera 

P-M-145 

P-M-146 

P-M-147 

HEMOPHILIA A INHIBITOR AND AUTOIMMUNNEUTROPENIA: CASE REPORT 

S. I. Heine* (DE), H. Reinhard, G. Pindur, N. Graf 

OPTIMIZING RFVIIA TREATMENT 

M. Hulikova* (SK), J. Hulikova 

ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN HEMOPHILIA PATIENTS WITH 

HUMAN IMMUNODEFICIENCY VIRUS 

A. Iorio* (IT), E. Marchesini, G. Agnelli 


P-M-148 

P-M-149 

P-M-150 

P-M-151 

P-M-152 

P-M-153 

P-M-154 

P-M-155 

NATIONAL STUDY OF INHIBITOR KINETICS AND TREATMENT RESPONSE IN 

HEMOPHILIA A AND B MEXICAN PATIENTS 

H. Luna (MX), C. Beltran, J. Mantilla, J. Lopez, I. Torres, J. Mundo, A. Esparza, 

A. R. Jaloma* 

RADIOISOTOPE SYNOVECTOMY WITH RHENIUM 186 FOR TREATMENT OF 

HEMOPHILIC SYNOVITIS 

K. Kavakli* (TR), S. Aydogdu, M. Taner, Y. Duman, K. Capaci, C. Balkan, D. Yilmaz, 

A. Oktay, G. Saydam 

10-YEARS EFFICACY, SAFETY AND INHIBITORS IN ONE PLASMA-DERIVED 

FACTOR VIII CONCENTRATE 

S. Gottstein (DE), M. Orlovic, C. Heinrichs, R. Klamroth* 

SUCCESSFUL ANGIOGRAPHIC EMBOLIZATION OF RECURRENT ELBOW JOINT 

BLEEDS IN FIVE PATIENT WITH SEVERE HAEMOPHILIA A 

R. Klamroth* (DE), E. Essers, S. Gottstein, M. Wilaschek, J. Oldenburg 

EVALUATION OF EFFICACY OF RADIOACTIVE SYNOVECTOMY IN RECURRENT JOINT 

BLEEDING IN HAEMOPHILIA 

A. Klukowska* (PL), Z. Czyrny, L. Krolicki, P. Laguna, M. Brzewski 

ANTIVIRAL TREATMENT OF HCV INFECTED YOUNG HAEMOPHILIACS – AN UPDATE 

OF 14 YEARS EXPERIENCE IN A PRIVATE PRACTICE CCC 

K. E. Koehler-Vajta* (DE), G. Froesner, R. Zachoval 

TRANSITION TO STANDARD HAEMOSTATIC THERAPY SCHEMES OF HEMOPHILIA IN 

RUSSIA (THE NATIONAL TREATMENT PROTOCOL FOR HEMOPHILIA PATIENTS) 

L. Kudryavceva* (RU), O. Plyushch, K. Kopylov, I. Tentsova, E. Likhacheva, E. Lopatina 

HAEMOTHORAX IN A BOY WITH SEVERE HAEMOPHILIA AND FACTOR VIII INHIBITOR 

P. Laguna* (PL), A. Klukowska, M. Brzewski, M. Matysiak 

175



P-M-156 

P-M-157 

P-M-158 

P-M-159 

P-M-160 

P-M-161 

EVALUATION OF THE EFFECTS OF A SINGLE INFUSION OF FACTOR VIII ON WHOLE 

BLOOD COAGULATION THROMBOELASTOGRAPHY IN PATIENTS WITH SEVERE 

HAEMOPHILIA 

C. Lambert* (BE), B. Dessomme, V. Deneys, C. Hermans 

REFORMULATED RECOMBINANT FACTOR IX: EFFICACY AND SAFETY IN 

PREVIOUSLY TREATED PATIENTS WITH MODERATELY SEVERE TO SEVERE 

HEMOPHILIA B 

T. Lambert* (FR), M. Recht, L. Valentino, J. S. Powell, C. Udata, S. T. Sullivan, 

D. A. Roth 

CLINICAL EXPERIENCE WITH A HIGH PURITY FACTOR IX CONCENTRATE IN YOUNG 

CHILDREN 

J. M. Lee* (UK), C. H. Dash, M. Matysiak, O. Stasyshyn, V. Drozdova, K. Vilchevska 

USE OF A HIGH PURITY FACTOR IX (FIX) CONCENTRATE IN SURGERY 

J. M. Lee* (UK), C. H. Dash, T. Chernova, T. Baglin, P. Collins, M. Serban, C. Hay, 

M. Matysiak, V. Mitchell, O. Plyusch, L. Rusen, O. Stasyshyn 

PERCUTANEOUS CATHETER EXTRACTION OF A RUPTURED PORT-A-CATH IN A 

SMALL CHILD WITH HAEMOPHILIA A AND F VIII INHIBITOR USING CONTINUOUS 

INFUSION OF RFVIIA 

G. Lischetzki* (DE), H. Topf, M. Rauh, A. Koch 

“PRIMARY” PROPHYLACTIC TREATMENT WITH RECOMBINANT ACTIVATED 

FACTOR VII (RFVIIA) DURING INMUNE TOLERANCE IN A HAEMOPHILIC CHILD 

M. Lopez Fernandez* (ES), C. Andon Saavedra, M. A. Amor Otero, J. Batlle 

Recombinant activated Factor VIIa or APCC 

P-M-162 

P-M-163 

P-M-164 

P-M-165 

P-M-166 

P-M-167 

RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF ACUTE POST 

PARTUM HEMORRHAGE: THE ITALIAN REGISTRY 

G. Barillari* (IT), M. Frigo, S. Malacarne, O. Ulrich, G. Farnia 

HIGH DOSES OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) IN A HEMOPHILIA A 

PATIENT WITH INHIBITOR 

C. Berger* (FR), J. Mattei, J. Reynaud, S. Thouvenin, C. Jerome, J. Stephan 

RECOMBINANT FVIIA USE IN THREE PRETERM NEONATES WITH DISSEMINATED 

INTRAVASCULAR COAGULATION 

S. G. Berrak* (TR), B. F. Cakir, B. D. Beker, C. Canpolat, E. Altuncu, H. Bilgen, E. Ozek 

USE OF RECOMBINANT FACTOR VIIA (RFVIIA) IN THE MANAGEMENT OF MAJOR 

HAEMORRHAGE- A SURVEY OF CURRENT UK PRACTICE 

T. T. Biss* (UK), J. P. Hanley 

RFVIIA IS EFFECTIVE ALTERNATIVE TO APCC IN PROPHYLAXIS OF BLEEDING 

DURING IMMUNE TOLERANCE PROTOCOL IN HAEMOPHILIAC WITH INHIBITOR 

J. Blatny* (CZ), S. Kohlerova, O. Zapletal, V. Fiamoli, M. Penka 

USE OF RFVIIA IN ELECTIVE SURGERY IN CASES WITH CONGENITAL 

COAGULOPATHIES AND INHIBITORS 

A. Boadas* (VE), A. Ruiz-Saez, F. Fernandez-Palazzi, M. Cedeño, S. Pachano, A. Aguiar, 

N. De Bosch 

176



P-M-168 

P-M-169 

COST-EFFECTIVENESS (CE) OF ACTIVATED PROTHROMBIN COMPLEX 

CONCENTRATE (APCC) VS. RECOMBINANT FVIIA IN PROPHYLAXIS IN HEMOPHILIA 

PATIENTS WITH INHIBITORS 

P. Bonnet (US), B. Yoon*, B. Ewenstein, W. Wong 

HEMOPHILIA PATIENTS WITH INHIBITORS UNDERGOING MAJOR ORTHOPEDIC 

SURGERIES: COST-MINIMIZATION ANALYSIS OF ACTIVATED PROTHROMBIN 

COMPLEX CONCENTRATE (APCC) AND RECOMBINANT FVIIA 

P. Bonnet (US), B. Yoon*, B. Ewenstein, W. Wong 

P-M-170 

P-M-171 

P-M-172 

WALL CLOT GROWTH IN PLASMA: EFFECT OF HIGH DOSES RECOMBINANT FVIIA 

J. Bordet* (FR), M. Ovanesov, J. Plantier, V. Volpert, F. Ataullakhanov, C. Négrier 

ECONOMIC BENEFITS OF KNEE SURGERY WITH RECOMBINANT ACTIVATED 

FACTOR VII IN HEMOPHILIA PATIENTS WITH INHIBITORS 

M. F. Botteman (US), R. Ballal, A. Joshi* 

RECOMBINANT ACTIVATED FACTOR VII VS. ACTIVATED PROTHROMBIN COMPLEX 

CONCENTRATE AS ON-DEMAND TREATMENT OF JOINT BLEEDS IN HEMOPHILIACS 

WITH INHIBITORS: A SYSTEMATIC LITERATURE REVIEW 

F. McCraken (UK), S. Thurston, A. Joshi*, B. Heeg, B. Verheggen, M. F. Botteman, 

B. Van Hout 


P-M-173 

P-M-174 

P-M-175 

P-M-176 

EFFECT OF RECOMBINANT FACTOR VIIA VARIANT (NN1731) ON PLATELET 

FUNCTION, CLOT STRUCTURE AND FORCE ONSET TIME IN BLOOD FROM HEALTHY 

VOLUNTEERS AND HEMOPHILIA PATIENTS 

D. F. Brophy* (US), E. J. Martin, M. E. Nolte, J. G. Kuhn, M. E. Carr, M. Ezban 

PROTHROMBIN COMPLEX CONCENTRATE FOR REVERSAL OF ORAL 

ANTICOAGULATION THERAPY IN URGENT SITUATIONS. EXPERIENCE OF A SINGLE 

CENTER 

M. Carvalho* (PT), J. Carneiro, C. Monteiro, R. Pereira 

LOW-DOSE (1.2MG) RFVIIA TO REVERSE WARFARIN THERAPY IN CRITICALLY ILL 

PATIENTS WITH MAJOR BLEEDING 

W. E. Dager* (US), J. H. King, R. C. Gosselin, R. C. Regalia, P. Rivera, D. Williamson, 

J. T. Owings, R. H. White 

MONITORING OF RECOMBINANT FVIIA BY THROMBIN GENERATION TEST 

Y. Dargaud* (FR), A. Lienhart, C. Négrier 

Inherited and acquired platelet disorders 

P-M-177 

P-M-178 

P-M-179 

GPIIB-IIIA INTEGRIN MUTATIONS IDENTIFIED IN 19 GLANZMANN THROMBASTENIC 

PATIENTS AND 3 CARRIERS 

V. Jallu* (FR), C. Kaplan 

ELTROMBOPAG, THE ORAL PLATELET GROWTH FACTOR, INCREASED PLATELET 

COUNT AND DID NOT AFFECT PLATELET FUNCTION WHEN ADMINISTERED TO 

HEALTHY MALE SUBJECTS 

J. M. Jenkins* (US), D. A. Collins, D. Williams, V. S. Kitchen 

8 NOVEL MUTATIONS IDENTIFIED GLANZMANN THROMBASTHENIA FAMILIES FROM 

CHINA 

P. Jin* (CN), X. Wang, Q. Ding, H. Wang 

177



P-M-180 

P-M-181 

P-M-182 

P-M-183 

P-M-184 

P-M-185 

P-M-186 

P-M-187 

P-M-188 

P-M-189 

P-M-190 

FUNCTIONAL ANALYSES OF THE LEU752ARG AND GLN891STOP ASSOCIATED WITH 

GLANZMANN THROMBASTHENIA 

P. Jin* (CN), X. Wang, Q. Ding, H. Wang 

GENETIC ANALYSIS OF BERNARD SOULIER PATIENTS IN IRAN: REPORT OF FIVE 

NOVEL MUTATIONS 

A. Kazemi* (IR), A. Taghavi, M. Faranoush, F. A. Ala, G. Rastegar Lari, M. Jazebi, 

S. Ravanbod, M. Rassoulzadegan, M. Baghaipour 

CONTRIBUTION OF ROTATION THROMBOELASTOGRAPHY (RT) IN PERIOPERATIVE 

MANAGEMENT OF PATIENTS WITH GLAZMANN’S THROMBASTHENIA (GT) 

P. Kotsi (GR), A. Kouramba*, I. Anastasopoulou, E. Laiou, C. Tsoucala, O. Katsarou, 

A. Karafoulidou 

THE EFFECT OF INTRANASAL DESMOPRESSIN VS. ORAL TRANEXAMIC ACID ON 

MENSTRUAL BLOOD LOSS AMONG WOMEN WITH MENORRHAGIA AND ABNORMAL 

LABORATORY HEMOSTASIS: A MULTICENTER, RANDOMIZED CROSS-OVER STUDY 

P. A. Kouides* (US), J. A. Heit, C. S. Philipp, S. F. Stein, A. S. Lukes, N. I. Skerrette, 

V. R. Byams, N. F. Dowling, C. H. Miller, R. Kulkarni 

DIFFERENTIAL DETECTION OF WILD-TYPE AND MUTANT MYH9 MRNA AND 

NMMHC-IIA POLYPEPTIDE REVEALS DOMINANT-NEGATIVE EFFECT IN 

GRANULOCYTES AND HAPLOINSUFFICIENCY IN PLATELETS IN PATIENTS WITH 

MYH9 DISORDERS 

S. Kunishima* (JP), T. Matsushita, T. Kojima, H. Okada, T. Yamazaki, M. Hamaguchi, 

H. Saito 

IMMUNOGLOBULINE ANTI-D (WINRHO) IN CRHONIC CHILDOOD IDIOPATHIC 

THROMBOCYTOPENIC PURPURA (ITP), ANALYSIS OF “IMMATURE PLATELET 

FRACTION (I.P.F.)” AND ASYMPTOMATIC THROMBOCYTOPENIA 

G. Mancuso* (IT), F. Gagliano, G. Licastro, M. Calabrò, M. Diquattro 

RFVIIA IN THE TREATMENT OF GLANZMANN'S THROMBASTHENIA - CASE REPORT 

L. Marques (PT), M. Alves, M. Antunes*, M. Diniz 

LABORATORY CHARACTERISTICS OF WOMEN WITH MENORRHAGIA: A MULTI-SITE 

U.S. STUDY 

C. H. Miller* (US), J. A. Heit, P. A. Kouides, A. S. Lukes, C. S. Philipp, S. F. Stein, 

N. Dowling, V. R. Byams, P. Rawlins, R. Kulkarni 

JAK2 V617F MUTATION IS ASSOCIATED WITH THE LEUKOCYTE COUNT AND BONE 

MARROW CD34+ CELLS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 

M. J. Moreno* (ES), C. Martinez, J. Rivera, F. Ferrer, L. Navarro-Nuñez, F. Ortuño, 

V. Vicente, M. L. Lozano 

CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA (CAMT): CLINICAL AND 

BIOLOGICAL CHARACTERIZATION OF FIVE NEW MUTATIONS 

P. Noris* (IT), A. Savoia, C. Dufour, F. Locatelli, F. Di Bari, C. Ambaglio, V. Rosti, 

M. Zecca, S. Ferrari, A. Corcione, M. Di Stazio, M. Seri, C. Balduini 

TREATMENT OF GASTROINTESTINAL BLEEDING AND ANGIODYSPLASIA IN 

GLANZMANN THROMBASTHENIA WITH OCTREOTIDE 

C. Faurie-Bonnafous* (FR), S. Clayessens, J. Viallard, D. Laharie, A. T. Nurden, 

P. Nurden, P. Sié 

178



P-M-191 

PREDICTION OF PRIMARY HEMOSTATIC DEFECT TYPE AND SEVERITY WITH THE 

PFA-100 CLOSURE TIME 

B. R. Gudmundsdottir* (IS), M. Agustsdottir, P. T. Onundarson 

Inherited coagulation disorders 

P-M-192 

P-M-193 

P-M-194 

VITAMIN K-INDUCED VARIATION OF COAGULATION PHENOTYPE IN VKORC1 

HOMOZYGOUS DEFICIENCY 

G. Marchetti* (IT), B. Lunghi, M. Lapecorella, A. Canella, P. Caruso, G. Mariani, 

F. Bernardi, S. Sbrighi 

A RARE CONGENITAL BLEEDING DISORDER: F.VII DEFICIENCY (CASE REPORT) 

K. Martinova* (MK), O. Muratovska, S. Glamocanin, Z. Antevska, B. Coneska, S. Koceva 

TWO NOVEL MUTATIONS AND FOUR NOVEL POLYMORPHISMS IN THE FACTOR VII 

GENE 

N. C. J. Mathijssen* (NL), M. Den Heijer, P. C. M. Van Hoogen, S. C. M. Schoormans, 

M. G. J. Van Kraaij, I. R. O. Nováková, W. L. Van Heerde 


P-M-195 

P-M-196 

P-M-197 

P-M-198 

P-M-199 

P-M-200 

P-M-201 

P-M-202 

HEREDITARY DYSFUNCTIONAL FACTOR X – IS THAT PASSOVOY FACTOR? 

S. C. Nair (IN), S. Baidya*, D. Sukumaran, V. Sudhakar, A. Srivastava 

A MULTICENTRE PROSPECTIVE OPEN-LABEL STUDY ASSESSING 

PHARMACOKINETICS, CLINICAL EFFICACY AND SAFETY OF A TRIPLE-SECURED 

FIBRINOGEN CONCENTRATE: FIBRINOGENE T-I 

C. Négrier* (FR), J. Borg, S. Claeyssens, P. De Moerloose, M. Dreyfus, J. Goudemand, 

Y. Gruel, F. Peyvandi, C. Rothschild, M. Alessi, J. Scherrmann, T. Waegemans, 

B. Padrazzi 

HOMOZYGOUS FACTOR V DEFICIENCY WITH MILD CLINICAL PHENOTYPE 

J. Hewitt* (CA), K. Talbot, J. Song, M. Ho, E. L. G. Pryzdial, R. T. A. MacGillivray, 

C. J. Carter 

THE CANADIAN RARE INHERITED BLEEDING DISORDERS REGISTRY (RIBDR) OF 

COAGULATION FACTOR DEFICIENCIES AND PLATELET FUNCTION DISORDERS 

M. L. Rand* (CA), D. Clark, I. Walker, J. Wu 

GENETIC ANALYSIS OF PATIENTS WITH FACTOR XIII DEFICIENCY IN IRAN: REPORT 

OF FOUR NOVEL MUTATIONS 

G. Rastegar Lari* (IR), G. Tamaddon, P. Eshghi, S. Hejazi, S. Ravanbod, 

M. Rassoulzadegan, M. Baghaipour, M. Jazebi, M. Faranoush, A. Tabatabaey, 

M. S. Enayat, F. A. Ala, A. Kazemi 

ANKLE REPLACEMENT IN SEVERE BLEEDING DISORDERS: RETROSPECTIVE STUDY 

ON 17 CASES 

P. Rospide* (FR), J. Asencio, B. Di Fazio, C. Leonardi, B. Polack, R. Navarro, 

C. Biron-Andreani, J. Schved 

NORMAL VALUES FOR FACTOR VII ACTIVITY IN NORMAL PREGNANCY AND IN THE 

PREGNACY OF WOMEN WITH CONGENITAL FACTOR VII DEFICIENCY 

H. Rott* (DE), G. Kappert, S. Halimeh, H. Trobisch 

SEVERE FACTOR XI DEFICIENCY IN PREGNANT WOMEN: A PROTOCOL FOR 

LABOUR MANAGEMENT WITH FACTOR XI CONCENTRATE 

M. M. Salces* (ES), V. J. Yuste, M. A. Román, I. F. Bello, M. Q. Molina, J. R. Garrido, 

F. H. Navarro 

179



P-M-203 

P-M-204 

P-M-205 

P-M-206 

P-M-207 

P-M-208 

P-M-210 

P-M-211 

P-M-212 

A DECREASED INCIDENCE RATE OF ISCHEMIC STROKE IN PATIENTS WITH SEVERE 

FACTOR XI DEFICIENCY SUGGESTS THAT THE DEFICIENCY CONFERS PROTECTION 

O. Salomon* (IL), D. M. Steinberg, N. Koren-Morag, U. Seligsohn 

NOVEL MUTATIONS IN THE FACTOR V GENE OF TAIWANESE FACTOR V DEFICIENCY 

PATIENTS 

M. C. Shen* (TW), Y. F. Wu, B. D. Lin, H. Y. Lin, J. S. Lin, T. Y. Chung, C. H. Chang 

COAGULATION ABNORMALITIES IN WOMEN WITH VERIFIED MENORRHAGIA – IS IT 

TIME FOR INCLUSION OF COAGULATION SCREENING IN DIAGNOSTIC ALGORITHM? 

S. M. Simic (RS), N. Andjelkovic*, P. Djurdjevic, A. L. Djukic, J. Antovic 

A NOVEL MECHANISM FOR CONGENITAL AFIBRINOGENEMIA BASED ON 

PSEUDOEXON ACTIVATION IN THE FIBRINOGEN GAMMA-CHAIN GENE 

S. Spena* (IT), R. Asselta, M. Platè, G. Castaman, S. Duga, M. L. Tenchini 

DATABASE ON RARE BLEEDING DISORDER (RBDS): PHENOTYPE AND GENOTYPE 

ANALYSIS ON 400 AFFECTED PATIENTS 

M. Spreafico* (IT), M. Menegatti, I. Garagiola, R. Palla, L. Tagliabue, M. Karimi, M. Lak, 

A. Srivastava, R. Saxena, S. Shetty, K. Kavakli, M. B. Dolnicar, S. Aronis-Vournas, 

R. Asselta, S. Duga, P. M. Mannucci, F. Peyvandi 

FACTOR VII GENOTYPE AND CLINICAL PROFILE IN 6 IRANIAN PATIENTS WITH 

CONGENITAL FACTOR VII DEFICIENCY 

A. Tabatabaey* (IR), S. Ravanbod, M. Baghaipour, M. Enayat, F. Ala, G. Rastegar-Lari 

SEVERE FACTOR VII DEFICIENCY DUE TO MUTATIONS IN THE FACTOR VII GENE 

PROMOTER 

O. Chafa (DZ), R. Kastally, A. Reghis, A. M. Fischer, J. Tapon-Bretaudière*, M. L. Aubry 

EVALUATION OF LIPOPROTEIN (A) IN ARGENTINIAN WOMEN WITH ADVERSED 

PREGNANCY OUTCOME 

M. E. Vega-Ostertag* (AR), J. M. Marquez, R. R. Forastiero, F. Pagani 

COMBINED FACTOR V AND FACTOR VIII DEFICIENCY IN INDIA - A SERIES OF 

31 PATIENTS 

A. Viswabandya* (IN), S. C. Nair, S. Baidya, V. Mathews, B. George, M. Chandy, 

A. Srivastava 

Acquired coagulation disorders incl. DIC 

P-M-213 

P-M-214 

P-M-215 

P-M-216 

TREATMENT OF DIC AS A COMPLICATION OF POLYTRANSFUSION AT PATIENT WITH 

OBSTETRIC HEMORRHAGE-CASE REPORT 

R. S. Apostolovska* (MK), S. Kostovska, V. Dejanova, V. Neceva, V. Zaturovska 

CHILDHOOD GERM CELL TUMOR PRECEDING BY CHRONIC LONGSTANDING DIC 

S. Alavi* (IR), M. Arzanian, S. Shamsian, H. Mahmoodi 

POINT OF CARE INR MONITORING IN CHILDREN WITH VENTRICULAR ASSIST 

DEVICES 

M. E. Bauman* (CA), J. Conway, H. Buchholz, I. Rebeyka, M. Massicotte, L. Mitchell 

WHOLE-BLOOD CLOTTING FOR EVALUATING THROMBIN GENERATION IN CHRONIC 

LIVER FAILURE 

F. Carmassi* (IT), N. De Bortoli, P. Pietrini, S. Marchi, F. De Negri, F. Pentimone 

180



P-M-217 

P-M-218 

P-M-219 

TIME COURSE OF COAGULATION FACTORS IN OVERT DISSEMINATED 

INTRAVASCULAR COAGULATION: A CASE STUDY 

P. Carraro* (IT), H. Afshar, B. Fonnesu, M. Plebani 

ACUTE THROMBOSIS IN A PATIENT WITH ACQUIRED FVIII INHIBITOR: CASE REPORT 

E. A. D'Amico* (BR), M. G. Serpa, A. K. Zeinad, P. R. Villaça, M. Park, R. P. Bassitt, 

D. F. Chamone 

MUNCHAUSEN SYNDROME X COAGULOPATHIES 

P. R. Villaça (BR), R. P. Bassitt, A. K. Zeinad, D. F. Chamone, E. A. D'Amico* 

P-M-220 

P-M-221 

HEMOSTATIC CHANGES IN BRAZILIAN SPOTTED FEVER 

B. E. Alves (BR), R. N. Angerami, J. M. Annichino-Bizzacchi, G. S. Araujo, V. Castro, 

L. J. Silva, E. V. De Paula* 

COMBINATION THERAPY OF A PORCINE BONE TRAUMA FOLLOWING A DILUTIONAL 

COAGULOPATHY BY PROTHROMBIN COMPLEX CONCENTRATE (PCC) AND 

FIBRINOGEN 

G. Dickneite* (DE) 


P-M-222 

P-M-223 

P-M-224 

P-M-225 

P-M-226 

P-M-227 

P-M-228 

P-M-229 

THE BIPHASIC APTT WAVEFORM AS A BIOMARKER FOR TARGETING TREATMENT 

WITH RECOMBINANT ACTIVATED PROTEIN C (APC) 

T. Dutt* (UK), C. Powell, C. Downey, C. H. Toh 

EFFICACY OF ANTI-COAGULATION AND ANTI-INFLAMATORY THERAPY FOR SEVERE 

SEPSIS 

Y. Eguchi* (JP) 

A NEW MODE OF PROTHROMBIN TIME (PT) REPORTING SPECIFIC FOR LIVER 

DISEASES 

V. Eschwège* (FR), L. Bellest, R. Poupon, O. Chazouillères, A. Robert 

DENGUE FEVER AND THROMBOCYTOPENIA: A DEADLY DUO 

J. Fareed* (US), A. Lale, S. Lale, R. Bick 

THE AUTOMATED ENDOGENOUS THROMBIN POTENTIAL (ETP) TEST TO REFLECT 

COAGULATION CHANGES IN PATIENTS WITH CIRRHOSIS OF THE LIVER 

A. P. Gadisseur* (BE), J. Schouten, S. Francque, I. Vangenechten, F. Vertessen, 

P. Michielsen, M. G. Van Der Planken 

THE PROGRESS AND CHARACTERISTICS OF DISSEMINATED INTRAVASCULAR 

COAGULATION DIAGNOSED BY NEWLY ESTABLISHED DIAGNOSTIC CRITERIA FOR 

CRITICALLY ILL PATIENTS 

S. Gando* (JP), D. Saito, T. Mayumi, H. Ogura, K. Koseki, T. Ikeda, H. Ishikura, T. Iba, 

M. Ueyama, Y. Eguchi, Y. Ohtomo, K. Okamoto, S. Kushimoto, S. Endo, S. Shimazaki 

THROMBOCYTOPENIA AND CONGENITAL RADIAL DYSPLASIA: A CONTINUUM 

SPECTRUM OF DISEASES. CASE REPORT 

G. Giordano* (IT), S. Piano, C. Cerletti, M. Missere, M. Ciuffreda, M. Crescente, 

M. Donati, G. De Gaetano, S. Storti 

PROSPECTIVE EVALUATION OF A SIMPLIFIED SCORE FOR THE PREDICTION OF 

DISSEMINATED INTRAVASCULAR COAGULATION IN SEPSIS 

G. Lissalde-Lavigne* (FR), C. Combescures, E. Dorangeon, L. Muller, C. Bengler, 

J. Y. Lefrant, J. C. Gris 

181



P-M-230 

P-M-231 

P-M-232 

SIMPLE COAGULATION TESTS IMPROVE EARLY MORTALITY PREDICTION IN ICU 

PATIENTS WITH SEPTIC SHOCK 

G. Lissalde-Lavigne* (FR), C. Combescures, E. Dorangeon, L. Muller, C. Bengler, 

J. Y. Lefrant, J. C. Gris 

VITAMIN K DEFICIENCY IN PATIENTS WITH CANCER REFERRED TO A HOSPITAL 

PALLIATIVE CARE TEAM 

D. J. Harrington* (UK), C. Seton-Jones, S. Rangarajan, D. J. Card, R. Gorska, K. Voong, 

M. J. Shearer, T. Beynon, H. Western 

HEPARIN AND BLEEDING HISTORY IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS 

H. Hertfelder (DE), H. Seidel*, K. Alfter, U. W. Kolck, B. Rott, E. Höbert, S. Flommersfeld, 

I. V. Kügelgen, J. Homann, J. Oldenburg, G. J. Molderings 

Perioperative haemostasis 

P-M-233 

P-M-234 

P-M-235 

P-M-236 

P-M-237 

P-M-238 

P-M-239 

P-M-240 

P-M-241 

EXCESS THROMBIN GENERATION IN PATIENTS AFTER ON-PUMP CARDIAC 

SURGERY 

V. König* (DE), M. Reinhöfer, V. Oberle, J. Gummert, D. Barz, G. Marx, W. Lösche 

THE VALUE OF ROTEM THROMBOLELASTOMETRY TO DETECT DISTURBED 

HAEMOSTASIS AND BLEEDING RISK IN ON-PUMP CARDIAC SURGERY 

W. Lösche* (DE), M. Reinhöfer, C. Macholdt, M. Brauer, J. Gummert, D. Barz, G. Marx 

SPANISH CONSENSUS STATEMENT ON PHARMACOLOGIC ALTERNATIVES TO 

ALLOGENEIC BLOOD TRANSFUSIONS: THE SEVILLE’S DOCUMENT* 

J. A. Páramo* (ES), S. Leal, M. Munoz, J. Garcia-Erce 

DEFINITIVE PACEMAKER'S IN ANTICOAGULATED PATIENTS 

M. Quintana* (ES), M. Sánchez, M. Taberna, A. A. Simón, A. Gonzalez 

SURGICAL BLEEDING AFTER PREOPERATIVE UNFRACTIONATED HEPARIN AND LOW 

MOLECULAR WEIGHT HEPARIN AT CORONARY BYPASS SURGERY 

G. Renda (IT), R. Di Pillo, A. D'Alleva, A. Sciartilli, M. Zimarino, E. De Candia, 

R. Landolfi, G. Di Giammarco, R. De Caterina* 

PHASE 3 STUDY COMPARING RECOMBINANT HUMAN THROMBIN AND BOVINE 

THROMBIN FOR SURGICAL HEMOSTASIS 

K. Renkens (US), W. Chapman, F. Weaver, A. Murphy, T. C. Reynolds, J. Pribble* 

DETECTION OF ANTI-HAEMOSTATIC EFFECT OF PLASMA DILUTION VIA THROMBIN 

GENERATION 

S. E. M. Schols* (NL), P. E. J. Van Der Meijden, J. Curvers, J. W. M. Heemskerk, 

E. C. M. Van Pampus 

UNFRACTIONATED HEPARIN (UFH) OR LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) 

AS PERIOPERATIVE BRIDGING THERAPY IN PATIENTS WITH MECHANICAL HEART 

VALVES (MHVS) ON LONG-TERM ORAL ANTICOAGULANTS (OAC): RESULTS FROM 

THE REGIMEN REGISTRY 

A. C. Spyropoulos* (US), A. S. Dunn, A. G. G. Turpie, S. Kaatz, J. Douketis, 

A. K. Jacobson, H. Petersen for the Regimen Investigators 

RETRANSFUSION OF PERICARDIAL BLOOD DOES NOT TRIGGER SYSTEMIC 

COAGULATION DURING CARDIOPULMONARY BYPASS 

J. M. Van Den Goor (NL), R. Nieuwland*, P. M. Rutten, J. G. Tijssen, C. Hau, A. Sturk, 

L. Eijsman, B. A. De Mol 

182



P-M-242 

P-M-243 

MANAGEMENT OF ORTHOPAEDIC SURGICAL PROCEDURES IN PATIENTS WITH 

HAEMOPHILIA – A RETROSPECTIVE COMPARISON BETWEEN INTERMITTENT BOLUS 

FACTOR INFUSIONS VS. CONTINUOUS FACTOR INFUSION FROM A TERTIARY 

CENTRE IN INDIA 

A. Viswabandya* (IN), M. Nithyanath, V. M. Cherian, V. Lee, V. Mathews, S. Baidya, 

S. C. Nair, B. George, M. Chandy, A. Srivastava 

TREATMENT OF SURGICAL PATIENTS WITH FRESH FROZEN PLASMA AT THE 

CLINICAL HOSPITAL CENTER RIJEKA 

N. Vukelic Damijani* (HR), S. Balen, L. Caser 

P-M-244 

Platelets 

DOES TRANEXAMIC ACID DECREASE ERYTHROCYTE TRANSFUSION IN PATIENTS 

UNDERGOING HIP FRACTURE SURGERY WITH FONDAPARINUX FOR PREVENTION 

OF VENOUS THROMBOEMBOLISM? 

P. J. Zufferey* (FR), M. Miquet, S. Quenet, S. Laporte, V. Chambefort, P. Mismetti, 

S. Molliex, P. Martin 


Structural biology and drug design 

P-M-245 

P-M-246 

DESIGN OF A PLATELET SUBSTITUTE UTILISING HOST FIBRINOGEN TO ENHANCE 

HAEMOSTASIS 

J. A. Appleby* (UK), G. F. Walker, S. M. Middleton, A. H. Goodall 

THE PLAQUE LIPID LYSOPHOSPHATIDIC ACID STIMULATES PLATELETS NOT 

THROUGH THE LPA1, LPA2 AND LPA3 RECEPTOR 

A. L. Khandoga* (DE), P. Goyal, R. Tsukahara, D. D. Miller, G. Tigyi, W. Siess, N. Wilke 

Biochemistry and signal transduction 

P-M-247 

P-M-248 

P-M-249 

P-M-250 

P-M-251 

P-M-252 

DYNAMIC SIGNALLING EVENTS AND FIBRIN-INDEPENDENT RETRACTION 

CONTRIBUTE TO THROMBUS STABILITY UNDER SHEAR 

J. M. Auger* (UK), S. P. Watson 

AKT ACTIVATION BY PHOSPHAPHATIDYLINOSITOL-3,4,5-TRISPHOSPHATE IN HUMAN 

PLATELETS IS DEPENDENT ON EXTRACELLULAR CA2+ 

K. S. Authi* (UK), N. Kassouf, A. Ambily 

EFFECT OF NYTROXYL (HNO ) AND NITRIC OXIDE (NO) ON PROTEIN KINASE 

ACTIVATION PATHWAY IN HUMAN PLATELET 

E. Bermejo (AR), Y. Powazniak, D. Sáenz, M. F. Alberto, S. Bari, M. A. Lazzari*, 

R. Rosenstein 

EFFECT OF NYTROXYL AND NITRIC OXIDE ON HUMAN PLATELET ARACHIDONATE 

METABOLISM 

E. Bermejo (AR), D. Sáenz, M. Chianelli, S. Bari, M. A. Lazzari*, R. Rosenstein 

ANALYSIS OF THE INTERACTOME IN HUMAN PLATELETS 

M. Dittrich (DE), S. Mietner, N. Guenther, U. Walter, T. Dandekar, I. Birschmann* 

HIGH-AFFINITY GLUTAMATE TRANSPORTERS OF BLOOD PLATELETS AS POTENTIAL 

PERIPHERAL MARKERS TO ANALYZE GLUTAMATE TRANSPORT ACTIVITY IN BRAIN 

T. A. Borisova* (UA), L. Kasatkina 

183



P-M-253 

P-M-254 

P-M-255 

P-M-256 

P-M-257 

P-M-258 

P-M-259 

P-M-260 

P-M-261 

P-M-262 

P-M-263 

P-M-264 

DIFFERENCES IN PLATELET RESPONSE TO ADP AND CRP ARE CORRELATED WITH 

VARIATION IN THE RESTING PLATELET TRANSCRIPTOME 

P. Burns (UK), A. Gusnanto, P. Ellis, W. Angenent, F. P. Dudbridge, R. Dunn, 

R. W. Farndale, S. F. Garner, C. I. Jones, C. F. Langford, C. M. Rice, J. Walton, 

W. H. Ouwehand, A. H. Goodall, N. A. Watkins* 

SPATIO-TEMPORAL CALCIUM SIGNALING ELICITED BY INTEGRIN ALPHA2-BETA1 

AND GLICOPROTEIN VI UNDER FLOW 

L. De Marco (IT), Z. M. Ruggeri, M. Jandrot-Perrus, M. Mazzucato*, M. R. Cozzi, 

M. Battiston 

THROMBIN-INITIATED PLATELET ACTIVATION IN VIVO IS VON WILLEBRAND FACTOR 

INDEPENDENT DURING THROMBUS FORMATION IN A LASER INJURY MODEL 

C. Dubois* (FR), L. Panicot-Dubois, J. F. Gainor, B. Furie, B. C. Furie 

CD148 IS A POSITIVE REGULATOR OF PLCGAMMA2 ACTIVATION BY GPVI 

S. M. Ellison* (UK), M. G. Tomlinson, A. Weiss, S. P. Watson, Y. A. Senis, J. Zhu 

A NOVEL FAMILY OF ALKYLATED QUINOLINES INHIBITS G PROTEIN-COUPLED 

RECEPTORS WITH PALMITOYLATED CYTOPLASMIC TAILS 

R. Flaumenhaft* (US), J. R. Dilks, D. S. Sim 

HYPERREACTIVE PLATELETS IN PATIENTS WITH GS DEFICIENCY 

K. Freson* (BE), V. Labarque, C. Thys, C. Wittevrongel, J. Jaeken, C. Van Geet 

IDENTIFICATION OF NOVEL TYROSINE PHOSPHORYLATED SIGNALLING PROTEINS 

FOLLOWING αIIBβ3-MEDIATED PLATELET SPREADING: INVOLVEMENT OF THE 

IMMUNOGLOBULIN SUPERFAMILY MEMBERS G6B-B AND G6F, AND THE NOVEL 

PLATELET ADAPTER DOK-3 

A. Garcia* (ES), Y. A. Senis, R. Antrobus, C. E. Hughes, S.C. Hughan, S. P. Watson, 

N. Zitzmann 

ROLE OF PI-3 KINASE BETA ISOFORM ON ADP-INDUCED PLATELET RESPONSES 

A. E. Garcia* (US), S. Kim, S. P. Jackson, S. P. Kunapuli 

INK4A/ARF DEFICIENT MICE HAVE A DEFICIENT PLATELET FUNCTION 

P. Garcia De Frutos (ES), L. Bellido-Martin*, M. Serrano, S. Perez-Pujol, J. Serratosa, 

G. Escolar 

ROLES OF THE C-TERMINAL TYROSINE RESIDUES OF LAT IN GPVI-INDUCED 

PLATELET ACTIVATION; INSIGHT INTO THE MECHANISM OF PLC GAMMA2 

ACTIVATION 

M. P. Gratacap (FR), S. Severin*, A. Ragab, E. Aguado, M. Malissen, M. Jandrot-Perrus, 

B. Malissen, J. Ragab-Thomas, B. Payrastre 

REACTIVE OXYGEN SPECIES DERIVED FROM PLATELETS REDUCE THE ACTION OF 

NITRIC OXIDE 

M. Grenegard* (SE), E. G. Lindstrom 

BETA-N-ACETYLHEXOSAMINIDASE (BETA-HEX), A PLATELET LYSOSOMAL ENZYME, 

POTENTIATES THROMBIN-INDUCED PLATELET ACTIVATION BY ACTING ON GPV 

R. Rossi* (IT), S. Giannini, S. Mencarelli, E. Falcinelli, C. Emiliani, P. Gresele 

184



Other glycoproteins 

P-M-265 

P-M-266 

PROTHROMBOTIC EFFECTS OF FIBRONECTIN ISOFORMS CONTAINING THE EDA 

DOMAIN 

A. K. Chauhan* (US), J. Kisucka, M. T. Walsh, F. A. Moretti, F. E. Baralle, A. F. Muro, 

D. D. Wagner 

NOVEL PLATELET TRANSMEMBRANE PROTEINS: IDENTIFICATION AND ANALYSIS 

S. F. Garner* (UK), A. Walker, C. I. Jones, E. Gray, J. Hogwood, I. C. Macaulay, 

I. Salles, H. Deckmyn, N. A. Watkins, W. H. Ouwehand, M. Steward 

P-M-267 

P-M-268 

P-M-269 

GLYCOPROTEIN IIB/IIIA RECEPTOR DENSITY MEASUREMENT. IMPLICATIONS IN THE 

MONITORING OF ANTIPLATELET DRUGS 

O. M. Iqbal* (US), T. Parks, D. Hoppensteadt, J. Fareed 

IDENTIFICATION OF CRITICAL RESIDUES IN A GPVI BINDING PEPTIDE 

G. E. Jarvis* (UK), N. Raynal, D. Bihan, R. W. Farndale 

INFLUENCE OF PLATELET GP6 HAPLOTYPES (GP6A AND GP6B) 

E. Trifiro* (IT), Y. Cheli, K. Furihata, F. M. Pulcinelli, T. J. Kunicki 


P-M-270 

P-M-271 

P-M-272 

P-M-273 

P-M-274 

FUNCTIONAL ANALYSIS OF ANTI-GPVI MONOCLONAL ANTIBODIES WITH DISTINCT 

BINDING SITES 

Y. Matsumoto* (JP), H. Takizawa, X. Gong, A. Concepcion, N. N. Tandon, J. Kambayashi 

EPITOPE MAPPING OF COLLAGEN BINDING SITE IN HUMAN GLYCOPROTEIN VI 

(GPVI) 

M. Niimi* (US), L. Tao, J. Kambayashi, B. Sun 

THE ROLE OF PLATELET GLYCOPROTEIN VI IN ARTERIAL THROMBOSIS 

P. Marchese* (US), F. Almus-Jacobs, Y. Cheli, J. Ware, T. J. Kunicki, Z. M. Ruggeri 

INHIBITION OF CYTOSKELETAL ASSEMBLY BY CYTOCHALASIN D PREVENTS 

ENLARGEMENT OF RAFTS ACCOMPANIED BY GPVI ACCUMULATION IN 

COLLAGEN-STIMULATED PLATELETS 

H. Suzuki* (JP), M. Kurihara, H. Takayama 

CLEC-2, A NOVEL PLATELET ACTIVATION RECEPTOR, IS INVOLVED IN 

PODOPLANIN-MEDIATED PLATELET ACTIVATION BY CANCER CELLS 

K. Suzuki-Inoue* (JP), Y. Kato, O. Inoue, M. Kato Kaneko, K. Mishima, Y. Yatomi, 

Y. Ozaki 

Platelets physiology and pharmacology 

P-M-275 

P-M-276 

DOES ADMINISTRATION OF LANSOPRAZOLE AFFECT ASA ANTIPLATELET FUNCTION 

IN HIGH RISK CARDIOVASCULAR PATIENTS? PRELIMINARY RESULTS 

I. Anastasopoulou* (GR), E. Laiou, G. Sakizlis, C. Tsoucala, M. Gavalaki, 

A. Adamopoulos, G. Stergiou, K. Markakis, A. Karafoulidou 

CYP2C19*2 POLYMORPHISM INFLUENCES PLATELET FUNCTIONNALITY IN 

RESPONSE TO CLOPIDROGEL TREATMENT 

C. Bal Dit Sollier (FR), B. Boval, K. Peoc'H, P. Henry, E. Houdard, I. Crassard, 

S. Bellucci, L. Drouet* 

185



P-M-277 

P-M-278 

P-M-279 

P-M-280 

P-M-281 

P-M-282 

P-M-283 

P-M-284 

P-M-285 

P-M-286 

P-M-287 

P-M-288 

P-M-289 

P-M-290 

186 

FUNCTIONAL VARIABILITY OF PLATELET RESPONSE TO CLOPIDOGREL 

CORRELATES WITH P2Y12 RECEPTOR OCCUPANCY 

C. Bal Dit Sollier (FR), N. Berge, L. Hovsepian, B. Boval, L. Drouet* 

MODULATION OF PLATELET FUNCTION BY THE ENDOCANNABINOID 

2-ARACHIDONOYLGLYCEROL 

S. Baldassarri* (IT), A. Bertoni, P. Lova, C. Sarasso, M. Zanfa, M. Catani, L. Avigliano, 

M. Maccarrone, M. Torti, F. Sinigaglia 

REDUCED BLEEDING TIME PROLONGATION FOR THE REVERSIBLE P2Y12 

ANTAGONIST AZD6140 COMPARED WITH THE THIENOPYRIDINE, CLOPIDOGREL, IN 

BOTH A RAT AND DOG MODEL OF COMBINED THROMBOSIS AND HEMOSTASIS 

J. A. Björkman* (SE), J. J. J. Van Giezen, H. Zachrisson 

RED LASER RADIATION INCREASES PLATELET RESPONSE TO ADP 

I. A. Budnik* (RU), G. E. Brill, L. V. Gasparyan 

THE NEGATIVE EFFECT OF LEVOBUPIVACAINE ON COLLAGEN-INDUCED PLATELET 

AGGREGATION 

Y. Chang* (TW), C. Liao, C. Tseng, Y. Lin, Y. Day 

GALLIC ACID BLUNTS PLATELET INHIBITION BY ASPIRIN AND OTHER 

POLYPHENOLS: IMPLICATIONS FOR THE ANTITHROMBOTIC PROPERTIES OF 

ASPIRIN AND DIETARY POLYPHENOLS 

M. Crescente* (IT), C. Cerletti, G. De Gaetano 

ANTI-INFLAMMATORY EFFECS OF CLOPIDOGREL IN THE MOUSE 

V. Evangelista* (IT), G. Dell'Elba, N. Martelli, C. Amore, A. Piccoli, L. Totani, S. Manarini, 

R. Pecce 

INFLUENCE OF CYP2C19 AND CYP3A4 GENE POLYMORPHISMS ON CLOPIDOGREL 

RESPONSIVENESS IN HEALTHY SUBJECTS 

P. Fontana* (CH), J. Hulot, P. de Moerloose, P. Gaussem 

INFLUENCE OF NEUROHYPOPHYSIAL C-TERMINAL OLYGOPEPTIDES ON PLATELET 

AGGREGATION 

M. G. Golubeva* (RU), V. P. Golubovich 

CIRCADIAN VARIATION IN THE PLATELET RESPONSE AND THE EFFECT OF 

MELATONIN 

A. H. Goodall* (UK), A. Murray, T. E. B. James, D. Chan 

TRANSIENT REVERSAL OF THE ANTI-PLATELET EFFECT OF ASPIRIN AFTER 

ADMINISTRATION OF UNFRACTIONATED HEPARIN IN HEALTHY SUBJECTS 

A. H. Goodall (UK), N. R. Sheehan, C. I. Jones*, C. Chambers, T. E. James, 

G. McMahon 

SUCCESSFUL ANTICOAGULATION OF INFANTS TO ADULTS WITH BIVALIRUDIN IN 

EXTRACORPOREAL MEMBRANOUS OXYGENATION (EMCO) 

R. C. Gosselin (US), W. Dager*, R. Pretzlaff, G. Raff, R. Calhoun, J. King, R. White 

THE EFFECTS OF DOCOSAHEXAENOIC ACID IN PLATELETS (AN EX VIVO STUDY) 

AND IN MEGAKARYOCYTIC CELLS (AN IN VITRO STUDY) 

N. Guillot* (FR), M. Carreras, M. Laville, M. Lagarde, E. Vericel 

MYONECROSIS IS PREDICTED BY HIGH REACTIVITY TO MULTIPLE PLATELET 

AGONISTS: A TRANSLATIONAL STUDY OF PATIENTS UNDERGOING STENTING 

TREATED WITH BIVALIRUDIN AND HIGH DOSE CLOPIDOGREL 

K. P. Bliden* (US), J. Dichiara, U. S. Tantry, A. Singla, P. A. Gurbel



TTP/HUS and ADAMTS 13 

P-M-291 

P-M-292 

CORRELATIONS BETWEEN ADAMTS13 ACTIVITY AND INHIBITOR LEVELS: 

OBSERVATIONS AND IMPLICATIONS FOR RESOURCE UTILIZATION 

K. D. Friedman* (US), T. J. Raife, J. L. Endres, B. C. Pietz 

ACTIVE SITE-INHIBITED RFVIIA BLOCKS PLATELET STRING FORMATION ON INTACT 

ENDOTHELIUM ACTIVATED WITH TNF-ALPHA AND SHIGA TOXIN-1 

E. F. Grabowski* (US), E. Nestoridi, R. Kushak, J. R. Ingelfinger 

P-M-293 

P-M-294 

CHARACTERIZATION OF ADAMTS13/FXI COMPLEX FROM PLASMA AND 

QUANTITATION BY ELISA IN NORMAL DONORS AND TTP PATIENTS 

R. S. Greenfield* (US), E. Guinto, N. Grafos, H. J. L. Fryer, S. Ranzurmal 

A PHARMACEUTICALLY LICENSED SOLVENT/DETERGENT (S/D) TREATED PLASMA 

AND A UNIVERSALLY APPLICABLE DEVELOPMENT PRODUCT IN TTP AND HUS: 

QUANTIFICATION OF ADAMTS13 AND FACTOR H LEVELS 

A. Heger* (AT), C. Kannicht, J. Roemisch, T. Svae 


P-M-295 

P-M-296 

P-M-297 

P-M-298 

P-M-299 

P-M-300 

P-M-301 

P-M-302 

IMMUNO-PURIFICATION OF PLASMA ADAMTS13 AND ITS PHYSICO-CHEMICAL 

CHARACTERIZATION 

H. Hiura* (JP), A. Isonishi, S. Kato, M. Matsumoto, T. Matsui, Y. Fujimura 

THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) FOLLOWING CARDIAC 

SURGERY: AN EMERGING SYNDROME 

S. J. Jubelirer* (US), H. L. Ratliff, D. J. Cotes, M. A. Riley, C. A. Welch 

THREE NEW POLYMORPHISMS LOCATED IN THE INTRON 2 OF THE ADAMTS13 GENE 

A. Kempfer* (AR), L. Keller, C. Farias, A. Woods, A. Sanchez-Luceros, Y. Powazniak, 

M. Carrivale, M. Lazzari 

VWF-CLEAVING SERINE PROTEASES ISOLATION DIFFERENT FROM ADAMTS13 

A. Kempfer* (AR), C. Farias, Y. Powazniak, A. Woods, J. Calderazzo, L. Keller, 

M. Lazzari 

SERIAL MONITORING OF ADAMTS13- AND VWF-RELATED PARAMETERS IN PATIENTS 

WITH THROMBOTIC THROMBOCYTOPENIC PURPURA: PREDICTION OF RESPONSE 

TO THERAPY, RISK OF RELAPSE, AND LONG-TERM COURSE 

P. N. Knoebl* (AT), S. Koder, K. Varadi, P. L. Turecek, H. Vetr, P. Quehenberger, 

C. Müllner, V. Kolovratova, I. Pabinger 

ACTIVITIES AND POLYMORPHISMS OF ADAMTS13 IN THE JAPANESE GENERAL 

POPULATION 

K. Kokame* (JP), Y. Kokubo, A. Okayama, T. Miyata 

ALTERNATION OF VON WILLEBRAND FACTOR AND ADAMTS13 ACTIVITY AND ITS 

CLINICAL SIGNIFICANCE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA 

SYNDROME 

N. Koyama* (JP), K. Makinodann, S. Tamaki, A. Fukuoka, K. Hamada, M. Matsumoto, 

Y. Fujimura, H. Kimura 

PLATELET ADAMTS13 AND IN VITRO EXPRESSION STUDY OF A PATIENT AFFECTED 

BY CONGENITAL TTP 

S. Lavoretano* (IT), R. Lombardi, I. Garagiola, R. Palla, A. Afrasiabi, P. M. Mannucci, 

F. Peyvandi 

187



P-M-303 

P-M-304 

P-M-305 

P-M-306 

P-M-307 

THROMBOTIC THROMBOCYTOPENIC PURPURA IN PATIENT WITH LOW ADAMTS-13 

ACTIVITY LEVELS BUT NO INHIBITORY AUTOANTIBODIES 

A. Lombardi* (IT), F. Tezza, P. Scarparo, S. Vettore, M. Scapin, M. Randi, F. Fabris 

ANALYSIS OF ADAMTS13 IN PATIENTS WITH COLLAGEN DISEASE-ASSOCIATED 

TMAS 

T. Matsuyama* (JP), M. Matsumoto, A. Isonishi, M. Uemura, S. Inokuma, Y. Fujimura 

A ROLE OF THE ADAMTS13 GENE IN ACUTE ACQUIRED THROMBOTIC 

THROMBOCYTOPENIC PURPURA (TTP) 

S. C. Meyer* (CH), C. R. Largiadèr, G. Mäder, I. Sulzer, B. Lämmle, 

J. A. Kremer Hovinga 

ADAMTS-13 WITHIN THROMBUS DOWN-REGULATES THROMBUS FORMATION 

UNDER FLOW CONDITIONS 

S. Moriguchi-Goto* (JP), A. Yamashita, N. Tamura, K. Soejima, T. Nakagaki, S. Goto, 

Y. Asada 

OVEREXPRESSION OF ADAMTS13 BY LENTIVIRAL VECTOR ENCODING HUMAN 

ADAMTS13 GENE OFFERS SYSTEMIC PROTECTION AGAINST ARTERIAL 

THROMBOSIS IN A MOUSE MODEL 

M. Niiya (US), M. Endo, D. Shang, P. W. Zoltick, N. E. Muvarak, A. W. Flake, X. Zheng* 

Platelet function tests 

P-M-308 

P-M-309 

P-M-310 

P-M-311 

P-M-312 

P-M-313 

P-M-314 

CLINICAL EXPERIENCE WITH PLATELET AGGREGATION TESTING FOR ASPIRIN AND 

CLOPIDOGREL 

S. Jang* (US), G. Murugesan, K. Kottke-Marchant 

PLATELET FUNCTION THROMBOELASTOGRAPHY (PFT) 

F. G. Pluthero (CA), M. L. Rand, L. R. Brandao, V. S. Blanchette, W. H. Kahr* 

STUDY OF IN VIVO AND IN VITRO ADMINISTERED ASPIRIN'S ANTIPLATELET EFFECT: 

POSSIBLE MECHANISMS OF ASPIRIN RESISTANCE 

N. Kiss* (HU), E. Toth-Zsamboki, B. J. Beres, K. Vargova, G. Kerecsen, I. Preda, 

R. G. Kiss 

ASPIRIN EFFICACY:ANALYSIS OF WHOLE BLOOD-AGGREGATION USING THE 

SCREEN FILTRATION PRESSURE METHOD 

H. Kondo* (JP), A. Tabuchi, R. Taniguchi, M. Kawato, T. Ikeda, T. Morimoto, T. Kita, 

H. Horiuchi 

TEST OF ASPIRIN RESISTANCE 

S. R. Kristensen* (DK), E. H. Madsen, N. Gehr, N. L. Johannesen, E. B. Schmidt, 

T. S. Poulsen 

P2Y12 ANTAGONIST COMPLEMENTARY TO ASPIRIN THERAPY IS SUPERIOR TO 

ASPIRIN ALONE IN PATIENTS AFTER CARDIOSURGERY OPERATIONS 

W. Kuliczkowski* (PL), J. Golanski, R. Golanski, A. Iwaszkiewicz, L. Polonski, C. Watala 

THE METHODOLOGICAL PROBLEMS IN BLOOD PLATELET INVESTIGATION ARE 

STILL ACTUAL 

W. Kuliczkowski (PL), J. Golanski, M. Dobaczewski, C. Watala* 

188



P-M-315 

P-M-316 

P-M-317 

MONITORING OF PLATELET FUNCTION AFTER CLOPIDOGREL TREATMENT 

Y. Lee* (KR), H. Kim, H. Kang, H. Cho 

IMPAIRED RESPONSIVENESS OF PLATELETS TO EPINEPHRINE IN CHINESE 

RELATED TO A2A ADRENOCEPTOR POLYMORPHISMS 

T. Lin* (TW), J. Lin, T. Chen, Y. Wang, Y. Yang 

REFERENCE RANGE OF PLATELET FUNCTION ANALYZER-100 CLOSURE TIMES IN 

HEALTHY CHINESE 

J. Lin* (TW), C. Lai, M. Shen, S. Kuo 

P-M-318 

P-M-319 

P-M-320 

THE INFLUENCE OF THE HEMODIALYSIS PROCEDURES ON PLATELET AND 

HEMOSTATIC FUNCTIONS 

C. Wang* (TW), S. Hung, J. Jiang, M. Chang, C. Wu, T. Lin 

UNEXPLAINED PROLONGED PLATELET FUNCTION ANALYZER (PFA-100) CLOSURE 

TIME INDUCED BY SAMPLE ANTICOAGULANT 

R. M. Loreth* (DE), G. Blauth, F. W. Albert 

RESPONSE TO ASPIRIN AND CLOPIDOGREL IN HEALTHY MEN 

E. H. Madsen* (DK), E. B. Schmidt, T. S. Poulsen, S. R. Kristensen 


P-M-321 

P-M-322 

P-M-323 

P-M-324 

P-M-325 

P-M-326 

P-M-327 

DETERMINATION OF CLOPIDOGREL MAIN METABOLITE IN PLASMA – USEFUL TOOL 

FOR THERAPY MONITORING? 

H. Mani* (DE), S. W. Toennes, B. Linnemann, J. Schwonberg, G. F. Kauert, 

E. Lindhoff-Last 

PLATELET FUNCTION (PFA-100) AND ACTIVATION IN PATIENTS WITH CHRONIC 

PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE DISORDERS: ROLE OF THE JAK2 

V617F MUTATION 

M. J. Moreno* (ES), C. Martínez, L. Navarro-Núñez, F. Ferrer, V. Vicente, M. L. Lozano, 

M. H. González, J. Rivera 

COMPARISON OF TWO WHOLE BLOOD PLATELET FUNCTION ASSAYS: PFA-100® 

AND A NEW MULTIPLE ELECTRODE AGGREGOMETRY (MULTIPLATE®) FOR 

CONTROL OF ASPIRIN AND/OR CLOPIDOGREL EFFECT 

I. Martin-Toutain (FR), J. Collet, M. Genevee, M. Couty, G. Montalescot, A. Ankri* 

PLATELET FUNCTION TESTING IN CHILDREN UNDER 1 YEAR 

M. C. Mathias* (UK), K. Khair, R. Liesner, C. Burgess 

COMPARISON OF SINGLE AND SEVEN-DAY ASPIRIN PLATELET RESPONSE REVEALS 

DOSAGE EFFECT AT 81 AND 325 MG 

D. L. McGlasson* (US), G. A. Fritsma 

POINT-OF-CARE ASSESSMENT OF PERI-OPERATIVE PLATELET FUNCTION USING 

THROMBOELASTOGRAPH PLATELET MAPPING 

C. N. Melikian* (UK), S. V. Mallett 

AUDIT OF SCREENING FOR VON WILLEBRANDS DISEASE AND PLATELET FUNCTION 

ABNORMALITIES USING THE PFA-100 

J. Needham* (UK), J. Taylor, A. Roy, A. Milne, S. Knight, Y. Stebbings 

189



Laboratory methods and experimental models 

P-M-328 

P-M-329 

P-M-330 

P-M-331 

P-M-332 

P-M-333 

P-M-334 

P-M-335 

P-M-336 

P-M-337 

P-M-338 

P-M-339 

P-M-340 

P-M-341 

190 

CHARACTERIZATION OF A NEW METHOD TO ASSESS PLATELET ACTIVATION AND 

ERYTHROCYTE LYSIS DURING EXPOSURE TO PATHOPHYSIOLOGICAL SHEAR 

STRESS 

J. C. Kermode* (US), G. W. Burgreen, Q. Zheng, T. Ladner, S. Majumdar 

PRELIMINARY RESULTS ON EFFECTIVENESS AND SAFETY OF COMBINED 

ANTICOAGULANT AND ANTIPLATELET THERAPY 

E. Laiou* (GR), I. Anastasopoulou, P. Kotsi, C. Tsoucala, K. Markakis, A. Karafoulidou 

COMPARISON OF TWO ASSAYS FOR THE MEASUREMENT OF URINARY 11-DEHYDRO 

THROMBOXANE B2 

M. Johnston* (CA), S. Wentworth, M. Lauzon, J. W. Eikelboom 

AGGREGATION TEST FOR DETECTION CLOPIDOGREL RESISTANCE 

J. Maliskova* (CZ), L. Slavik, V. Krcova, P. Novak, J. Galuszka, M. Hutyra 

USE OF A CLINICAL ALGORITHM IN THE DIAGNOSIS OF HEPARIN INDUCED 

THROMBOCYTOPENIA 

E. R. McBride* (CA), A. Shawwa, I. Sadek 

VASCULAR WALL ALTERATIONS AND MATRIX EXPOSURE FOLLOWING LASER- 

INDUCED INJURY OF MOUSE MESENTERIC ARTERIOLES 

C. Nonne* (FR), A. Eckly, B. Hechler, J. P. Cazenave, F. Lanza, C. Gachet 

USE OF HAEMOPHILIA A ZEBRAFISH FOR SENSITIVE SCREENING AND 

CHARACTERISATION OF NOVEL PLATELET CANDIDATE GENES DERIVED FROM 

POST-GENOME STUDIES FOR PRO-THROMBOTIC FUNCTION 

M. N. O'Connor* (UK), I. I. Salles, W. H. Ouwehand, H. Deckmyn, D. L. Stemple 

PERFORMANCES OF A NEW ELISA (ZYMUTEST HIA®) FOR THE DIAGNOSIS OF 

HEPARIN-INDUCED THROMBOCYTOPENIA 

C. Pouplard (FR), E. Rouvier, S. Regina, Y. Gruel* 

NASCOLA SURVEY OF HIT TESTING IN NORTH AMERICA 

E. A. Price (US), C. P. M. Hayward, K. A. Moffat, J. C. Moore, T. E. Warkentin, 

J. L. Zehnder* 

AN EVALUATION OF SINGLE PORTION REAGENT VIALS FOR ROTEM ANALYSIS 

N. Rahe-Meyer* (DE), M. Winterhalter, T. Lang, C. Solomon 

THROMBOCYTE RETRACTION HAS NOT INFLUENCE ON BLOOD CLOT 

DEFORMABILITY 

A. V. Savushkin* (RU) 

EFFECT OF ANTI-PLATELET DRUGS ON PLATELET AGGREGATION AND THROMBUS 

FORMATION INDUCED BY HUMAN ATHEROSCLEROTIC PLAQUES 

S. Penz* (DE), A. Reininger, O. Tóth, H. Deckmyn, R. Brandl, W. Siess 

THE USE OF ATOMIC FORCE MICROSCOPY TO STUDY COLLAGEN-PLATELET 

INTERACTIONS 

A. M. C. Simpson* (UK), R. W. Farndale, V. Shahin 

MONOCYTE PARAMETERS TO DISCRIMINATE ESSENTIAL FROM REACTIVE 

THROMBOCYTOSIS 

M. Vasse* (FR), A. Jean, N. Gromellon, J. Piquenot, J. Basuyau, C. Bastard, 

B. Lenormand



New antiplatelet agents and drug design 

P-M-342 

P-M-343 

ANTIPLATELET ACTIVITY OF EPIGALLOCATECHIN GALLATE IS MEDIATED BY THE 

INHIBITION OF PLCGAMMA2 PHOSPHORYLATION, ELEVATION OF PGD2 

PRODUCTION AND MAINTENANCE OF CALCIUM-ATPASE PUMP 

Y. Jin* (KR), M. Cho, J. Lee, J. Yu, J. Im, E. Park, H. Yoo, T. Kim, Y. Yun 

P2Y12 BLOCKADE BY PRASUGREL ACTIVE METABOLITE YIELDS COMPLETE 

INHIBITION OF P2Y12-MEDIATED AMPLIFICATION OF PLATELET RESPONSES 

H. M. Judge* (UK), R. J. Buckland, A. Sugidachi, J. A. Jakubowski, R. F. Storey 

P-M-344 

P-M-345 

RISTOCETIN-INDUCED AGGREGATION OF HUMAN GPIBALPHA TRANSGENIC MICE IS 

INHIBITED BY ANTI-HUMAN GPIBALPHA ANTIBODIES IN THE PRESENCE OF HUMAN 

PLASMA 

A. Y. Kim* (US), A. Goel, X. Tian, S. R. Hui, T. K. Biswas, J. Ware, J. L. Miller 

ANTITHROMBOTIC EFFECT OF ADENOSINTHREEPHOSPHATE AT INTRODUCTION BY 

AN ANIMALS WITH DISTURB OF HAEMOSTATIC SYSTEM 

L. A. Lyapina* (RU), V. E. Pastorova 


P-M-346 

P-M-347 

P-M-348 

P-M-349 

P-M-350 

P-M-351 

P-M-352 

P-M-353 

INHIBITION OF PLATELET FUNCTION BY THE ANTI-VON WILLEBRAND FACTOR 

APTAMER, ARC1779 

P. G. Merlino (US), M. Gilbert, H. Lagasse, J. L. Diener, H. Marsh* 

THE LEECH PRODUCT SARATIN IS A POTENT INHIBITOR OF PLATELET INTEGRIN 

ALPHA2BETA1 AND VWF BINDING TO COLLAGEN 

T. C. White* (US), M. A. Berny, D. K. Robinson, H. Yin, W. F. Degrado, S. R. Hanson, 

O. J. T. McCarty 

NEW THIENYLACYLHYDRAZONE DERIVATIVES AS CYCLIC NUCLEOTIDES 

MODULATORS AND PLATELET AGGREGATION INHIBITORS 

A. L. P. Miranda* (BR), F. C. F. Brito, A. E. Kummerle, C. M. Fraga, E. J. Barreiro 

MODULATION OF HEPARIN-PF4 ANTIBODY-MEDIATED PLATELET ACTIVATION BY 

A NOVEL GPIIB/IIIA RECEPTOR ANTAGONIST: IMPLICATIONS IN THE MANAGEMENT 

OF HIT 

S. A. Mousa (US), S. Ahmad* 

GENERATION AND CHARACTERIZATION OF A RECOMBINANT BLOCKING 

ANTI-GLYCOPROTEIN VI SINGLE CHAIN ANTIBODY FRAGMENT 

J. Muzard* (FR), I. Minullina, S. Loyau, P. Billiald, M. Jandrot-Perrus 

THROMBOSTATIN FM19 - A THROMBIN RECEPTOR ACTIVATION ANTAGONIST 

A. H. Schmaier* (US), F. Burke, M. Warnock, M. Nieman, J. Hilfinger, H. I. Mosberg 

THE PHARMACOLOGICAL PROFILE OF DZ-697B, A NOVEL ANTI-PLATELET AGENT 

T. Shibutani* (JP), S. Muramatsu, S. Takahashi, Y. Kaneda, Y. Ogihara, T. Shibano 

IN VIVO PHARMACOLOGICAL STUDIES OF AN ANTI-GPVI ANTIBODY THAT 

IMMUNODEPLETES GPVI WITHOUT PLATELET ACTIVATION 

M. Shinozaki (JP), H. Takahashi, M. Honda, Y. Yatagai, T. Kawahara, K. Naitoh, J. Hirose, 

K. Nakayama*, Y. Hosaka, S. Furusako, H. Takayama 

191



Vascular biology 

Endothelial cells and endothelial progenitor cells 

P-M-354 

P-M-355 

P-M-356 

P-M-357 

P-M-358 

P-M-359 

P-M-360 

P-M-361 

P-M-362 

P-M-363 

P-M-364 

P-M-365 

INDUCTION OF ENDOTHELIAL CELL HYPERPERMEABILITY BY EXTRACELLULAR 

RNA 

S. Fischer* (DE), T. Gerriets, M. Walberer, E. Stolz, K. Zheleva, C. Wessels, S. Kostin, 

K. T. Preissner 

FACTOR VII ACTIVATING PROTEASE INHIBITS VASCULAR ENDOTHELIAL GROWTH 

FACTOR-MEDIATED PROGENITOR CELL HOMING AND DIFFERENTIATION INTO 

ENDOTHELIAL CELLS 

S. Rentala (DE), O. Uslu, L. Muhl, K. T. Preissner, S. M. Kanse* 

DISINTEGRIN SUPPRESSES HUMAN VASCULAR ENDOTHELIAL CELL MIGRATION 

AND INVASION BY REGULATING PLATELET ACTIVATION 

D. Kim* (KR), Y. Jang, O. Jeon, D. Kim, W. Choi, J. Rhee 

CHARACTERIZATION OF VASCULAR ENDOTHELIAL CELLS WITH NULL 

THROMBOXANE A2 SYNTHASE 

S. Lin* (TW), J. Hsu, I. Yu, S. Lin 

A COMPARATIVE ANALYSIS OF THE RESPONSE TO INFLAMMATORY STIMULI OF 

BLOOD- AND MESENCHYMAL STEM CELL–DERIVED ENDOTHELIAL PROGENITOR 

CELLS 

J. W. Liu* (CH), H. Bounameaux, E. K. O. Kruithof 

EFFECT OF HUMAN TERT TRANSFECTION ON GENE EXPRESSION PROFILING IN 

NORMAL HUMAN CORONARY ARTERY ENDOTHELIAL CELLS 

Y. Matsubara* (JP), M. Murata, M. Yabe, Y. Ikeda 

EFFECTS OF LOW DOSE ENDOTOXEMIA ON ENDOTHELIAL PROGENITOR CELLS IN 

HUMANS 

F. B. Mayr* (AT), A. O. Spiel, J. M. Leitner, C. Firbas, W. Sieghart, B. Jilma 

MODULATION OF NITRIC OXIDE PRODUCTION BY CULTURED ENDOTHELIAL CELLS 

I. A. Osadchenko* (UA), T. N. Kovalenko, G. G. Skibo 

DIAMOND PARTICLES OF MICROMETRIC SIZE ARE INTERNALIZED 

BY ENDOTHELIAL CELLS 

Z. Pawlowska* (PL), W. Okroj, H. Jerczynska, M. Kaminska, P. Komorowski, 

B. Walkowiak 

TESTOSTERONE INDUCES PHOSPHORYLATION OF P38 AND JNK IN HUVEC 

Y. Powazniak* (AR), A. C. Kempfer, C. Farías, L. Keller, M. P. Dominguez, 

J. C. Calderazzo, M. A. Lazzari 

PROCOAGULANT EFFECT OF DEXAMETHASONE IN HUMAN UMBILICAL VEIN 

ENDOTHELIAL CELLS: A POTENTIAL MECHANISM OF GLUCOCORTICOID-INDUCED 

OSTEONECROSIS 

C. Séguin* (CA), M. Kerachian, D. Cournoyer, T. Y. K. Chow, E. J. Harvey 

EFFECTS OF SHORT TERM STATIN PRE-TREATMENT AND SUBSEQUENT LOW DOSE 

ENDOTOXEMIA ON CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN HEALTHY 

VOLUNTEERS 

A. O. Spiel* (AT), F. B. Mayr, J. M. Leitner, C. Firbas, W. Sieghart, B. Jilma 

192



P-M-366 

CLOPIDOGREL TREATMENT SIGNIFICANTLY DECREASES CIRCULATING 

ENDOTHELIAL CELL COUNT IN PATIENTS WITH STABLE ANGINA 

K. Vargova* (HU), E. Toth-Zsamboki, P. Gulacsi-Bardos, B. J. Beres, R. G. Kiss, I. Preda 

Smooth muscle cells 

P-M-367 

THE INHIBITORY ACTIVITY AND MECHANISM OF BUD-030, A NOVEL INHIBITOR OF 

VASCULAR SMOOTH MUSCLE CELLS 

K. Chung (KR), K. Cho*, S. Hong, S. Kang, T. Lee 

P-M-368 

P-M-369 

P-M-370 

EPOTHILONE B INHIBITS NEOINTIMAL FORMATION AFTER RAT CAROTID INJURY 

THROUGH THE REGULATION OF CELL CYCLE-RELATED PROTEINS 

Y. Lim* (KR), T. Kim, Y. Jin, D. Kim, J. Kwon, J. Son, J. Jung, M. Avery, J. Hong, Y. Yun 

INHIBITION OF AIRWAY SMOOTH MUSCLE CELL ADHESION AND MIGRATION BY THE 

DISINTEGRIN DOMAIN OF ADAM-15 

D. Lu* (UK), M. Scully, S. Xie, M. Sukkar, F. Chung, X. Lu, V. Kakkar 

RECOMBINANT HUMAN THROMBOMODULIN PROMOTES SMOOTH MUSCLE CELL 

MIGRATION 

H. Wu* (TW), F. Chou, S. Liu, G. Shi 


P-M-371 

OBOVATOL INHIBITS VASCULAR SMOOTH MUSCLE CELL PROLIFERATION AND 

NEOINTIMAL FORMATION AFTER CAROTID INJURY IN RATS 

Y. Yun* (KR), Y. Lim, T. Kim, Y. Jin, J. Kwon, D. Kim, S. Lee, B. Kwon, J. Hong 

Vasculogenesis 

P-M-372 

P-M-373 

P-M-374 

P-M-375 

QUANTITATIVE ANALYSIS OF GENE EXPRESSION FOR VASCULAR ENDOTHELIAL 

GROWTH FACTOR AND ITS APPLICATION 

X. Bai* (CN), J. Fu, K. Ding, J. Cen, Z. Wang, C. Ruan 

DEFIBROTIDE PROTECTS ENDOTHELIAL CELLS AGAINST STRESS-INDUCED CELL 

DEATH VIA INHIBITION OF THE EXTRINSIC APOPTOSIS PATHWAY 

G. Eissner* (IT), C. Echart, M. Iacobelli, T. Ignoni, L. Ferro 

EXPRESSION OF MT1-MMP IN HUMAN VASCULAR ENDOTHELIAL CELL LINES AND 

THE CONSTRUCTION OF ITS EUKARYOTIC EXPRESSION VECTOR 

J. Jiang* (CN), X. Hu, Z. Ma, N. Dong, X. Bai, C. Ruan 

ROLE OF THYROID HORMONE ANALOGS IN ANGIOGENESIS AND THE 

DEVELOPMENT OF COLLATERALS IN RABBIT HIND LIMB ISCHEMIA MODEL 

E. El Eter (SA), H. Rabee, S. A. Mousa*, A. Alkayali 

Atherosclerosis 

P-M-376 

P-M-377 

RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (RAGE) EXPRESSED ON 

HEK293 CELLS BINDS OXIDIZED LOW DENSITY LIPOPROTEINS (OXLDL) 

J. Martin* (UK), C. McDermott-Roe, K. Morser, J. McGregor 

HMGB1 PLAYS A CENTRAL ROLE IN ATHEROTHROMBOSIS 

I. Maruyama* (JP), K. Kawahara, T. Ito, Y. Oyama, T. Hashiguchi, K. Inoue 

193



P-M-378 

P-M-379 

P-M-380 

P-M-381 

P-M-382 

P-M-383 

P-M-384 

P-M-385 

P-M-386 

P-M-387 

P-M-388 

P-M-389 

TISSUE FACTOR-DEPENDENT COAGULANT ACTIVITY OF PLATELET-MONOCYTE 

COMPLEXES IN CHRONIC RENAL FAILURE (CRF), ASSOCIATION WITH HEMOSTATIC 

ACTIVITY, INFLAMMATION, OXIDATIVE DAMAGE AND ENDOTHELIAL DYSFUNCTION 

O. Panes* (CL), L. Vásquez, C. Martínez, R. Tagle, E. Pais, J. Pereira, F. Leighton, 

D. Mezzano 

THROMBOSPONDIN1 GENE DEFICIENCY ATTENUATES ATHEROSCLEROTIC PLAQUE 

BURDEN BUT ACCENTUATES INFLAMMATORY CELL PLAQUE CONTENT IN APOE- 

DEFICIENT MICE 

R. Moura* (BE), M. Tjwa, P. Vandervoort, J. Lawler, M. Hoylaerts 

THE DISTRIBUTION OF FACTOR SEVEN ACTIVATING PROTEASE (FSAP) IN CAROTID 

AND CORONARY ATHEROSCLEROTIC PLAQUES IN SUBJECTS GENOTYPED FOR 

THE MARBURG I POLYMORPHISM 

M. Grebe (DE), R. Voss, B. Parviz, A. Barth, H. Tillmanns, D. G. Sedding, 

H. Hoelschermann, S. M. Kanse* 

EARLY INCREASE OF OXIDATIVE STRESS AND SOLUBLE CD40L IN CHILDREN 

P. Pignatelli* (IT), F. Martino, E. Martino, F. Morrone, R. Carnevale, S. Di Santo, 

A. Martini, L. Loffredo, F. Violi 

PATHOGEN BURDEN AND CORONARY ARTERY DISEASE 

V. S. Rao* (IN), K. S. Renuka, B. K. Natesha, J. Shanker, M. Mukherjee, V. V. Kakkar 

PLASMA LEVELS OF COAGULATION AND INFLAMMATORY MARKERS IN SUBJECTS 

AFFECTED WITH CORONARY ARTERY DISEASE 

V. Rao* (IN), B. K. Natesha, S. Kanjilal, M. Mukherjee, V. V. Kakkar 

AGE-DEPENDENT INCREASED ARTERIAL STIFFNESS IS ASSOCIATED WITH 

COMPOSITE CHANGES IN PRO- AND ANTI-COAGULANT REACTIONS IN 

SUBCLINICAL ATHEROSCLEROSIS 

V. Regnault* (FR), A. Kearney-Schwartz, A. Benetos, A. Membre, T. Lecompte, J. P. Max, 

C. Labat, S. N. Thornton, P. Lacolley 

BENEFICIAL EFFECT OF 1-YEAR OPTIMAL MEDICAL TREATMENT, INDEPENDENT OF 

ADDITIONAL PTA, ON INFLAMMATION IN PATIENTS WITH PERIPHERAL ARTERIAL 

DISEASE (PAD) 

I. Seljeflot* (NO), M. Nylaende, A. Kroese, B. Morken, E. Stranden, G. Sandbaek, 

A. Lindahl, H. Arnesen 

COMPARATIVE STUDY OF THE EFFECTS OF NATURAL HONEY, SESAME OIL, AND 

SOY MILK CONSUMPTION ON BLOOD LEVEL OF LIPID PEROXIDATION AND TOTAL 

PHENOLIC COMPOUNDS 

C. Settasatian* (TH), N. Settasatian, Y. Teerajetgul, S. Sirijaichingkul 

DEXTROMETHORPHAN REDUCES ATHEROSCLEROSIS AND NEOINTIMA FORMATION 

IN MICE 

G. Shi* (TW), S. Liu, H. Wu 

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) THR325ILE AND FACTOR 

XII C46T POLYMORPHISMS IN ATHEROSCLEROTIC RENAL ARTERY STENOSIS 

M. Smid* (NL), A. W. Plat, H. E. J. H. Stoffers, H. M. H. Spronk, P. W. De Leeuw, 

A. A. Kroon, H. Ten Cate 

LIPID, INFLAMMATORY AND HAEMORHEOLOGICAL PROFILES ARE SIGNIFICANTLY 

AFFECTED BY FARMED FISH EATING: AN INTERVENTION STUDY 

F. Sofi* (IT), A. Gori, F. Cesari, R. Paniccia, L. Mannini, A. Casini, G. Parisi, G. Giorgi, 

B. Poli, R. Abbate, G. Gensini 

194



P-M-390 

P-M-391 

LOCALISATION OF COAGULATION PROTEINS WITHIN THE ARTERIAL VESSEL WALL 

IN RELATION TO PROGRESSION OF ATHEROSCLEROSIS 

H. M. H. Spronk* (NL), D. Van Der Voort, S. Heeneman, P. Kassak, K. Hamulyak, 

M. J. A. P. Daemen, H. Ten Cate 

DNA REPAIR GENE XRCC1 AND XPD POLYMORPHISMS AND THEIR ASSOCIATION 

WITH CORONARY ARTERY DISEASE RISKS AND MICRONUCLEUS FREQUENCY 

T. Ulutin* (TR), M. Guven, G. S. Guven, E. Oz, A. Ozaydin, B. Batar, N. Domanic 

P-M-392 

P-M-393 

P-M-394 

POLYMORPHISMS IN COAGULATION FACTORS ARE NOT ASSOCIATED WITH THE 

RISK OF RECURRENT MAJOR ARTERIAL CARDIOVASCULAR EVENTS IN MEN AFTER 

A FIRST MYOCARDIAL INFARCTION: RESULTS OF 11 YEARS FOLLOW-UP 

M. D. Van Der Krabben* (NL), C. J. M. Doggen, J. G. Van Der Bom, F. R. Rosendaal 

TISSUE TRANSGLUTAMINASE DOES NOT STABILIZE ARTERIAL PLAQUES IN THE 

APOE DEFICIENT MOUSE 

H. Williams (UK), R. J. Pease*, R. M. Graham, C. L. Jackson, P. J. Grant 

THE EFFECTS OF BLOCKING P2Y12 RECEPTOR IN ARTEROSCLEROSIS PRODUCED 

BY MURINE ALLO-TRANSPALANTATION 

K. Yashiro* (JP), Y. Matsumoto, Y. Suzuki, K. Kondo, K. Umemura 


P-M-395 

ANTIPROLIFERATIVE ACTIVITY OF YQN1, A NEWLY SYNTHESIZED INDOLEDIONE 

DERIVATIVE, ON PDGF-BB-STIMULATED AORTIC VASCULAR SMOOTH MUSCLE 

CELLS 

Y. Yun* (KR), J. Seo, T. Kim, H. Han, Y. Jin, K. Oh, C. Ryu 

Inflammation, cytokines and auto 

P-M-396 

P-M-397 

P-M-398 

P-M-399 

P-M-400 

P-M-401 

RELATIONSHIP BETWEEN OXIDATIVE STRESS, ENDOTHELIAL INJURY AND 

COAGULATION ACTIVATION IN ADVANCED CHRONIC HEART FAILURE 

I. Korzh* (UA), I. Fedotova 

VON WILLEBRAND FACTOR RELATED PARAMETERS IN SEVERE SEPSIS AND 

SEPTIC SHOCK 

J. A. Kremer Hovinga* (CH), S. Zeerleder, P. Kessler, T. Romani De Wit, 

J. A. van Mourik, C. Hack, H. ten Cate, P. H. Reitsma, W. A. Wuillemin, B. Lämmle 

EFFECT OF ANTIINFLAMMATORY DRUGS ON HUMAN NEUTROPHILS IN 

ENDOTHELIAL CELL DAMAGE INDUCED BY SHIGA TOXIN-1 

V. I. Landoni* (AR), L. P. D'Atri, M. V. Ramos, G. Fernandez, B. Rearte, E. Laborde, 

M. Palermo, M. Schattner, M. Isturiz 

ATP VIA P2X7 MODULATES THE TLR-DEPENDENT EXPRESSION AND ACTIVITY OF 

HUMAN NEUTROPHIL INFLAMMASOME 

C. Lecut* (BE), C. Faccinetto, V. Bours, C. Oury 

A NATURAL EXTRACT FROM PIPER PHILIPPINUM (2R,3R)-2-(3’,4’- 

DEHYDROXYBENZYL)-3-(3’’-4’’-DIMETHOXYBENZYL)BUTYROLACTONE (PP-6) 

SUPPRESS FMLP-INDUCED SUPDROXIDE PRODUCTION BY INHIBITION 

FMLP-RECEPTOR BINDING IN HUMAN NEUTORPHIS 

Y. J. Huang* (TW), I. S. Chen, C. H. Liao 

BENEFICIAL EFFECTS OF ANTIPLATELET DRUGS IN SEPSIS: FIRST DATA FROM A 

CLINICAL AND ANIMAL STUDY 

W. Lösche* (DE), J. Winning, J. Reichel, J. Hamacher, Y. Eisenhut, M. Kohl, 

H. P. Deigner, R. A. Claus, M. Bauer 

195



P-M-402 

P-M-403 

P-M-404 

P-M-405 

P-M-406 

P-M-407 

P-M-408 

P-M-409 

P-M-410 

P-M-411 

P-M-412 

P-M-413 

P-M-414 

HEPCIDIN IN HEMODIALYZED AND PERITONEALLY DIALYZED PATIENTS: 

A LINK BETWEEN ANEMIA AND INFLAMMATION? 

J. Malyszko* (PL), J. S. Malyszko, K. Pawlak, M. Mysliwiec 

HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) AND THE RISK OF FIRST EVER 

ISCHEMIC STROKE IN HEALTHY PEOPLE 

L. Masotti* (IT), G. Landini, R. Cappelli 

MODIFIED CRP ENHANCES PLATELET ADHESION AND THROMBUS GROWTH ON 

COLLAGEN 

B. Molins* (ES), E. Peña, G. Vilahur, C. Mendieta, L. Badimon 

LDL-CHOLESTEROL ENHANCES PLATELET RECRUITMENT VIA 

GP91PHOX-MEDIATED CD40L UPREGULATION 

P. Pignatelli* (IT), S. Di Santo, V. Sanguigni, R. Carnevale, F. Violi, V. Muscolo 

ASSOCIATION OF CYTOMEGALOVIRUS (CMV) AND PROATHEROGENIC BIOMARKERS 

IN CORONARY ARTERY DISEASE (CAD) 

V. S. Rao* (IN), B. K. Natesha, J. Shanker, S. Kanjilal, M. Mukherjee, V. V. Kakkar 

USE OF THROMBOELASTOGRAPHY TO DEFINE THE ROLE(S) OF NEUTROPHIL 

ELASTASE DURING NORMAL HAEMOSTASIS IN VITRO 

V. Ho (CA), M. E. Nesheim, J. A. Samis* 

THE RESULTS OF OUR FEBRILE NEUTROPENIA MANAGEMENT REPORTS FOR 

THREE YEARS 

H. H. S. Sayilan Sen* (TR), Z. Salcioglu, F. Akici, G. Aydogan, O. Ulucakli, O. Yanilmaz, 

N. Aktay Ayaz, H. Aldemir 

INCREASED EXPRESSION OF AND ENHANCED PLATELET REACTIVITY TO 

FRACTALKINE IN TYPE-II DIABETIC ZDF-RATS 

A. Schäfer* (DE), C. Schöpp, C. Schulz, U. Flierl, J. Pfrang, S. Massberg, J. Bauersachs 

THE CHEMOKINE FRACTALKINE MEDIATES LEUKOCYTE RECRUITMENT TO 

INFLAMMATORY ENDOTHELIUM AT ARTERIAL SHEAR RATES IN VIVO AND IN VITRO 

C. Schulz* (DE), A. Schäfer, M. Stolla, J. Bauersachs, S. Massberg, M. L. Von Brühl 

CHANGES OF INFLAMMATORY MARKERS DURING FOLLOW-UP OF PATIENTS WITH 

HEART FAILURE UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY 

F. Sofi* (IT), A. Michelucci, A. Gori, G. Ricciardi, P. Pieragnoli, M. Lenti, F. Cesari, 

A. Abdullahi Said, R. Abbate, G. Gensini 

INHIBITION OF PROTEASE-ACTIVATED RECEPTOR (PAR)-4 PROTECTS FROM 

MULTI-ORGAN FAILURE IN A MURINE MODEL OF DISSEMINATED INTRAVASCULAR 

COAGULATION (DIC) 

S. H. Slofstra (NL), A. P. Groot, P. H. Reitsma, T. Lindhout, H. ten Cate, C. A. Spek* 

LUNG INFLAMMATION AND THROMBOGENIC RESPONSES IN A TIME COURSE STUDY 

OF WILD TYPE AND REPAIR DEFECTIVE CSB -/- MICE EXPOSED TO OZONE 

I. M. Kooter (NL), K. Frederix*, F. R. Cassee, R. van Oerle, H. M. H. Spronk, 

H. Ten Cate 

THE PROCOAGULANT EFFECTS OF PARTICULATE MATTER, A COMPONENT OF AIR 

POLUTION, IN THE LUNGS 

K. Frederix* (NL), I. M. Kooter, M. E. Gerlofs-Nijland, R. Van Oerle, K. Hamulyak, 

H. ten Cate, H. M. H. Spronk 

196



Restenosis 

P-M-415 

P-M-416 

CORONARY ARTERY IN-STENT STENOSIS PERSISTS DESPITE INHIBITION OF THE 

VON WILLEBRAND FACTOR-COLLAGEN INTERACTION IN BABOONS 

S. F. De Meyer* (BE), S. Staelens, P. N. Badenhorst, H. Pieters, S. Lamprecht, J. Roodt, 

S. Janssens, M. Meiring, K. Vanhoorelbeke, A. Bruwer, S. Brown, H. Deckmyn 

NITRIC OXIDE LEVELS ARE INCREASED FOLLOWING BRACHYTHERAPY COMPARED 

TO STENTING. IMPLICATIONS IN CORONARY RESTENOTIC COMPLICATIONS 

J. Fareed (US), O. Iqbal*, D. Fareed, D. Hoppensteadt, F. Leya, J. M. Walenga 

P-M-417 

P-M-418 

ASSOCIATION BETWEEN METHYLENETETRAHYDROFOLATE REDUCTASE AND 

INFLAMMATORY MARKERS IN THE INCHIANTI STUDY 

A. M. Gori* (IT), B. Giusti, A. M. Corsi, I. Sestini, C. Saracini, P. Bolli, F. Lauretani, 

S. Bandinelli, L. Ferrucci, G. F. Gensini, R. Abbate 

TETRASPANIN CD9 MODULATES VASCULAR SMOOTH MUSCLE CELL MIGRATION 

AND PROLIFERATION IN VITRO AND NEOINTIMA FORMATION IN VIVO 

K. J. Prakash (US), C. Zhang, C. M. Longhurst, Y. Lu, L. K. Jennings*, J. Jacobs 


P-M-419 

P-M-420 

CHAOTIC ADVECTION IN STENOSED ARTERIES 

G. Károlyi* (UK), A. Schelin, C. Grebogi, N. A. Booth, A. Moura 

CORONARY INSTENT RESTENOSIS OF DRUG-ELUTING STENTS IS ASSOCIATED 

WITH SERUM LEVELS OF MMP-9 

K. M. Katsaros* (AT), W. S. Speidl, S. P. Kastl, D. Scheinig, K. Huber, D. Glogar, 

J. Wojta, G. Christ, G. Maurer 

Cell-cell interactions 

P-M-421 

P-M-422 

P-M-423 

P-M-424 

P-M-425 

P-M-426 

CORTICAL NEURONS AGGREGATE IN RESPONSE TO PLASMIN FORMED AT THEIR 

SURFACE BY TPA 

E. Angles-Cano (FR), B. Ho-Tin-Noe*, H. Enslen, J. Corsi, R. Lijnen 

INHIBITION BY SOY ISOFLAVONES OF HUMAN POLYMORPHONUCLEAR LEUKOCYTE 

FUNCTION 

S. Rotondo (IT), K. Krauze-Brzósko, S. Manarini, N. Martelli, R. Pecce, V. Evangelista, 

M. Donati, C. Cerletti* 

PLATELET BUT NOT LEUKOCYTE ACTIVATION IS A PREREQUISITE FOR 

PLATELET-LEUKOCYTE INTERACTION IN HUMAN WHOLE BLOOD 

B. Izzi* (IT), A. Pampuch, G. De Gaetano, C. Cerletti 

ACTIVATED PLATELETS ENHANCE THE ADHERENCE TO AND INVASION OF 

ENDOTHELIAL CELLS BY STAPHYLOCOCCUS AUREUS 

B. E. Kehrel (DE), S. Niemann*, C. Heilmann, G. Peters, H. K. Van Aken 

CYTOKINE-INDUCED MONOCYTE-ENDOTHELIAL CELL INTERACTIONS: EFFECT ON 

PAI-1 LEVELS 

J. Orbe (ES), M. Valgañón, J. A. Rodriguez, M. Belzunce, J. A. Paramo* 

DETERMINANTS OF PLATELET AGGREGATE FORMATION WITH EITHER 

POLYMORPHONUCLEAR LEUKOCYTES OR MONOCYTES IN HUMAN WHOLE BLOOD 

A. Pampuch* (IT), B. Izzi, S. Costanzo, B. Vohnout, L. Iacoviello, M. Donati, C. Cerletti, 

G. De Gaetano 

197



P-M-427 

INCREASED ADHESION TO ENDOTHELIAL CELLS OF ERYTHROCYTES FROM 

PATIENTS WITH POLYCYTHEMIA VERA IS MEDIATED BY LAMININ ALPHA5 CHAIN 

AND LU/BCAM 

M. Wautier (FR), W. El Nemer, P. Gane, J. Rain, C. Le Vankim, J. Wautier* 

Mechanical stimuli/rheology 

P-M-428 

P-M-429 

P-M-430 

MOLECULAR AND CELLULAR DYNAMICS OF MOESIN IN VASCULAR CELLS VIA 

MECHANO-TRANSDUCTION 

M. Britto* (IE), P. Fitzpatrick, G. Meade, P. A. Cahill, P. M. Cummins, R. P. Murphy 

THE MECHANO-REGULATION OF LASP-1 IN THE PATHOGENESIS OF 

CARDIOVASCULAR DISEASE 

P. Fitzpatrick* (IE), M. Britto, G. Meade, P. A. Cahill, P. M. Cummins, R. P. Murphy 

BIOMECHANICAL PROPERTIES OF VON WILLEBRAND FACTOR BINDING TO 

PLATELET GLYCOPROTEIN IB RECAPITULATED BY THE DIMERIC A1 DOMAIN 

J. N. Orje* (US), M. Machin, J. R. Roberts, R. A. McClintock, R. Habermann, P. Canu, 

Z. M. Ruggeri 

Microparticles 

P-M-431 

P-M-432 

P-M-433 

P-M-434 

P-M-435 

P-M-436 

P-M-437 

P-M-438 

P-M-439 

198 

STRATEGIES FOR CHARACTERIZING THE PHOSPHO- AND GLYCOPROTEOMES OF 

MICROPARTICLES DERIVED FROM INTERLEUKIN-1BETA STIMULATED PANCREATIC 

BETA-CELLS 

S. S. Jensen* (DK), O. Østergaard, J. M. McGuire, F. Pociot, M. R. Larsen 

MICROPARTICLES IN THROMBIN GENERATION - A SIGNIFICANT PARAMETER 

INFLUENCING PEAK THROMBIN LEVELS 

V. Kaufmann* (AT), J. Mager, S. Eichinger, B. R. Binder 

ROLE OF ENDOTHELIAL CELL-DERIVED MICROPARTICLES IN PATIENTS WITH 

CHRONIC HEART FAILURE 

O. Korzh* (UA), S. Krasnokutskiy 

CISPLATIN INDUCES IN VITRO THROMBIN GENERATION VIA FORMATION OF 

PROCOAGULANT ENDOTHELIAL MICROPARTICLES 

D. Lechner* (AT), M. Kollars, A. Gleiss, S. Eichinger, P. A. Kyrle, A. Weltermann 

EFFECT OF PRE-ANALYTICAL VARIABLES ON MICROPARTICLE NUMBERS 

S. F. Lynch* (UK), D. Stirling, C. A. Ludlam 

GENDER AND MENSTRUAL CYCLE INFLUENCE CIRCULATING MICROPARTICLES 

R. Nieuwland* (NL), B. Toth, K. Nikolajek, A. Rank, K. Friese, C. J. Thaler 

INHIBITION OF MICROPARTICLE RELEASE TRIGGERS ENDOTHELIAL APOPTOSIS 

R. Nieuwland (NL), M. N. Abid-Hussein, A. N. Böing*, A. Sturk, C. M. Hau 

MICROPARTICLES DURING THE COURSE OF PAINFUL CRISES IN SICKLE CELL 

DISEASE 

R. Nieuwland* (NL), E. J. Van Beers, M. C. L. Schaap, R. J. Berckmans, A. Sturk, 

B. J. Biemond 

SIMVASTATIN-INDUCED ENDOTHELIAL CELL DETACHMENT AND MICROPARTICLE 

RELEASE ARE PRENYLATION DEPENDENT 

M. Diamant (NL), M. E. Tushuizen, M. N. Abid-Hussein, C. M. Hau, A. N. Böing, 

Sturk, R. Nieuwland*



P-M-440 

EFFECTS OF PITAVASTATIN AND EICOSAPENTAENOIC ACID ON PLATELET-DERIVED 

MICROPARTICLES AND ADIPONECTIN IN HYPERLIPIDEMIC PATIENTS WITH TYPE 2 

DIABETES MELLITUS 

S. Nomura* (JP), N. Inami, A. Shouzu, S. Omoto, A. Tanaka, M. Nanba, Y. Shouda, 

N. Takahashi, Y. Kimura, T. Iwasaka 

P-M-441 

P-M-442 

P-M-443 

P-M-444 

CHANGES OF THE PLASMA LEVELS OF PLATELET AND ENDOTHELIAL 

MICROPARTICLES IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND 

ANTIHOSPHOLIPID SYNDROME 

D. Oh* (KR), M. M. J. Jang, M. M. S. Kang, S. S. J. Lee, S. S. Park, 

H. H. S. Yun-Choi, S. S. Y. Chong, Y. Y. G. Lee, S. S. Y. Oh, S. S. M. Bang 

STANDARDIZATION OF MICROPARTICLE COUNTING USING FLOW CYTOMETRY: NEW 

OPTIONS AND TOOLS FOR THE CONTROL OF CRITICAL INSTRUMENT SETTINGS 

S. Robert* (FR), P. Poncelet, L. Camoin, F. Dignat-Georges 

MEASURING MICROPARTICLES: PITFALLS AND MODIFICATIONS 

M. D. Shah* (US), A. Bergeron, J. Dong, J. A. Lopez 

CIRCULATING MICROPARTICLE (MP)-ASSOCIATED TISSUE FACTOR (TF) ACTIVITY 

AND THROMBOSIS IN CANCER PATIENTS 

M. E. T. Tesselaar* (NL), F. P. H. Romijn, I. K. Van Der Linden, R. M. Bertina, 

S. Osanto 


P-M-445 

COMPARISON OF DIFFERENT METHODS FOR ISOLATION AND STORAGE OF 

MICROPARTICLES FROM HUMAN BLOOD 

A. Weltermann* (AT), H. Weber, M. Kollars, P. A. Kyrle 

Thrombotic disorders and antithrombotic therapy 

Antiphospholipid antibodies and syndrome 

P-M-446 

PATIENTS WITH LUPUS ANTICOAGULANTS AND HISTORY OF THROMBOSIS CARRY 

ANTIBODIES TO BETA2-GLYCOPROTEIN I INHIBITING THE PHOSPHOLIPID 

OXIDATION-DEPENDENT ACTIVITY OF APC 

Y. Hu (US), P. Della Valle, O. Safa, M. M. Kobzdej, C. T. Esmon, A. D'Angelo, 

N. L. Esmon* 

P-M-447 ANTICARDIOLIPIN ANTIBODIES AND OUTCOME OF PREGNANCY – 

A RETROSPECTIVE 3 YEAR STUDY 

E. J. Ferguson (UK), J. Laird, C. Tait*, I. Walker 

P-M-448 

P-M-449 

P-M-450 

BILATERAL THROMBOSIS OF POSTERIOR SHORT CILIORETINAL VESSELS IN A 

PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME, HYPERHOMOCYSTEINE AND 

ETEROZIGOUS FOR MTHRF 

C. Giannarelli* (IT), M. Figus, F. De Negri, S. Taddei, M. Nardi 

EVALUATION OF A PROTOTYPE MULTIPLEX METHOD FOR EVALUATING 

PHOSPHOLIPID ANTIBODIES 

R. C. Gosselin* (US), K. A. Janatpour, J. T. Owings 

ARE ANTIPHOSPHOLIPID ANTIBODIES RISK FACTORS FOR CORONARY ARTERY 

DISEASE? 

T. P. Greco* (US), L. R. Lopez, A. Conti-Kelly, E. Matsuura, T. Greco Jr, K. J. Dier, 

G. Svanas, R. Doyle 

199



P-M-451 

P-M-452 

P-M-453 

P-M-454 

P-M-455 

P-M-456 

P-M-457 

P-M-458 

P-M-459 

P-M-460 

P-M-461 

P-M-462 

P-M-463 

PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID ANTIBODY SYNDROME PRESENT A 

NORMAL ENDOTHELIAL FUNCTION 

P. Gresele* (IT), R. Migliacci, C. Vedovati, C. Becattini, G. Guglielmini, A. Mezzasoma, 

C. Pegoraro, A. Ruffatti, V. Pengo 

ANTIPHOSPHOLIPID ANTIBODIES DISTURB 2D LATTICE FORMATION OF ANNEXINE 

A5 ON ACTIVATED PLATELETS 

N. Jacobs (NL), P. De Groot, L. Hiddink, R. Woestenenk, J. Boezeman, 

W. L. Van Heerde* 

THROMBOPHILIA DOES NOT INCREASE THE RISK FOR RECURRENT THROMBOSIS 

IN PEDIATRIC APS 

G. Kenet* (IL), Y. Berkun, S. Padeh, J. Barash, Y. Uziel, L. Harel, M. Mukamel, 

S. Ravel-Vilk 

LUPUS ANTICOAGULANT: LABORATORY DIAGNOSIS FROM PATIENTS WITH 

THROMBOSIS 

V. A. Kobiljanskaja* (RU) 

INDETERMINATE RESULTS ARE COMMON IN LUPUS ANTICOAGULANT TESTING 

K. Kottke-Marchant* (US), S. Jang 

ANTIPHOSPHOLIPID ANTIBODIES AND EX-VIVO ENDOTHELIAL PERTURBATION 

D. Mari* (IT), M. Cugno, M. O. Borghi, M. Gerosa, C. Grossi, V. De Angelis, 

G. Magnaghi, A. Tincani, L. Lonati, P. Riboldi, P. Meroni 

CLUSTERING OF SURFACE-BOUND BETA2-GLYCOPROTEIN I 

S. Matsumoto* (JP), A. Hayashi, E. Matsuura, K. Suzuki, H. Kato, H. Takeya 

CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME PRESENTING WITH ISOLATED 

ANTI-BETA2 GLYCOPROTEIN I ANTIBODY POSITIVITY 

C. M. Millar* (UK), P. Chowdary, S. Vinayagam, H. Beynon, E. G. Tuddenham 

ANTIPHOSPHOLIPID ANTIBODY TESTING IN PIEMONTE AND VALLE D’AOSTA: 

A MULTILABORATORY EXTERNAL QUALITY ASSURANCE (EQA) PROGRAM 

B. Montaruli (IT), A. Vaccarino, G. Mengozzi, M. Saitta, M. Bazzan* 

THE P38 MITOGEN-ACTIVATE PROTEIN KINASE (MAPK) PATHWAY MEDIATES THE 

INDUCTION OF TISSUE FACTOR EXPRESSION BY PHOSPHATIDYLSERINE- 

DEPENDENT ANTIPROTHROMBIN ANTIBODIES WITH LUPUS ANTICOAGULANT 

ACTIVITY 

K. Oku* (JP), T. Atsumi, O. Amengual, H. Kataoka, T. Horita, S. Yasuda, T. Koike 

ANTIPHOSPHOLIPID ANTIBODY SYNDROME IN THE THROMBOPHILIA PILOT 

PROJECT 

T. L. Ortel* (US), A. James, M. Beckman, N. Dowling, P. Bockenstedt, M. Manco-Johnson 

DOES TESTING FOR ANTI BETA-2 GLYCOPROTEIN 1 ANTIBODIES ALTER CLINICAL 

PRACTICE IN PATIENTS WITH THE ANTIPHOSPHOLIPID SYNDROME? 

M. M. Patnaik* (US), A. A. Killeen, M. T. Reding, R. S. Kasthuri 

PSGL1 AND LDL-RECEPTORS MEDIATE ADHESION OF LEUKOCYTES TO 

BETA2-GLYCOPROTEIN-I 

R. Pendu* (NL), C. Weeterings, R. T. Urbanus, M. T. T. Pennings, C. V. Denis, 

P. G. De Groot, P. J. Lenting 

200



Thrombophilia and familial thrombosis 

P-M-464 

P-M-465 

PROTHROMBOTIC FACTORS AND OXIDATIVE STRESS MARKERS IN 

A TYPE 2 DIABETES POPULATION 

G. Barillari* (IT), E. Fabbro, R. Daminato, M. Turello, E. Bigotto, A. Ceriello 

INFLUENCE OF FV LEIDEN ON THE KINETICS OF THROMBIN FORMATION AS 

DETERMINED BY THE THROMBIN DYNAMICS TEST (TDT) 

A. Calatzis* (DE), M. Spannagl, W. Schramm 

P-M-466 FACTOR V LEIDEN AS A THROMBOPHILIA'S MARKER IN LIVER TRANSPLANTATION - 

AN EVALUATION 

M. M. Campos* (PT), I. R. Santos, M. E. Ribeiro, A. R. Lorga, A. L. Cordeiro 

P-M-467 

P-M-468 

ANTITHROMBIN DEFICIENCY IN THE GENERAL POPULATION IS RARELY DUE TO AT 

GENE MUTATIONS, WHICH ARE MAINLY REPRESENTED BY ALA384SER MUTATION 

G. Castaman (IT), S. H. Giacomelli*, M. Simioni, D. Madeo, A. Tosetto, F. Rodeghiero 

MORE SEVERE HYPERCOAGULABLE STATE IN PROTHROMBIN G20210A CARRIERS 

THAN IN NON-CARRIERS WITH COMPARABLE PROTHROMBIN LEVELS 

E. Castoldi* (NL), P. Simioni, D. Tormene, M. C. L. G. Thomassen, L. Spiezia, 

S. Gavasso, J. Rosing 


P-M-469 

P-M-470 

P-M-471 

P-M-472 

P-M-473 

P-M-474 

P-M-475 

NECESSITY OF SCREENING FOR THROMBOPHILIA AT DIAGNOSIS OF VENOUS 

THROMBOEMBOLISM: OUTLINE OF THE NOSTRADAMUS INTERVENTION TRIAL 

D. M. Cohn* (NL), S. Middeldorp 

INFLUENCE OF TESTING FOR INHERITED THROMBOPHILIA ON RECURRENCE OF 

VENOUS THROMBOEMBOLISM 

M. Coppens* (NL), J. H. Reinders, C. J. M. Doggen, S. Middeldorp, F. R. Rosendaal 

DETECTING PROTHROMBOTIC STATES USING A THROMBIN GENERATION TEST IN 

RELATIVES OF PATIENTS WITH VENOUS THROMBOEMBOLISM AND FACTOR V 

LEIDEN 

F. Couturaud* (FR), J. Duchemin, J. Abgrall, C. Leroyer, D. Mottier 

THROMBOPHILIA IN HIV-INFECTED PATIENTS WITH OSTEONECROSIS: IS THERE A 

REAL CONNECTION? THE FIRST CASE-CONTROL STUDY 

G. F. De Larrañaga* (AR), E. Bottaro, M. Martinuzzo, M. Iglesias Varela, R. Forastiero, 

Y. Adamczuk, N. Gómez, J. Benetucci 

INHERITED THROMBOPHILIC ABNORMALITIES AND RISK OF PORTAL VEIN 

THROMBOSIS: A META-ANALYSIS 

F. Dentali* (IT), M. Galli, M. Gianni, W. Ageno 

EVALUATION OF THROMBIN GENERATION CAPACITY IN PLASMA FROM PATIENTS 

WITH HIGH LEVELS OF FVIII, FIX OR FXI AND ONE SPONTANEOUS VENOUS 

THROMBOEMBOLIC EVENT 

C. Duboscq* (AR), J. Ceresetto, C. Shanley, G. Stemmelin, C. Doti, M. Vicente, 

G. Castedo, M. Melgar, E. Bullorsky 

CEREBROVASCULAR THROMBOSIS DURING ESTROPROGESTINIC THERAPY 

IN A YOUNG WOMAN 

C. Durante (IT), A. Steffan* 

201



P-M-476 

P-M-477 

P-M-478 

P-M-479 

P-M-480 

P-M-481 

P-M-482 

P-M-483 

P-M-484 

ENDOTHELIAL PROTEIN C RECEPTOR A1 AND A3 HAPLOTYPES AND THE RISK OF 

VENOUS THROMBOEMBOLISM IN CARRIERS OF THE PROTHROMBIN G20210A 

MUTATION 

S. Navarro* (ES), P. Medina, A. Estellés, A. Vayá, P. Cubillo, Y. Mira, P. Villa, 

F. Ferrando, R. M. Bertina, F. España 

PROTHROMBIN AND F1+2 LEVELS ARE SIGNIFICANTLY INCREASED IN 

SYMPTOMATIC COMPARED WITH ASYMPTOMATIC FAMILY MEMBERS CARRYING THE 

PROTHROMBIN G20210A MUTATION 

P. Medina* (ES), S. Navarro, Y. Mira, A. Estellés, A. Vayá, P. Villa, F. Ferrando, 

P. Cubillo, R. M. Bertina, F. España 

MANAGEMENT OF AT ACTIVITY LEVELS WITH ANTITHROMBIN ALFA IN HEREDITARY 

AT DEFICIENT PATIENTS DURING SURGERY 

J. T. M. Frieling (US), R. C. Tait*, J. Bonfiglio, H. J. Drenth 

PREGNANT HEREDITARY ANTITHROMBIN DEFICIENT WOMEN REQUIRE A DISTINCT 

DOSING STRATEGY FOR THE MANAGEMENT OF AT ACTIVITY LEVELS WITH 

ANTITHROMBIN ALFA 

J. T. M. Frieling* (US), H. J. Drenth, J. Bonfiglio, R. C. Tait 

RISK STRATIFICATION OF RECURRENT VENOUS THROMBOEMBOLISM 

R. B. Zotz* (DE), A. Gerhardt, H. Segendorf, B. Maruhn-Debowski, R. E. Scharf 

ANTICOAGULATION IN A PATIENT WITH SEVERE PREECLAMPSIA, POSITIVE 

ANTIBETA2-GLYCOPROTEIN I ANTIBODIES AND HOMOZIGOSITY FOR PAI-1 

AND MTHFR 

H. Guglielmone* (AR), S. Minoldo, G. Jarchum 

PAI-1 GENE 4G/5G GENOTYPE AS AN ADDITIONAL RISK FACTOR IN PATIENTS WITH 

THROMBOSIS: A RETROSPECTIVE COHORT STUDY 

H. Guglielmone* (AR), S. Minoldo, G. Jarchum 

RISK FACTORS AND OUTCOME OF PEDIATRIC THROMBOTIC EPISODES IN A SINGLE 

CENTER 

A. Gurgey* (TR), S. Aytac, B. Tavil, S. Unal, F. Gumruk 

SENSITIVITY OF THE HEMOSIL THROMBOPATH ASSAY TO DEFECTS IN THE PROTEIN 

C ANTICOAGULANT PATHWAY 

K. P. Hickey (UK), P. C. Cooper*, S. Kitchen 

Genetic determinants and epidemiology 

P-M-485 

P-M-486 

P-M-487 

P-M-488 

RESISTANCE TO OAC ASSOCIATED TO A NEW POINT MUTATION IN VKORC1 GENE 

K. Peoc'H (FR), C. Bal Dit Sollier, S. Pruvot, S. Thomas, D. Paulin, L. Drouet* 

THROMBOPHILIC POLYMORPHISMS IN PEDIATRIC CATHETER RELATED VERSUS 

NON CATHETER RELATED VENOUS THROMBOEMBOLISM 

V. V. Balasa* (US), M. Kim, R. A. Gruppo 

IS PROTEIN S (PS) DEFICIENCY RARER IN THE BASQUES? 

F. Bauduer* (FR), L. Ducout 

IL 1A –899C/T AND IL4 –589C/T ARE ASSOCIATED WITH VENOUS 

THROMBOEMBOLISM 

M. Beckers* (NL), H. Ruven, M. Prins, D. Biesma 

202



P-M-489 

P-M-490 

VENOUS THROMBOEMBOLISM ASSOCIATED POLYMORPHISMS IN SLOVENE 

POPULATION 

M. Bedencic* (SI), M. Bozic, M. Stegnar 

‘IN VIVO’ TOLL-LIKE RECEPTOR 4 MRNA LEVELS ARE ASSOCIATED WITH RISK OF 

MYOCARDIAL INFARCTION IN MEN 

S. Bezzina Wettinger* (MT), C. A. Spek, E. Paffen, A. Felice, F. R. Rosendaal, 

C. J. M. Doggen, P. H. Reitsma 

P-M-491 

P-M-492 

P-M-493 

1800NOCLOTS – WHAT HAVE WE LEARNED FROM THIS FREE CONSULTATIVE 

SERVICE 

A. K. C. Chan* (CA), S. Siciliano 

COAGULATION FACTORS IX - XIII AND RISK OF FUTURE VENOUS THROMBOSIS: 

THE LONGITUDINAL INVESTIGATION OF THROMBOEMBOLISM ETIOLOGY (LITE) 

M. Cushman* (US), E. O'Meara, S. R. Heckbert, W. Rosamond, A. R. Folsom 

POLYMORPHISMS OF VON WILLEBRAND FACTOR (VWF) GENE PROMOTER 

MODULATE THE CORTICOSTEROID-MEDIATED INCREASE IN VWF LEVELS IN 

CUSHING’S SYNDROME: A POTENTIAL MODEL OF TRANSCRIPTIONAL REGULATION 

AND A NEW THROMBOTIC MARKER 

V. Daidone* (IT), F. Sartorello, M. Sztukowska, N. Albiger, C. Scaroni, F. Mantero, 

A. Pagnan, S. Casonato 


P-M-494 

P-M-495 

P-M-496 

P-M-497 

P-M-498 

P-M-499 

P-M-500 

INVESTIGATION OF THROMBOPHILIA DURING PREGNANCY AND PUERPERIUM: 

A STUDY FROM NORTH INDIA 

R. Das* (IN), J. Ahluwalia, G. Garewal, P. Malhotra, N. Varma, S. Prabhakar, S. Varma 

HAPLOTYPES OF THE C-REACTIVE PROTEIN GENE, PLASMA CRP LEVELS AND THE 

RISK OF MYOCARDIAL INFARCTION IN MEN 

M. C. H. De Visser* (NL), E. Paffen, H. L. Vos, R. M. Bertina, C. J. M. Doggen, 

F. R. Rosendaal 

THE 3’UTR PROTHROMBIN GENE POLYMORPHISMS IN THROMBOHILIC SERBIAN 

POPULATION 

V. Djordjevic* (RS), A. Nestorovic, B. Tomic, P. Miljic, D. Mikovic, M. Kovac, 

N. Antonijevic, L. Rakicevic, D. Radojkovic 

ABNORMALITIES IN THE SEROTONIN METABOLISM: A PATHOGENIC HYPOTHESIS 

FOR CENTRAL RETINAL VEIN OCCLUSION (CRVO) 

L. Drouet* (FR), M. Paques, K. Peoc'H, J. Callebert, V. Krivosic, B. Boval, J. Launay, 

A. Gaudric 

APO B ECORI AND INSERTION/DELETION POLYMORPHISMS IN BRAZILIAN YOUNG 

PATIENTS WITH ISQUEMIC STROKE 

L. M. S. Dusse (BR), C. G. M. Santos, M. G. Carvalho, A. P. S. M. Fernandes*, 

A. P. Sabino, D. D. Ribeiro 

PREVALENCE OF POLYMORPHISMS IN EXONS 6 E 7 OF ABO LOCUS AND THEIR 

ASSOCIATION WITH VENOUS THROMBOSIS IN YOUNG BRAZILIAN PATIENTS 

S. G. Paiva (BR), M. G. Carvalho, A. P. Sabino, D. D. Ribeiro, K. G. Braga, 

M. O. Sousa, L. M. S. Dusse, A. P. S. M. Fernandes* 

EPIDEMIOLOGIC, LABORATORY EVALUATION AND CLINICAL CHARACTERISTICS IN 

PATIENTS WITH THROMBOSIS 

M. Faranoush* (IR), P. Vossough, F. Ala, G. Rastegarlari, H. Sadeghi, F. Namakian, 

M. Malek, M. Babaei, M. Golpayegani, M. Jazebi, T. Shahshahani, S. Hejazi, 

A. Hedayatiasl, J. Alavitoosi 

203



P-M-501 

P-M-502 

P-M-503 

P-M-504 

P-M-505 

P-M-506 

THROMBOSIS IN BETA THALASSEMIA MAJOR 

M. Faranoush* (IR), F. Ala, P. Vossough, G. Rastegarlari, M. Jazebi, T. Shahshahani, 

S. Hejazi, F. Namakian, M. Golpayegani, A. Hedayatiasl 

G20210A PROTHROMBIN MUTATION IS MORE FREQUENT IN PATIENTS WITH 

ADVANCED STAGES OF PERIPHERAL ARTERIAL DISEASE (PAD) 

E. Favaretto* (IT), E. Conti, M. Filippini, C. Pili, C. Legnani, G. Palareti 

CYP 2C19*2 AND MDR1+3435C ALLELES CONTRIBUTE TO LOW RESPONSE TO 

CLOPIDOGREL IN ACUTE CORONARY SYNDROME 

C. Frere* (FR), T. Cuisset, P. Morange, J. Quilici, N. Saut, L. Camoin, J. Bonnet, 

I. Juhan-Vague, M. Alessi, M. Aillaud 

FIVE PROTHROMBOTIC POLYMORHISMS AND VENOUS THROMBOEMBOLISM 

A. García-Raso (ES), A. B. Santos, V. P. Moreno, M. Raquel, S. Dolores, P. Llamas* 

THE T ALLELE OF THE FXII 46C/T GENE POLYMORPHISM IS RISK FACTOR FOR ICD 

IN SPANISH POPULATION 

A. García-Raso (ES), V. P. Moreno, M. J. García-Bueno, C. Sánchez, A. Drozdowskyj, 

A. García-Torres, D. Subirá, P. Llamas* 

SEVEN NOVEL MISSENSE MUTATIONS IN THE VITAMIN K EPOXIDE REDUCTASE 

COMPLEX SUBUNIT 1 (VKORC1) CAUSE HEREDITARY COUMARIN RESISTANCE 

C. Geisen* (DE), K. Sittinger, G. Spohn, D. M. Dimichele, H. Haubelt, M. Heistinger, 

J. G. Kadar, B. Kemkes-Matthes, R. Klamroth, P. Lages, E. Lindhoff-Last, 

B. Luxembourg, B. Mansouri Taleghani, H. Pollmann, M. Spannagl, R. Zimmermann, 

E. Seifried, J. Oldenburg 

Cancer and thrombosis 

P-M-507 

P-M-508 

P-M-509 

P-M-510 

P-M-512 

P-M-513 

PROGNOSTIC SIGNIFICANCE FOR VENOUS THROMBOEMBOLISM (VTE) OF 

HEMOSTATIC MARKERS IN PATIENTS WITH MULTIPLE MYELOMA (MM) RECEIVING 

THALIDOMIDE 

A. Falanga* (IT), L. Russo, A. Vignoli, D. Balducci, M. Marchetti, T. Barbui, M. Galli 

UPREGULATION OF INFLAMMATORY MEDIATORS IN LUNG CANCER AND THEIR 

MODULATION BY ORAL ANTICOAGULANT THERAPY 

D. Hoppensteadt* (US), M. Demir, J. Cunanan, W. Jeske, O. Iqbal, R. Bick, J. Fareed 

HYPERCOAGULABILITY IN OVARIAN CANCER REVISITED: A PROSPECTIVE 

ANALYSIS OF COAGULATION AND PLATELET ACTIVATION MARKERS 

J. L. Francis* (US), G. Bigsby, H. Desai, M. Amaya, E. Coll, L. Robles, A. Drexler, 

P. Faust, F. Langer, E. Reyes, A. Amirkhosravi 

A STUDY OF D-DIMER LEVELS IN CANCER PATIENTS DURING ANTINEOPLASTIC 

TREATMENT 

F. Garry* (IE) 

A PROPOSAL OF SCORING SYSTEM IN ASSESSMENT OF THROMBOTIC RISK IN 

CANCER PATIENT. A MONOCENTRIC STUDY 

G. Giordano* (IT), G. Farina, R. Tambaro, M. Specchia, S. Papini, M. Piunno, 

C. Antonelli, B. Zappacosta, S. Storti 

THE DISCRIMINATION OF GENERIC FORMS OF LMW HEPARIN USING A PROTEOMIC 

BLOOD BASED APPROACH 

C. A. Goodwin* (UK), M. F. Scully, A. K. Kakkar 

204



P-M-514 

P-M-515 

THE DISCRIMINATION OF GENERIC FORMS OF LMW HEPARIN USING A PROTEOMIC 

CELL-BASED APPROACH 

C. A. Goodwin* (UK), R. Clutterbuck, M. F. Scully, A. K. Kakkar 

INTERACTIONS WITH P-SELECTIN AND ANTIMETASTATIC ACTIVITIES OF 

NADROPARIN AND UFH 

S. Alban* (DE), R. J. Ludwig 

P-M-516 

P-M-517 

P-M-518 

PLASMA LEVELS OF PROTHROMBIN FRAGMENT F1+2, D-DIMER, AND 

PROTHROMBIN TIME IN GASTRIC CANCER PATIENTS CORRELATE WITH CLINICAL 

STAGE AND LYMPH NODE METASTASIS 

J. Han* (KR), R. Koh, S. Lee, S. Kim, S. Oh, S. Kim, M. Kim, H. Kwon, H. Kim 

UPREGULATION OF NITRIC OXIDE AND ASYMMETRIC DIMETHYLARGININE LEVELS 

IN MALIGNANCY ASSOCIATED THROMBOSIS AND THEIR MODULATION BY 

ANTICOAGULANTS 

D. Hoppensteadt* (US), W. P. Jeske, D. Fareed, O. Iqbal, R. Bick, J. Fareed 

ANALYSIS OF SURFACE AND SOLUBLE L-SELECTIN IN RELATION TO FLOW 

CYTOMETRIC PROGNOSTIC MARKERS IN CHRONIC LYMPHOCYTIC LEUKEMIA 

J. Kappelmayer* (HU), I. Balogh, F. Kiss, R. Szasz, J. Jako 


P-M-519 

P-M-520 

P-M-521 

P-M-522 

P-M-523 

P-M-524 

P-M-525 

LOW MOLECULAR WEIGHT HEPARINS ARE EFFECTIVE AND SAFE IN 

THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA PATIENTS DURING THE 

INDUCTION THERAPY 

P. Kessler* (CZ), L. Pour, E. Gregora, M. Zemanova, M. Penka, J. Gumulec, Z. Adam, 

J. Bacovsky, M. Brejcha, M. Fenclova, H. Frankova, K. Havlikova, P. Hausdorf, 

A. Heindorfer, V. Heinzova, M. Holikova, M. Krejci, K. Kubackova, E. Langrova, 

F. Lehanka, V. Maisnar, I. Meluzinova, Y. Stavarova, J. Straub, A. Svobodnik, V. Scudla, 

E. Sumna, J. Ullrychova, L. Walterova, R. Hajek 

LOW MOLECULAR WEIGHT HEPARIN (LMWH) AND CANCER SURVIVAL. 

A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS IN PATIENTS WITH AND 

WITHOUT VTE 

S. Laporte* (FR), G. Meyer, H. Buller, H. Decousus, N. Moulin, M. Cucherat, P. Mismetti 

EPIDEMIOLOGICAL STUDY: CAUSES OF DETHS IN PTOLEMAIDA CITY 

P. E. Makris* (GR), M. P. Makris, S. I. Papamichos, L. P. Makris 

THROMBIN GENERATION IN CHRONIC MYELOPROLIFERATIVE DISORDERS (MPD) 

M. Marchetti* (NL), H. M. H. Spronk, R. Van Oerle, A. Vignoli, L. Russo, J. Ilcheff, 

K. Hamulyak, T. Barbui, A. Falanga, H. Ten Cate 

INFLUENCE OF JAK2 V617F AND OTHER GENETIC RISK FACTORS IN THROMBOSIS 

AND HEMORRHAGE IN PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE 

DISORDERS [PH(-) MPD] 

M. J. Moreno* (ES), L. Navarro-Núñez, M. L. Lozano, B. Bellosillo, V. Roldán, J. Rivera, 

N. García-Barberá, J. Nieto, C. Besses, V. Vicente, C. Martínez 

POST-THROMBOTIC SYNDROME IN CHILDREN SURVIVING ACUTE LYMPHOBLASTIC 

LEUKEMIA 

S. Kuhle (CA), M. Spavour, P. Massicotte, J. Halton, I. Cherrick, D. Dix, D. Mahony, 

S. Desai, L. G. Mitchell* 

ANTI-CANCER EFFICACY OF LOW MOLECULAR WEIGHT HEPARIN IN THROMBOSIS- 

ASSOCIATED TUMOR GROWTH 


205



P-M-526 

P-M-527 

P-M-528 

P-M-529 

ANTI-METASTASIS EFFICACY OF LOW MOLECULAR WEIGHT HEPARIN IN 

EXPERIMENTAL METASTASIS MODEL 

S. A. Mousa* (US), K. B. Johansen, J. L. Francis, A. Amirkhosravi 

ANTITHROMBOTIC EFFICACY OF LOW MOLECULAR WEIGHT HEPARIN IN 

HYPERCOAGULATION STATES AND CANCER-ASSOCIATED THROMBOSIS 


ACTIVATED COAGULATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES 

H. F. S. Negaard* (NO), P. O. Iversen, B. Ostenstad, N. Iversen, P. A. Holme, 

P. M. Sandset 

WARFARIN USE AND THE DECREASED RISK OF PROSTATE CANCER 

L. Opatrny* (CA), J. A. Delaney, V. Tagalakis, S. R. Kahn, S. Suissa 

Deep vein thrombosis and pulmonary embolism 

P-M-530 

P-M-531 

P-M-532 

P-M-533 

P-M-534 

P-M-535 

P-M-536 

P-M-537 

P-M-538 

QUANTIFICATION OF ADAMTS13 ANTIGEN, ACTIVITY AND ADAMTS13/FXI COMPLEX 

FROM PATIENTS WITH HEMOSTATIC/THROMBOTIC DISORDERS 

H. J. L. Fryer* (US), E. Guinto, N. Grafos, J. Wu, R. S. Greenfield 

CLINICAL RISK FACTORS AND 3 MONTHS OUTCOMES OF SYMPTOMATIC CALF VEIN 

THROMBOSIS: FINDINGS FROM THE OPTIMEV COHORT 

J. Galanaud* (FR), A. Khau Van Kien, C. Boubakri, G. Pernod, G. Boge, J. Laroche, 

J. Gris, I. Quere, J. Bosson 

DEEP VENOUS THROMBOSIS IN THE ANTENATAL PERIOD IN A LARGE COHORT OF 

PREGNANCIES FROM WESTERN INDIA 

K. Ghosh* (IN), S. Vora, S. Shetty 

DIAGNOSTIC ACCURACY OF THE TRIAGE D-DIMER TEST FOR EXCLUSION OF 

VENOUS THROMBOEMBOLISM IN OUTPATIENTS 

T. Ghys* (BE), I. Verschraegen, W. Achtergael, B. Leus, K. Jochmans 

DIFFERENTIAL VENOUS THROMBOEMBOLISM PROPHYLAXIS PRESCRIPTION IN 

PATIENTS WITH SURGICAL AND NON-SURGICAL CONDITIONS ADMITTED TO 

SURGICAL UNITS 

H. Gibbs* (AU), R. Collins, J. Gibbs 

FURTHER VALIDATION AND SIMPLIFICATION OF THE WELLS CLINICAL DECISION 

RULE IN PULMONARY EMBOLISM 

N. S. Gibson* (NL), M. Sohne, M. J. H. Kruip, L. W. Tick, V. E. Gerdes, P. M. Bossuyt, 

P. S. Wells, H. R. Buller 

MISUSE OF THE D-DIMER TEST IN HOSPITALISED PATIENTS 

P. Girard* (FR), S. Lenoir, J. Stern, C. Strauss, R. Caliandro, J. Le Guillou, C. Touitou 

D-DIMER LEVELS CORRELATE WITH MORTALITY IN PATIENTS WITH ACUTE 

PULMONARY EMBOLISM: FINDINGS FROM THE RIETE REGISTRY 

E. Grau* (ES), J. Tenias, M. Soto, M. Gutierrez, R. Lecumberri, J. Perez, G. Tiberio 

PROGNOSTIC FACTORS OF SHORT-TERM SURVIVAL IN PATIENTS WITH DEEP VEIN 

THROMBOSIS: FINDINGS FROM A PROSPECTIVE REGISTRY (RIETE) 

E. Grau* (ES), J. Tenias, M. Soto, M. Gutierrez, R. Lecumberri, J. Perez, G. Tiberio 

206



P-M-539 

P-M-540 

ESTIMATING THE INFLUENCE OF MEASUREMENT VARIABILITY ON DIAGNOSTIC 

ERRORS: A BAYESIAN MODEL APPLIED TO QUANTITATIVE D DIMER ASSAYS FOR 

THE EXCLUSION OF VENOUS THROMBOSIS 

F. Guerrero* (FR), D. Concordet, G. Freyburger, P. Sie 

EVALUATION OF VENOUS THROMBOEMBOLIC RISK PROFILES IN ACUTELY ILL 

MEDICAL PATIENTS IN HOSPITAL AND OUTPATIENT SETTINGS: THE STATUS 

REGISTRY 

S. K. Haas* (DE), K. Kroeger, V. Regitz-Zagrosek, S. M. Schellong, R. B. Zotz, 

C. Kienitz, D. Paar 

P-M-541 

P-M-542 

P-M-543 

THE PREDICTIVE VALUE OF CRP, D-DIMER AND CLINICAL PROBABILITY TO 

EXCLUDE DVT IN PERSONS ADMITTED TO HOSPITAL FOR DVT 

J. B. Hansen* (NO), E. Esaiasen, I. Lægreid, A. Vik 

PREVALENCE OF DEEP VENOUS THROMBOSIS OR PULMONARY EMBOLISM 

(DVT/PE) IN PSYCHIATRY PATIENTS 

K. Hanzawa* (JP), T. Okamoto, K. Sato, J. Hayashi, K. Toyooka 

RELATIONSHIP BETWEEN THE DIAMETER OF SOLEUS VEIN AND D-DIMER 

K. Hanzawa* (JP), T. Okamoto, K. Sato, J. Hayashi 


P-M-544 

P-M-545 

P-M-546 

P-M-547 

P-M-548 

P-M-549 

P-M-550 

P-M-551 

P-M-552 

EXPERIENCES IN THERAPY AND OUTCOME OF ADOLESCENTS WITH ACUTE 

VENOUS THROMBOSIS 

C. Heller* (DE), T. Klingebiel, W. Kreuz 

MATRIX METALLOPROTEIN-9 IS ELEVATED IN BLOOD FROM PATIENTS WITH 

PULMONARY EMBOLISM AND RIGHT VENTRICULAR HYPOKINESIS ON 

ECHOCARDIOGRAPHY 

J. Hernandez* (US), J. A. Kline 

RISK FACTORS OF INCOMPLETE RECANALISATION AFTER DEEP VEIN THROMBOSIS 

J. Hirmerova* (CZ), J. Seidlerova 

THROMBIN GENERATION TEST – AN EXPERIENCE OF ONE CENTRE IN 

THROMBOPHILIA PATIENTS 

A. Hlusi* (CZ), L. Slavik, P. Novak, J. Prochazkova, V. Krcova 

INCIDENCE OF DEEP VEIN THROMBOSIS (DVT) IN NON-SURGICAL PATIENTS AT 

HOSPITAL ADMISSION 

P. Hoffmanns* (DE), H. Lawall, W. Hoffmanns, A. Pira, U. Rapp, C. Diehm 

PULMONARY EMBOLISM, OBESITY, DIABETES, AND HYPERTENSION AMONG 

AMERICAN CAUCASIANS IN THE GATE STUDY 

C. Hooper* (US), C. Lally, N. Dowling, H. Austin 

NOVEL RISK FACTORS FOR DEEP VEIN THROMBOSIS IN HOSPITALIZED PATIENTS 

A. K. Jaffer* (US), E. Mady, S. Mallick, R. Tadros, A. Sekhon, J. Bartholomew, 

D. J. Brotman 

ASSESSMENT RISK FACTOR IN THE MANAGEMENT OF PATIENTS WITH SUSPECTED 

DEEP VENOUS THROMBOSIS 

F. Jalali* (IR) 

VENOUS FUNCTION AND CLINICAL OUTCOME FOLLOWING DEEP VEIN THROMBOSIS 

F. Jalali* (IR) 

207



P-M-553 

P-M-554 

P-M-555 

P-M-556 

P-M-557 

P-M-558 

P-M-559 

P-M-560 

P-M-561 

P-M-562 

P-M-563 

P-M-564 

P-M-565 

VARIABILITY IN ANTICOAGULANT DOSING RECOMMENDATIONS; RESULTS FROM 

TWO UK NEQAS FOR BLOOD COAGULATION EXERCISES 

I. Jennings* (UK), D. P. Kitchen, S. Kitchen, T. A. L. Woods, I. D. Walker 

LOCAL THROMBOLYTIC THERAPY FOR ACUTE ILIOFEMORAL DEEP VENOUS 

THROMBOSIS IS EFFECTIVE AND PRESERVES VENOUS VALVE FUNCTION. 

A PROSPECTIVE ONE-CENTRE STUDY OF 86 CASES 

M. Joergensen* (DK), S. Just, N. Baekgaard, L. Panduro 

WHOLE BLOOD AND PLASMA THROMBIN GENERATION ASSAYS IN PATIENTS WITH 

A HISTORY OF VENOUS THROMBOEMBOLISM 

D. W. Jones* (UK), M. J. Gallimore, G. Evans, K. A. Tappenden, M. Winter, I. J. Mackie 

IS THERE A CONNECTION BETWEEN THORACIC OUTLET SYNDROME AND 

THROMBOSIS OF SIGMOID SINUS? 

V. V. Jovanoska (AL), I. I. J. Jovanoski* 

THROMBOSIS V.SUBCLAVIAE AND THORACIC OUTLET SYNDROME PAGET-VON 

SCHROTTER SYNDROME 

V. V. Jovanoska* (AL), I. I. J. Jovanoski 

P-SELECTIN (P-SEL) GENE HAPLOTYPES MODULATE SOLUBLE (S) 

P-SEL LEVELS AND INCREASE THE RISK OF VENOUS THROMBOEMBOLISM (VTE) 

L. Jungbauer (AT), C. Ay*, A. Kaider, S. Koder, S. Panzer, I. Pabinger, C. Mannhalter 

FREQUENCY OF “SPECIAL POPULATION” CHARACTERISTICS IN VENOUS 

THROMBOEMBOLISM PATIENTS IN CLINICAL PRACTICE: EFFECT ON PATIENT 

MANAGEMENT 

L. Cook (CA), S. R. Kahn*, J. Goodwin, M. J. Kovacs 

SYMPTOMATIC THROMBOSIS COMPLICATIONS IN VENOUS MALFORMATION 

A. Khau Van Kien* (FR), M. Bigorre, J. Galanaud, H. Vernhet, M. Chammas, J. Laroche, 

D. Bessis, A. Jaussent, C. Daily, I. Quéré 

ASSESSMENT OF ACTIONS FOR IMPROVING PREVENTION OF THROMBOEMBOLIC 

DISEASE IN MEDICAL PATIENTS 

G. R. Khayat (LB), C. Khayat*, I. Ibrahim, C. Baaklini 

MULTICENTER, PROSPECTIVE VALIDATION OF A DECISION RULE TO REDUCE 

EXCESS DIAGNOSTIC TESTING FOR PULMONARY EMBOLISM IN THE EMERGENCY 

DEPARTMENT 

J. A. Kline* (US), J. A. Kline, D. M. Courtney, M. P. Than, C. Kabrhel, C. L. Moore, 

H. A. Smithline, M. C. Plewa, T. R. McCubbin, P. B. Richman, B. J. O'Neil, 

D. M. Beam, K. E. Nordenholz, C. L. Johnson 

COMPARISON OF THE REVISED GENEVA RULE WITH WELLS RULE FOR ASSESSING 

CLINICAL PROBABILITY OF PULMONARY EMBOLISM 

F. A. Klok* (NL), E. Kruijswijk, J. Spaan, M. Nijkeuter, A. Perrier, G. Le Gal, 

M. V. Huisman 

RISK FACTORS FOR MORTALITY THREE MONTHS AFTER PULMONARY EMBOLISM 

F. A. Klok* (NL), M. Nijkeuter, M. V. Huisman 

JAK2-V617F IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM 

M. N. Lauw* (NL), E. B. Bus, A. F. Y. Van Wulfften Palthe, C. H. Homburg, M. Coppens, 

S. Middeldorp, C. E. Van Der Schoot, H. R. Koene 

208



P-M-566 

P-M-567 

FIBRINOGEN THR312ALA BUT NOT FXIIIA VAL34LEU AND FXIIIB HIS95ARG 

POLYMORPHISMS ASSOCIATED WITH THAI DEEP VENOUS THROMBOSIS 

N. Komanasin* (TH), P. Angchaisuksiri, P. Mongkolwongroj, M. Puntumetakul, K. Aryuchai 

HEART-TYPE FATTY ACID BINDING PROTEIN IS PREDICTIVE FOR MORTALITY IN 

PATIENTS WITH ACUTE PULMONARY EMBOLISM 

M. J. H. A. Kruip* (NL), M. M. A. L. Pelsers, M. M. Troost, M. V. Huisman, 

M. Nijkeuter, J. F. C. Glatz, F. W. G. Leebeek 

P-M-568 

P-M-569 

P-M-570 

AIR TRAVEL AND VENOUS THROMBOSIS: A SYSTEMATIC REVIEW 

S. Kuipers* (NL), A. J. M. Schreijer, S. C. Cannegieter, F. R. Rosendaal, S. Middeldorp 

VKORC1 GENETIC POLYMORPHISM IS ASSOCIATED TO VENOUS 

THROMBOEMBOLISM: RESULTS FROM THE EDITH STUDY 

K. Lacut (FR), G. Le Gal*, C. Larramendy-Gozalo, J. Duchemin, B. Mercier, L. Gourhant, 

D. Mottier, L. Becquemont, E. Oger, C. Verstuyft 

RISK OF RECURRENCE AFTER A FIRST VENOUS THROMBOEMBOLIC EVENT IN 

YOUNG WOMEN 

C. Laczkovics* (AT), H. Grafenhofer, A. Kaider, P. Quehenberger, R. Simanek, 

C. Mannhalter, K. Lechner, I. Pabinger 


P-M-571 

P-M-572 

P-M-573 

P-M-574 

P-M-575 

P-M-576 

P-M-577 

A COMPARISON OF ANTICOAGULANTS (AC) FOR VENOUS THROMBOEMBOLISM 

(VTE) PROPHYLAXIS (PROPH) AFTER ORTHOPEDIC SURGERY (OS) USING A 

CLINICAL COST-EFFECTIVENESS ANALYSIS (CEA) APPROACH 

A. Lazo-Langner* (CA), D. A. Coyle, N. J. Barrowman, T. Ramsay, P. S. Wells, 

D. Scarvelis, M. A. Forgie, M. A. Rodger 

DEFINING BENEFIT-RISK TRADEOFF VALUES FOR VENOUS THROMBOEMBOLISM 

(VTE) PROPHYLAXIS AFTER ORTHOPEDIC SURGERY (OS) 

A. Lazo-Langner* (CA), D. A. Coyle, P. S. Wells, D. Scarvelis, M. A. Forgie, 

M. A. Rodger 

SECULAR TRENDS IN STUDIES EVALUATING VENOUS THROMBOEMBOLISM (VTE) 

PROPHYLAXIS AFTER ORTHOPEDIC SURGERY (OS) 

A. Lazo-Langner* (CA), D. A. Coyle, P. S. Wells, D. Scarvelis, M. A. Forgie, 

M. A. Rodger 

SPONTANEOUS DEEP VEIN THROMBOSIS OF THE UPPER EXTREMITIES: RISK 

FACTORS AND LONG TERM FOLLOW UP 

D. Lechner* (AT), C. Wiener, S. Eichinger, A. Weltermann, L. Eischer, P. A. Kyrle 

DIFFERENT CUT-OFF VALUES OF THREE D-DIMER (DD) TESTS TO ESTABLISH 

DURATION OF ORAL ANTICOAGULATION TREATMENT (OAT) AFTER A VENOUS 

THROMBOEMBOLISM (VTE) 

C. Legnani* (IT), B. Cosmi, M. Cini, S. Mattarozzi, G. Palareti, A. Tripodi, A. Tosetto 

EFFECTS OF AGE AND DIFFERENT CUT-OFF VALUES ON USE OF D-DIMER (DD) 

TESTING TO ESTABLISH DURATION OF ORAL ANTICOAGULATION TREATMENT (OAT) 

AFTER VENOUS THROMBOEMBOLISM (VTE) 

C. Legnani* (IT), B. Cosmi, M. Cini, S. Mattarozzi, V. Pengo, G. Palareti 

HIGHER FIBRIN MONOMERS (FM) LEVELS AFTER ORAL ANTICOAGULATION (OAT) 

WITHDRAWAL ARE ASSOCIATED WITH INCREASED RISK OF VENOUS 

THROMBOEMBOLISM (VTE) RECURRENCE 

C. Legnani* (IT), B. Cosmi, M. Cini, S. Mattarozzi, G. Palareti 

209



P-M-578 

INNOVANCE D-DIMER ASSAY TO ASSESS THE INDIVIDUAL RISK OF VENOUS 

THROMBOEMBOLISM (VTE) RECURRENCE AFTER ANTICOAGULATION (OAT) 

WITHDRAWAL 

C. Legnani* (IT), B. Cosmi, M. Cini, S. Mattarozzi, G. Palareti 

Ischaemic heart disease 

P-M-579 

P-M-580 

P-M-581 

P-M-582 

P-M-583 

P-M-584 

P-M-585 

P-M-586 

P-M-587 

P-M-588 

P-M-589 

LOW MOLECULAR THIOLS, PRO-COAGULANT STATE AND NATURAL ANTIOXIDANT 

SYSTEM IN HEMODIALYSIS PATIENTS 

F. Alberto* (AR), M. F. Hendler, S. S. Meschengieser, A. Bernasconi, R. Heguilen, 

M. A. Lazzari 

FV LEIDEN, THE APOE GENOTYPE AND OTHER GENE POLYMORPHISMS IN PATIENTS 

UNDERGOING CARDIAC SURGERY 

J. Bach* (DE), I. Kammerer, F. Isgro, W. Saggau, P. Hellstern 

ELEVATED FACTOR XIII LEVEL IS ASSOCIATED WITH AN INCREASED RISK OF 

MYOCARDIAL INFARCTION IN WOMEN 

Z. Bereczky* (HU), E. Balogh, É. Katona, L. Kárpáti, I. Czuriga, I. Édes, L. Muszbek 

MODULATION OF THE RISK OF CORONARY ARTERY DISEASE BY THE INTERACTION 

BETWEEN FACTOR XIII SUBUNIT A VAL34LEU POLYMORPHISM AND FIBRINOGEN 

CONCENTRATION IN THE HUNGARIAN POPULATION 

Z. Bereczky (HU), É. Katona*, E. Balogh, Z. Pocsai, I. Czuriga, G. Széles, R. Ádány, 

I. Édes, L. Muszbek 

DIFFERENT PATTERN OF TF EXPRESSION IN PLATELETS, LEUKOCYTES AND 

AGGREGATES OF CAD PATIENTS 

M. Brambilla (IT), D. Colnago, M. Demetrio, G. Marenzi, K. Gertow, E. Tremoli, 

M. Camera* 

EVALUATION OF THE EFFECT OF TWO DIFFERENT DOSES OF ASPIRIN IN PATIENTS 

UNDERGOING CABG 

M. Brambilla* (IT), C. Centenaro, E. Tremoli, A. Parolari, M. Camera 

NT-PROBNP, AND NOT TF, FM, PAPP-A, MPO OR CD40 LIGAND, PREDICTS 

RECURRENT TROPONIN-T POSITIVE CARDIAC EVENTS FOLLOWING AN ACUTE 

MYOCARDIAL INFARCTION 

T. Brügger-Andersen* (NO), H. Aarstøy, H. Grundt, M. Mehus, D. W. T. Nilsen 

ASSOCIATION OF OXIDIZED LDL AND LP(A) LIPOPROTEIN WITH EXTENT OF 

CORONARY ARTERY DISEASE BY ANGIOGRAPHY 

L. M. Lima (BR), M. G. Carvalho*, C. P. F. Neto, J. C. F. Garcia, M. O. Sousa 

CORONARY ARTERY DISEASE (CAD): LACK OF ASSOCIATION BETWEEN 

APOB/APOA-I RATIO AND ATHEROMATOSIS EXTENT 

L. M. Lima (BR), M. G. Carvalho*, C. P. F. Neto, J. C. F. Garcia, M. O. Sousa 

LACK OF ASSOCIATION BETWEEN APOLIPOPROTEIN E POLYMORPHISM AND 

ATHEROMATOSIS EXTENT IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY 

M. G. Carvalho* (BR), L. M. Lima, A. P. Sabino, A. P. Fernandes, M. O. Sousa 

SECRETORY PHOSPHOLIPASE A2 AND HIGH-SENSITIVITY C-REACTIVE PROTEIN IN 

CORONARY ARTERY DISEASE 

M. G. Carvalho* (BR), L. M. Lima, C. P. F. Neto, J. C. F. Garcia, M. O. Sousa 

210



P-M-590 

P-M-591 

HYPERVISCOSITY AS A POSSIBLE DETERMINANT OF INFARCT SIZE IN PATIENTS 

WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION 

E. Cecchi* (IT), A. Alessandriello Liotta, A. M. Gori, S. Valente, C. Giglioli, C. Lazzeri, 

F. Sofi, G. F. Gensini, R. Abbate, L. Mannini 

EARLY EXCLUSION OF MYOCARDIAL INFARCTION IN PATIENTS WITH CHEST PAIN 

BY TROPONIN I IN CONJUNCTION WITH D-DIMER 

S. Chang* (TW), T. Chiu, H. Ning, J. Chen 

P-M-592 

P-M-593 

PLATELET MICROPARTICLES LEVELS AND PREVALENCE OF ANTIPROTHROMBIN 

AND ANTI-BETA-2-GLYCOPROTEIN I ANTIBODIES IN THROMBOANGIITIS 

OBLITERANS (BUERGER’S DISEASE) 

L. Darnige* (FR), D. Helley, D. M. Smadja, A. Bura, A. Bouziane, E. Lewkowicz, 

J. Emmerich, A. M. Fischer, J. N. Fiessinger 

THROMBIN GENERATION AND COAGULATION MARKERS IN PATIENTS WITH A FIRST 

ACUTE MYOCARDIAL INFARCTION 

A. W. J. H. Dielis* (NL), M. H. M. Winkens, H. M. H. Spronk, P. A. Wijers-Holys, 

R. Van Oerle, K. Hamulyák, J. L. Waltenberger, H. ten Cate 


P-M-594 

THROMBOXANE B2 IN PATIENTS WITH A FIRST ACUTE MYOCARDIAL INFARCTION: 

THE INFLUENCE OF TREATMENT WITH ACETYLSALICYLIC ACID 

A. W. J. H. Dielis* (NL), M. H. M. Winkens, H. M. H. Spronk, P. A. Wijers-Holys, 

R. Van Oerle, K. Hamulyák, J. L. Waltenberger, H. ten Cate 

Hormones, pregnancy, women’s issues 

P-M-595 

P-M-596 

P-M-597 

P-M-598 

P-M-599 

P-M-600 

P-M-601 

DIFFERENTIAL EFFECTS OF CONVENTIONAL AND LOW DOSE ORAL HORMONE 

THERAPY, TIBOLONE AND RALOXIFENE ON FUNCTIONALITY OF THE ACTIVATED 

PROTEIN C SYSTEM 

A. L. Eilertsen* (NO), S. Liestøl, M. Mowinckel, H. C. Hemker, P. Sandset 

DIFFERENTIAL EFFECTS OF CONVENTIONAL DOSE HORMONE THERAPY, LOW 

DOSE HT, TIBOLONE AND RALOXIFENE ON C-REACTIVE PROTEIN AND OTHER 

INFLAMMATORY MARKERS 

A. L. Eilertsen* (NO), L. Sandvik, B. Steinsvik, P. Sandset 

ESTABLISHING REFERENCE VALUES FOR COAGULATION PARAMETERS IN 

PREGNANT WOMEN 

T. Eller* (DE), C. Temal, U. Cirkel 

PREGNANCY ASSOCIATED ALTERATIONS OF THE INFLAMMATORY MEDIATORS, 

TISSUE FACTOR PATHWAY INHIBITOR AND PROTEIN Z 

J. Fareed* (US), J. Lavin, D. Hoppensteadt, J. Cunanan, J. Gianopoulos 

THROMBOPHILIA AND SPONTANEOUS ABORTION – THERAPY WITH LMW-HEPARI 

R. Fischer* (DE), R. Fischer, B. Kemkes-Matthes, A. Zimmermann, M. Bohlmann 

PREGNANCY MORBIDITY IS ASSOCIATED WITH LOW PLASMA TISSUE FACTOR 

PATHWAY INHIBITOR LEVELS, INCREASED THROMBIN GENERATION AND 

RESISTANCE TO ACTIVATED PROTEIN C 

C. Gardiner (UK), H. Cohen, S. J. Machin, I. J. Mackie* 

INTERACTION BETWEEN ORAL CONTRACEPTIVE USE AND COAGULATION FACTOR 

LEVELS IN DEEP VEIN THROMBOSIS 

R. B. Zotz* (DE), S. Klöckner, A. Gerhardt, R. E. Scharf 

211



P-M-602 

P-M-603 

P-M-604 

P-M-605 

P-M-606 

P-M-607 

P-M-608 

P-M-609 

P-M-610 

P-M-611 

P-M-612 

P-M-613 

P-M-614 

RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN A SUBSEQUENT 

PREGNANCY IN WOMEN WITH A FIRST HISTORY OF VENOUS THROMBOSIS 

A. Gerhardt* (DE), R. E. Scharf, R. B. Zotz 

MYOCARDIAL INFARCTION AFTER OVARIAN STIMULATION FOR INFERTILITY 

MANAGEMENT 

A. Girolami* (IT), F. Tezza, R. Scandellari, M. Scapin, B. Girolami 

RETINAL CENTRAL ARTERY OCCLUSION AFTER 10 PILLS OF DROSPIRENONE 

CONTAINING PREPARATION (YASMIN) 

A. Girolami* (IT), S. Vettore, R. Scandellari, P. Scarparo, B. Girolami 

VENOUS THROMBOSIS DURING ORAL CONTRACEPTION IN NORMAL OR 

THROMBOPHILIC WOMEN WHO HAD REMAINED ASYMPTOMATIC DURING PAST 

PREGNANCIES 

A. Girolami* (IT), R. Scandellari, L. Spiezia, E. Allemand, B. Girolami 

THROMBOPHILIA & RECURRENT FETAL LOSS: SHOULD WE SCREEN BOTH 

PARENTS? 

H. A. Goubran* (EG), M. Aboulghar, K. R. Gaber, S. Basha, N. Kassim, S. N. Amin, 

I. F. Iskander 

EFFICACY OF ENOXAPARIN IN PREVENTING ADVERSE FETO-MATERNAL OUTCOMES 

IN CARRIERS OF ANTICOAGULANTS DEFICIENCY 

E. Grandone* (IT), V. De Stefano, E. Rossi, F. Cappucci, T. Za, D. Colaizzo, G. Tiscia, 

M. Margaglione 

TF EXPRESSION IN HUMAN PLACENTA IS SIGNIFICANTLY ASSOCIATED WITH VEGF 

EXPRESSION 

E. Chinni (IT), D. Colaizzo, M. Margaglione, C. Rubini, G. Di Vagno, F. Giuliani, 

E. Grandone* 

DALTEPARIN SHORTENS HUMAN LABOR 

M. Hellgren* (SE), E. Andersson, B. Byström, M. Edlund, A. Holmberg, A. Klimavicute, 

M. Sennström, G. Tzortzatos, A. Malmström, G. Ekman-Ordeberg 

EVALUATION OF THROMBOPHILIA SCREENING IN WOMEN WITH OBSTETRICAL 

COMPLICATIONS: A "REAL WORLD" EXPERIENCE 

S. Henrard (BE), C. Maréchal, C. Lambert, V. Deneys, C. Hermans* 

THROMBOPHILIA RISK FACTORS ARE ASSOCIATED WITH PREGNANCY RELATED 

THROMBOEMBOLISM 

A. Hvas* (DK), J. Ingerslev, J. D. Salvig 

DELAYED HYPERSENSITIY TO LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN 

PREGNANCY 

B. F. Jacobson (ZA), E. Schapkaitz* 

INHERITED THROMBOPHILIA: INCIDENCE AND IMPACT ON PERINATAL OUTCOME IN 

SOUTH-WESTERN GREECE 

M. Karakantza* (GR), G. Androutsopoulos, A. Mougiou, G. Sakellaropoulos, G. Kourounis, 

G. Decavalas 

INFLUENCE OF INHERITED THROMBOPHILIA WITH RECURRENT PREGNANCY LOSS 

M. Karimi* (IR), R. Afrasiabi, J. Dehbozorgian, Z. Zolghadri, Z. Samsami, M. Yavarian, 

L. Badifard, F. Setoodegan, N. Jokar, J. Imani, M. Tavafoghi, A. Amiri, N. Jamalian 

212



Diabetes and metabolic disorders 

P-M-615 

P-M-616 

EVALUATION OF THE RELATIONSHIP BETWEEN GESTATIONAL DIABETES MELLITUS 

AND A HISTORY OF POLYCYSTIC OVARIAN SYNDROME 

M. Kashanian* (IR), Z. Fazi, A. Pirak 

RISK FACTORS IN WOMEN WITH GESTATIONAL DIABETES MELLITUS(GDM) 

M. Kashanian* (IR), M. Fekrat 

P-M-617 

RELATIONSHIP BETWEEN CIRCULATING THROMBOMODULIN LEVELS AND LATENT 

PROGRESSION OF ATHEROSCLEROSIS IN TYPE 2 DIABETIC PATIENTS 

O. Korzh* (UA), O. Pavlova, E. Lavrova 

P-M-618 RELATIONSHIP BETWEEN ENDOTHELIAL HAEMOSTATIC MARKERS IN TYPE 2 

DIABETIC PATIENTS 

O. Korzh* (UA), E. Lavrova, O. Pavlova 

P-M-619 

INCREASED PLATELET PROCOAGULANT ACTIVITY IN TYPE 2 DIABETIC PATIENTS: 

INHIBITION BY GPIIB/IIIA BLOCKADE 

N. Li* (SE), M. Razmara, P. Hjemdahl, C. Östenson, M. Johansson, M. Daleskog 


P-M-620 

P-M-621 

P-M-622 

P-M-623 

P-M-624 

P-M-625 

P-M-626 

P-M-627 

P-M-628 

ADIPOCYTOKINES AND VASCULAR ENDOTHELIUM IN DIABETIC AND NON-DIABETIC 

PERITONEALLY DIALYZED PATIENTS 

J. Malyszko* (PL), K. Pawlak, J. S. Malyszko, M. Mysliwiec 

FACTOR VON WILLEBRAND IN PATIENTS WITH METABOLIC SYNDROME 

E. G. Oganova* (BY) 

THE RISK FACTORS FOR THROMBOEMBOLISM IN PATIENTS WITH MECHANICAL 

VALVE 

H. Omori* (JP), K. M. Murasaki, Y. Uetsuka, N. Hagiwara, H. Kasanuki 

ELEVATED PLASMA FREE FATTY ACID LEVEL (MYRISTIC ACID, PALMITIC ACID, 

STEARIC ACID) IN TYPE 2 DIABETIC INDIVIDUAL 

Y. J. Ou* (TW), M. C. Hsieh, R. C. Jang, H. L. Wu 

THE EFFECT OF FIBRINOGEN GLYCATION ON FIBRIN NETWORK STRUCTURE OF 

TYPE II DIABETIC SUBJECTS 

M. Pieters* (ZA), N. Covic, F. H. Van Der Westhuizen, C. Nagaswami, Y. Baras, D. Loots, 

J. C. Jerling, J. W. Weisel, M. Pieters 

HYPERGLYCEMIA ACCELERATES ARTERIAL THROMBUS FORMATION AND 

ATTENUATES THE ANTITHROMBOTIC RESPONSE TO ENDOTOXIN IN MICE 

H. ten Cate (NL), H. M. H. Spronk*, H. R. Hansen, J. L. Wolfs, D. W. Sommeijer, 

L. W. Bruggemann, E. M. Beevers, C. A. Spek, P. H. Reitsma 

REDUCTION OF DIABETES-RELATED LIPID OXIDATIVE STRESS BY STATIN THERAPY 

AS MONITORED BY SERUM OXIDIZED LDL/B2GPI COMPLEX LEVELS 

G. Svanas* (US), M. Boisen, D. Oottamasathein, E. Matsuura, L. R. Lopez 

HAEMOSTASIS DISTURBANCES IN TYPE I AND II DIABETES MELLITUS 

P. Van Dreden (FR), A. Rousseau, T. Exner, M. Vasse, G. Ozenne, B. J. Woodhams* 

NUTRITIONALLY INDUCED OBESITY REDUCES THE ARTERIAL THROMBOTIC 

TENDENCY OF FACTOR V LEIDEN MICE 

N. Nagai (BE), H. R. Lijnen, F. Rosendaal, B. Van Hoef, M. Hoylaerts, B. Van Vlijmen* 

213



New antithrombotic agents and approaches 

P-M-629 

P-M-630 

P-M-631 

P-M-632 

P-M-633 

P-M-634 

P-M-635 

P-M-636 

P-M-637 

P-M-638 

P-M-639 

P-M-640 

INHIBITION OF THROMBIN GENERATION BY IDRAPARINUX AND THE INFLUENCE OF 

RFVIIA 

G. T. Gerotziafas* (FR), E. Verdy, T. Chakroun, M. M. Samama, I. Elalamy 

EFFECT OF PROLAME, A 17 BETA-AMINOESTROGEN DERIVATIVE, 

ON CELL HEMOSTASIS 

M. Gonzalez-Zarate* (MX), J. Fernandez-G, L. Del Valle-Mondragon, F. Tenorio-Lopez, 

N. Alvarado-Vazquez, E. Rodriguez-Maldonado, E. Zapata-Gomez, A. De La Peña 

UNFRACTIONATED HEPARIN MONITORING IN THE PRESENCE OF THE LONG-ACTING 

ANTI-XA AGENT IDRAPARINUX (SR34006): EFFECT OF EXOGENOUS ANTITHROMBIN 

I. Gouin-Thibault* (FR), M. M. Samama 

PEDIATRIC DOSING OF AND EXPERIENCE WITH FONDAPARINUX IN DEEP VENOUS 

THROMBOSIS 

E. F. Grabowski* (US), E. Van Cott 

PROTEIN C ACTIVATOR (PCA) INTERRUPTION OF THROMBUS PROPAGATION 

WITHOUT ANTIHEMOSTATIC SIDE EFFECT IN PRIMATES 

A. Gruber* (US), U. M. Marzec, L. Bush, E. I. Tucker, O. T. J. McCarty, S. R. Hanson, 

E. Di Cera 

PROTEIN C ACTIVATOR (PCA) TREATMENT IMPROVES THE NEUROLOGICAL 

OUTCOME OF EXPERIMENTAL THROMBOTIC ISCHEMIC STROKE IN MICE 

A. Gruber* (US), P. D. Hurn, S. Hurst, L. Bush, E. I. Tucker, S. R. Hanson, E. Di Cera 

EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS, 

PHARMACODYNAMICS AND TOLERABILITY OF RIVAROXABAN – 

AN ORAL, DIRECT FACTOR XA INHIBITOR 

A. Halabi* (DE), D. Kubitza, M. Zuehlsdorf, M. Becka, W. Mueck, H. Maatouk 

EFFECTS OF ARGATROBAN – A THROMBIN INHIBITOR - ON THE FIBRIN GEL 

PERMEABILITY AND THE HEMOSTASIS BALANCE IN PLASMA 

S. He* (SE), M. Blomback 

IN VITRO AND EX VIVO PROPERTIES OF LONG-ACTING REVERSIBLE 

OLIGOSACCHARIDES 

J. Herault* (FR), L. Millet, P. Savi, P. Duchaussoy, M. Petitou, P. Schaeffer, F. Bono, 

J. Herbert 

SULFATION OF THE 3-HYDROXYL GROUP OF THE REDUCING UNIT (H) ON 

ALKYLATED SULFATED PENTASACCHARIDE IS RESPONSIBLE FOR A HIGH AFFINITY 

FOR ANTITHROMBIN AND LONGER HALF LIFE IN ANIMALS 

J. Herault* (FR), P. Savi, P. Duchaussoy, M. Petitou, F. Bono, J. Herbert 

ORALLY ADMINISTERED HEPARIN HAS CUMULATIVE ANTITHROMBOTIC EFFECTS 

WHEN ADMINISTERED IN REPEATED DOSES 

L. M. Hiebert* (CA), T. Ping, S. M. Wice 

OLIGOSACCHARIDES FROM DIFFERENT LOW MOLECULAR WEIGHT HEPARINS 

HAVE DIFFERENT ANTICOAGULANT AND PROTAMINE SULPHATE NEUTRALIZATION 

PROFILES 

J. Hogwood* (UK), E. Gray, K. Johansen, M. Schroder, B. Mulloy 

214



P-M-641 

P-M-642 

ANTICOAGULANT EFFECT OF DANAPAROID, FONDAPARINUX, AND LEPIRUDIN IN 

CHILDREN COMPARED TO ADULTS 

V. Ignjatovic* (AU), R. Summerhayes, Y. Y. Yip, P. T. Monagle 

UFH PHARMACOLOGY IN CHILDREN 

V. Ignjatovic (AU), F. Newall*, L. Johnston, N. Cranswick, G. Lane, R. Summerhayes, 

P. Monagle 

P-M-643 

P-M-644 

P-M-645 

UNFRACTIONATED HEPARIN (UFH) PHARMACOKINETICS IN CHILDREN 

F. Newall* (AU), V. Ignjatovic, L. Johnston, R. Summerhayes, N. Cranswick, G. Lane, 

P. Monagle 

SHORT TERM BETAINE ADMINISTRATION IN PATIENTS WITH COLLAGEN VASCULAR 

DISEASE-MEDIATED SEVERE PULMONARY ARTERIAL HYPERTENSION 

O. M. Iqbal* (US), F. Tona, J. Fareed, G. Cella, J. Cunnanan, R. Ennamany, J. Messadek 

GPIIB-IIIA ANTAGONISTS HAVE A SIGNIFICANT EFFECT ON THROMBUS STABILITY 

BY DISPLACING BOUND FIBRINOGEN 

L. K. Jennings* (US), M. M. White, T. J. Kueter, H. E. Speich, S. N. Hill, A. D. Earhart, 

S. M. Slack 


P-M-646 

P-M-647 

P-M-648 

P-M-649 

DIFFERENTIAL EFFECTS OF FXA INHIBITORS AND HEPARINS IN SIMULATED 

ARTERIAL AND VENOUS THROMBOSIS 

J. M. Walenga* (US), W. P. Jeske, M. Prechel, J. Swank, D. Hoppensteadt, O. Iqbal, 

J. Cunanan, E. McGeehan, M. Bakhos 

GENERIC VERSIONS OF BRANDED LOW MOLECULAR WEIGHT HEPARINS CAN BE 

DIFFERENTIATED IN BIOLOGIC AND PHARMACOLOGIC ASSAYS 

W. P. Jeske* (US), P. Ackerman, A. Drenth, J. Walenga, M. Bakhos 

POTENTIAL OF THE FACTOR XA INHIBITOR RIVAROXABAN FOR THE 

ANTICOAGULATION MANAGEMENT OF PATIENTS WITH HEPARIN-INDUCED 

THROMBOCYTOPENIA 

W. P. Jeske (US), J. M. Walenga*, M. Prechel, D. Hoppensteadt, J. Swank, L. Sheen, 

F. Misselwitz, H. Messmore, M. Bakhos 

AN EVALUATION OF AN ARGATROBAN DOSE TITRATION NOMOGRAM 

J. M. Koerber* (US), J. C. Mattson, M. Kennedy, M. A. Smythe 

Clinical trials: oral anticoagulants incl. New compounds 

P-M-650 

P-M-651 

P-M-652 

SELF-CONTROL OF ORAL ANTICOAGULATION USING A PORTABLE PROTHROMBIN 

TIME MONITOR IN PAEDIATRIC CARDIAC PATIENTS 

M. Albisetti* (CH), M. Schmugge, E. Kaegi, U. Bauersfeld, M. Fasnacht 

SNAPSHOT OF WARFARIN TREATMENT IN DIFFERENT SETTINGS: A CROSS SECTION 

STUDY IN SWEDISH PRIMARY HEALTH CARE CENTERS VS ANTICOAGULATION 

CLINICS 

K. Arbring* (SE), T. L. Lindahl 

PERIODICAL LABORATORY EVALUATION OF PORTABLE COAGULOMETERS 

D. Barcellona (IT), L. Fenu, S. Cornacchini, F. Marongiu* 

215



P-M-653 

P-M-654 

P-M-655 

P-M-657 

P-M-658 

P-M-659 

P-M-660 

P-M-661 

P-M-662 

P-M-663 

P-M-664 

A PHASE II DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP 

RANDOMIZED STUDY OF EXTENDED PROPHYLAXIS WITH ODIPARCIL FOLLOWING 

TOTAL HIP ARTHROPLASTY (THA) 

S. M. Bates* (CA), H. Büller, M. R. Lassen, M. M. Samama, T. Whitsett, L. Fischer, 

T. M. Danoff, B. S. Froloshki, N. R. Asbel, J. S. Ginsberg 

INR STANDARDIZATION: FRENCH EXPERIENCE OF AN EXTERNAL QUALITY 

ASSESSMENT PROGRAM 

C. Bon* (FR), R. Meley 

SF-12 PHYSICAL COMPONENT SCORE IS AN INDEPENDENT PREDICTOR OF MAJOR 

HEMORRHAGE IN A COHORT OF ELDERLY PATIENTS ANTICOAGULATED FOR 

ATRIAL FIBRILLATION 

M. T. Brophy* (US), M. Young, D. Gagnon, E. Lawler, C. Cantillon, L. D. Fiore 

PERFORMANCE EVALUATION OF THE COAGUCHEK XS SYSTEM IN ROUTINE 

PATIENT ANTICOAGULATION MANAGEMENT CLINICS IN ISRAEL 

Y. Dickstein* (IL), D. D. A. Waitman, T. A. M. Van Den Besselaar 

6 MONTHS VERSUS PROLONGED ANTICOAGULATION FOR PREVENTION OF 

RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH HIGH FACTOR VIII 

LEVELS 

L. Eischer* (AT), V. Gartner, S. Schulman, C. Bialonczyk, M. Hirschl, P. Kyrle, 

S. Eichinger 

PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF RIVAROXABAN: 

A COMPARISON OF ONCE- AND TWICE-DAILY DOSING IN PATIENTS UNDERGOING 

TOTAL HIP REPLACEMENT (THR) 

B. I. Eriksson* (SE), F. Misselwitz, W. Mueck 

PREVENTION OF VENOUS THROMBOEMBOLISM VIA PARTIAL FACTOR IXA 

INHIBITION 

B. I. Eriksson* (SE), O. E. Dahl, M. R. Lassen, D. P. Ward, R. Rothlein, G. Davis, 

A. G. G. Turpie 

ANTIINFLAMMATORY EFFECTS OF ARGATROBAN CAN BE DIFFERENTIATED FROM 

OTHER DIRECT THROMBIN INHIBITORS. EXPERIMENTAL AND CLINICAL 

OBSERVATIONS 

J. Fareed* (US), R. Wahi, D. Hoppensteadt, V. Bansal, J. M. Walenga, B. Kaiser, R. Bick 

ARGATROBAN IS CAPABLE OF PASSING THROUGH THE BLOOD BRAIN BARRIER. 

POTENTIAL IMPLICATIONS IN THE MANAGEMENT OF THROMBOTIC STROKE 

J. Fareed* (US), D. Hoppensteadt, J. Maddineni, B. Kaiser, J. M. Walenga 

EXPOSURE-CLINICAL OUTCOME MODELING AND SIMULATION TO FACILITATE DOSE 

SELECTION OF APIXABAN IN SUBJECTS UNDERGOING ELECTIVE TOTAL KNEE 

REPLACEMENT SURGERY 

Y. Feng (US), L. Y. Li, A. Shenker, M. Pfister, Z. Yu* 

APIXABAN, AN ORAL DIRECT FACTOR XA INHIBITOR: MULTIPLE-DOSE SAFETY, 

PHARMACOKINETICS, AND PHARMACODYNAMICS IN HEALTHY SUBJECTS 

C. Frost (US), Z. Yu*, K. Moore, S. Nepal, Y. Barrett, R. Mosqueda-Garcia, A. Shenker 

216



P-M-665 

P-M-666 

APIXABAN, AN ORAL DIRECT, FACTOR XA INHIBITOR: SINGLE-DOSE SAFETY, 

PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY SUBJECTS 

C. Frost* (US), Z. Yu, S. Nepal, R. Mosqueda-Garcia, A. Shenker 

THALIDOMIDE AND THROMBOPROPHYLAXIS: TO WHOM AND WHEN 

A. García-Raso (ES), M. Callejas, A. Román, E. Prieto, C. Soto, C. Paniagua, 

J. L. Lopez Lorenzo, P. Llamas* 

Clinical trials: parenteral drugs (e.g.heparins/LMWH/fondaparinux) 

P-M-667 

P-M-668 

EFFICACY AND SAFETY OF A NOVEL HANSENULA POLYMORPHA -DERIVED 

RECOMBINANT RB-VARIANT HIRUDIN FOR THROMBOPROPHYLAXIS IN 

ORTHOPAEDIC PATIENTS 

H. A. Goubran* (EG), A. A. Z. Hanna, S. Sholkamy 

IS MODIFICATION OF DIET IN RENAL DISEASE (MDRD) FORMULA SIMILAR TO 

COCKCROFT-GAULT FORMULA TO ASSESS RENAL FUNCTION IN ELDERLY 

HOSPITALIZED PATIENTS TREATED WITH LOW MOLECULAR WEIGHT HEPARIN 

(LMWH)? 

I. Gouin-Thibault* (FR), E. Pautas, I. Mahé, C. Descarpentries, V. Nivet-Antoine, 

J. Golmard, V. Siguret 


P-M-669 

P-M-670 

P-M-671 

P-M-672 

P-M-673 

P-M-674 

P-M-675 

INFLUENCE OF INJECTION SITE ON PROPHYLACTIC DOSE ENOXAPARIN 

BIOAVAILABILITY IN OBESE PATIENTS 

M. Hacquard* (FR), D. Mainard, E. De Maistre, D. Wahl, T. Lecompte 

DIFFERENCES IN THE OLIGOSACCHARIDE COMPOSITION OF GENERIC VERSIONS 

OF ENOXAPARIN AND DALTEPARIN 

W. P. Jeske* (US), A. Brubaker, D. Hoppensteadt, J. M. Walenga, Q. Ma, J. Fareed 

THROMBIN GENERATION ASSESSMENT: MONITORING OF ANTICOAGULANT EFFECT 

OF LMWH TREATMENT AFTER STENTING IN PATIENTS WITH CAROTID ARTERY 

DISEASE 

K. Konstantinidis* (GR), T. Gerasimidis, I. Elalamy, E. Verdy, M. Samama, V. Garypidou, 

G. Gerotziafas 

THE EFFECT OF BIBT 986, A NOVEL SMALL MOLECULE DUAL INHIBITOR OF 

THROMBIN AND FACTOR XA, ON COAGULATION IN 

A MODEL OF ENDOTOXIN INDUCED, TISSUE FACTOR TRIGGERED COAGULATION 

ACTIVATION IN HUMANS 

J. M. Leitner* (AT), B. Jilma, F. B. Mayr, F. Cardona, C. Firbas, E. U. Graefe-Mody, 

K. Rathgen, H. Staehle, U. Schuehly, A. O. Spiel 

IRIS AN ONGOING, INTERNATIONAL, MULTICENTRE, OPEN, CENTRALLY 

RANDOMISED, PARALLEL GROUP STUDY WITH TINZAPARIN OR UNFRACTIONATED 

HEPARIN (UFH) ADMINISTERED SUBCUTANEOUSLY (SC) TO PATIENTS WITH DEEP 

VEIN THROMBOSIS (DVT) OR PULMUNARY EMBOLISM (PE). THE IRI 

A. Leizorovicz* (FR) 

THROMBOPHILIA IS ASSOCIATED WITH HEPARIN THROMBOPROPHYLAXIS FAILURE 

IN PATIENTS WITH ACUTE TRAUMATIC SPINAL CORD INJURY 

A. Lubetsky* (IL), D. Rubin-Asher, G. Zeilig, A. Ratner, A. Zivelin, I. Asher, U. Seligsohn 

DIFFERENTIAL DOSING OF ENOXAPARIN (ENOX) IN TERM AND PRETERM NEONATES 

J. I. Malowany* (CA), D. C. Knoppert, D. S. Lee, J. Wu, P. McCusker, P. Massicotte, 

S. Williams, A. K. C. Chan 

217



P-M-676 

P-M-677 

P-M-678 

P-M-679 

P-M-680 

P-M-681 

P-M-682 

P-M-683 

THROMBOPROPHYLAXIS WITH BEMIPARIN STARTED 6 HOURS AFTER HIP OR KNEE 

REPLACEMENT SURGERY: REVIEW OF CLINICAL AND POSTMARKETING 

EXPERIENCE 

J. Martínez-González* (ES), E. Rocha, P. Prandoni 

BENEFIT OF FONDAPARINUX IN THE LONG-TERM PREVENTION OF ISCHEMIC 

EVENTS IN PATIENTS WITH NON-ST ELEVATION ACUTE CORONARY SYNDROMES IN 

THE OASIS-5 TRIAL 

S. R. Mehta* (CA) 

BENEFIT-RISK RATIO OF FONDAPARINUX IN DIABETIC PATIENTS WITH ST 

ELEVATION MYOCARDIAL INFARCTION (STEMI): A SUBANALYSIS OF OASIS-6 

R. Peters (NL), S. R. Mehta 

EARLY SAFETY BENEFIT OF FONDAPARINUX VERSUS ENOXAPARIN IN PATIENTS 

WITH NON-ST ELEVATION ACUTE CORONARY SYNDROMES: A SECONDARY 

ANALYSIS OF THE OASIS-5 TRIAL 

S. R. Mehta (CA), J. Bassand 

FONDAPARINUX IS SAFER THAN ENOXAPARIN IN ELDERLY PATIENTS WITH NON-ST 

ELEVATION ACUTE CORONARY SYNDROMES: A SUBANALYSIS OF OASIS-5 

S. R. Mehta (CA), J. Bassand 

FONDAPARINUX REDUCED MAJOR BLEEDING VERSUS ENOXAPARIN IN PATIENTS 

WITH ACUTE CORONARY SYNDROME UNDERGOING EARLY INVASIVE MANAGEMENT 

EVEN IN THE CONTEXT OF TRANS-RADIAL CORONARY INTERVENTION: 

INSIGHTS FROM OASIS-5 

M. Hamon (FR), S. R. Mehta 

IMPACT OF RENAL FUNCTION ON THE BENEFIT-RISK RATIO OF FONDAPARINUX IN 

PATIENTS WITH NON-ST ELEVATION ACUTE CORONARY SYNDROMES IN 

THE OASIS-5 TRIAL 

K. A. Fox (UK), S. R. Mehta 

MORTALITY BENEFIT OF FONDAPARINUX VERSUS ENOXAPARIN IN DIABETIC 

PATIENTS WITH NON-ST ELEVATION ACUTE CORONARY SYNDROMES (NSTE-ACS): 

A SUBANALYSIS OF OASIS-5 

S. R. Mehta (CA), R. Peters 

Intravascular devices 

P-M-684 

P-M-685 

P-M-686 

RETRIEVABLE INFERIOR VENA CAVA (IVC) FILTERS IN A TERTIARY CARE 

POPULATION 

A. Alahmad (US), L. M. Ramirez, M. Sands, T. L. Carman* 

CATHETER-RELATED THROMBOSES IN NEWBORNS 

H. Hertfelder* (DE), M. Ehlen, B. Wiebe, U. Pohlmann, W. Wiebe 

POST-THROMBOTIC SYNDROME AFTER VENA CAVA FILTER PLACEMENT: 

A SYSTEMATIC REVIEW 

M. A. Fox (CA), S. R. Kahn* 

218



P-M-687 

P-M-688 

SIGNIFICANT REDUCTION OF VASCULAR GRAFT OCCLUSIONS IN CHRONIC 

HEMODIALYSIS PATIENTS WITH PEG-HIRUDIN (SPP200) 

J. Mann* (CH), S. J. Kuranoff, I. Navarro, J. Russo 

EVALUATION OF LASER-INDUCED THROMBOLYSIS IN THE RAT THROMBOSIS 

MODELS: A PULSED GREEN LASER TECHNIQUE 

Y. Matsumoto* (JP), D. Yamashita, Y. Yamashita, H. Okada, Y. Maeda, Y. Shimizu, 

T. Nakayama, K. Umemura 

P-M-689 

P-M-690 

P-M-691 

INFERIOR VENA CAVA FILTERS IN PEDIATRIC PATIENTS 

L. J. Raffini* (US), A. Cahill, J. Hellinger, C. Manno 

RETRIEVABLE VENA CAVA FILTERS FOR SECONDARY PREVENTION OF PULMONARY 

EMBOLISM IN ORTHOPAEDIC SURGERY 

K. Rivron-Guillot* (FR), S. Quenet, N. Moulin, H. Decousus, S. Laporte, F. G. Barral, 

P. Mismetti 

INTRACRANIAL STENTING IN FOUR PATIENTS WITH ACUTE ISCHEMIC STROKE 

M. T. Sartori* (IT), P. Amistà, M. Munari, S. M. Volpin, G. Pavesi, A. M. Basile, 

N. Cavasin 


P-M-692 

VENOUS THROMBOSIS AND THE POST THROMBOTIC SYNDROME AFTER FEMORAL 

CATHETERIZATION 

J. J. Sol (NL), H. Knoester, M. Peters, H. Van Ommen* 

Gene therapy of thromboembolic disorders 

P-M-693 

DUAL GENE TRANSFER OF FGF-2 AND PDGF-BB USING PLASMID DNA PROMOTES 

EFFECTIVE ANGIOGENESIS AND ARTERIOGENESIS IN A RODENT MODEL OF 

HINDLIMB ISCHEMIA 

E. V. De Paula* (BR), M. C. Flores-Nascimento, R. A. Garcia, C. D. Ramos, 

A. T. Guillaumon, V. R. Arruda, J. M. Annichino-Bizzacchi 

Innovation and technology 

Stem cells and cell therapy 

P-M-694 

P-M-695 

P-M-696 

P-M-697 

APPLICATION OF AUTOLOGOUS RED BLOOD CELLS CONCENTRATE DERIVED FROM 

UMBILICAL CORD BLOOD FOR THERAPY OF ANAEMIC NEONATES 

M. V. Appaloop* (RU), V. N. Veryasov, T. S. Foteeva, E. N. Baibarina 

A PILOT STUDY WITH AUTOLOGOUS BONE MARROW-DERIVED STEM CELL 

TRANSPLANTATION (ABSCT) IN PATIENTS WITH SEVERE PERIPHERAL ARTERIAL 

DISORDER (SPAD) 

Z. Boda* (HU), K. Farkas, J. Tóth, L. Jámbor, P. Soltész, K. Rázsó, T. Sipos, Z. Oláh, 

P. Ilonczai, K. Litauszky, Z. Veréb, É. Rajnavölgyi 

PROSTACYCLIN IMPROVES TRANSCORONARY MYOCARDIAL DELIVERY OF ADIPOSE 

TISSUE-DERIVED STROMAL CELLS 

R. De Caterina* (IT), R. Madonna, L. Rinaldi, C. Rossi, Y. Geng 

ACTIVATION OF BLOOD COAGULATION IN AB0-COMPATIBLE BLOOD BY 

MULTIPOTENT MESENCHYMAL STROMAL CELLS 

G. Elgue* (SE), I. Rasmusson, O. Korsgren, B. Nilsson, K. Le Blanc 

219



P-M-698 

P-M-699 

P-M-700 

P-M-701 

BONE MARROW-DERIVED MONONUCLEAR CELL THERAPY INDUCES DISTAL 

ANGIOGENESIS AFTER LOCAL INJECTION IN CRITICAL LEG ISCHEMIA 

J. Emmerich* (FR), J. Duong Van Huyen, D. Smadja, P. Bruneval, P. Gaussem, 

L. Dal Cortivo, P. Julia, J. Fiessinger, M. Cavazzana-Calvo, M. Aiach 

ALTERATIONS OF HEMOSTATIC PARAMETERS IN PATIENTS RECEIVING 

HEMATOPOIETIC STEM CELL TRANSPLANTATION 

Y. Han* (CN), X. Lu, D. Wu, A. Sun, C. Ruan, Z. Wang 

ENDOTHELIAL IMPACT OF ALLOGENEIC HEMATOPOIETIC STEM CELL 

TRANSPLANTATION 

A. D. Petropoulou* (FR), I. Elalamy, G. T. Gerotziafas, F. Rendu, M. M. Samama, 

J. P. Marie, B. Rio 

FUNCTIONAL ANALYSIS OF HUMAN PLATELETS IN NOD/SCID MICE 

I. I. Salles* (BE), S. F. De Meyer, A. Reynaert, C. Brunaud, K. Vanhoorelbeke, H. Deckmyn 

220

Mise en page 1 - ISTH 2009

Create successful ePaper yourself

Delete template?

Save as template?